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Background and aim: Oxidative stress is thought to play a central role in asthma. A 
decrease in dietary antioxidants intake has been suggested to play a part in the increase 
in prevalence of asthma in developed countries, but little information is available from 
developing countries. This thesis was aimed to assess the relation between intake of 
dietary antioxidants, fatty acids, and biomarkers of oxidative stress and of antioxidant 
status, and asthma symptoms, bronchial responsiveness (13HR), and lung function in 
young adults. 
Methods: 1,192 adults bom between 1974 and 1978 in Limache, a semi-rural area of 
Chile, participated in the study. They responded to a Spanish version of the European 
Community Health Research Survey questionnaire, were skin tested to eight allergens, 
and challenged with methacholine to assess BHR. Dietary intake was assessed with a 
food frequency questionnaire. Plasma levels of 172-isoprostanes, protein carbonyls, uric 
acid, and ferric reducing ability of plasma were assessed in half of the subjects. 
Results: The large majority of dietary antioxidants tested, including grouped fruits, 
vegetables, nutrients and flavonoids were unrelated to respiratory symptoms of asthma 
and BHR, or to measures of lung function. BHR slope (mg-1) was negatively associated 
with per-quintile intake of vitamin C (mg) (difference of means -0.35,95% CI: -0.67 
to -0.04). There was some evidence for a positive association between a greater FEVI 
(L) with total catechins (difference of means 0.04 U highest versus lowest quintile of 
intake (mg), 95 % CI: -0.03 to 0.11). 
Conclusion: This study provided little evidence of a protective effect of antioxidants 
on asthma and lung function, except for a marginal association between vitamin C and 
BHR, as well as between intake of catechins and lung function. Plasma biomarkers are 
unrelated to asthma in the general population. 
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CHAPTERI 
Introduction: The relationship between diet and asthma 
Asthma is a chronic disease highly prevalent in developed and some developing 
countries. Several aetiological risk factors have been identified for this disease, 
including genetic and environmental influences. Due to the rapid increase in the 
prevalence of asthma observed over the past three decades, it can be hypothesised that 
lifestyle-related to health and environmental factors play a role in the susceptibility of 
individuals. Dietary antioxidants are thought to be protective factors against the 
development of the disease. In this chapter the main environmental factors thought to 
play a role in asthma are described (Section 1.1). In section 1.2, the role that diet, and 
in particular antioxidants, have against asthma is illustrated as well as the 
epidemiological tools used to measure asthma and diet. The Chilean perspective in 
relation to diet and asthma is outlined in section 1.3. The specific objectives and the 
structure of this thesis are stated in Section 1.4. 
1.1 OVERVIEW OF THE BURDEN OF ASTHMA AND ITS RISK FACTORS 
Different definitions have been proposed for asthma. The common feature of asthma 
included in definitions is a chronic inflammatory condition in the airways with variable 
degree of obstruction and increased responsiveness to a number of factors [1,2]. Over 
the last two decades, there has been a growing interest in this complex disease, for 
which increasing rates of prevalence have been reported, especially in developed 
countries [3-5]. 
To date, most of the epidemiological evidence on the burden of asthma comes from 
developed populations. Estimates of prevalence in developing countries are scarce. The 
available data from Central and South American countries largely comes from children 
and suggests that the prevalence is similar to that observed in developed regions and 
can be as high as that found in countries reporting the highest rates in the world, such 
as the UK, Australia and New Zealand [6,7]. In Chile, a developing country with an 
emerging economy, the prevalence of asthma in children is as high as that reported in 
industrialised nations [8,9]. There is some evidence that asthma morbidity is an 
important component of total chronic respiratory diseases in the country, as gathered 
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from medical surveys of Chilean families [101. However, there are no comparable data 
on the prevalence and aetiological factors of asthma in adults using standardised 
epidemiological instruments. 
In spite of the epidemiological evidence for an increase in the prevalence of asthma in 
many countries, the causes of the increase are still debated. It has been postulated that 
asthmatic subjects may have a genetic predisposition to develop the disease [11]. 
Elements of the pathogenesis of asthma, including the immune response and the 
regulation of pro-inflammatory cytokines, are also at least partly under genetic control 
and are activated under environmental factors in genetically predisposed subjects [12, 
131. 
The rapid increase observed in asthma prevalence cannot be explained on the basis of 
genetic predisposition alone. Therefore, attention has been centred on a number of 
environmental factors to which such an increase could be attributed. Indoor and 
outdoor allergens, such as domestic mites, animal allergens, pollens, fungi and molds, 
have been suggested to have a role in the manifestation and persistence of asthma [14, 
15]. Environmental pollutants, mainly industrial smog and those derived from ozone 
and nitrogen oxides, may intensify clinical manifestations of asthmatic subjects [2]. 
The overall magnitude of the contribution of these factors in relation to the rapid 
increase of asthma is under debate. Although allergens seem to be strongly related to 
the prevalence of asthma, it does not appear that there has been a significant increase in 
population exposure to domestic allergens, including that to house dust mite [16]. In 
addition, air pollution has decreased in countries where an increase in asthma has been 
observed, including those of Western Europe, USA, Australia, and New Zealand. 
Furthermore, the worldwide pattern of air pollution and asthma distribution does not 
support air pollution as a major causative factor for asthma. 
Developed countries with a higher socio-economic level have the highest prevalence of 
asthma. It has been suggested that better hygienic conditions derived from this affluent 
status may be in part related to the increase in allergic diseases including asthma [17]. 
One of the underlying mechanisms hypothesised for the rise of atopy and asthma in 
industrialised countries, is the decrease in the incidence of early childhood infections, 
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and the consequent expansion of T helper type 2 lymphocytes (M), which would lead 
to an imbalance in the regulatory mechanisms of the inflammatory response later on in 
life [181. 
Children with siblings are thought to be more likely to acquire infections during their 
childhood and therefore would be protected against allergic diseases during adult life 
[19-21]. This observation has contributed to the hypothesis that family size and, in 
particular number of older siblings may be related to asthma. The evidence for this has 
emerged mainly since the 1990s [22], and changes in family size over the past 30 years 
do not appear to explain the increase in asthma observed in the same period in the 
United Kingdom or New Zealand, two of the countries with highest prevalence [231. 
1.2 THE RELATIONSHIP BETWEEN DIET AND ASTHMA IN THE EPIDEMIOLOGICAL SETTING 
Dietary intake is another factor postulated to play a role in the development of asthma, 
and possibly associated with the increased prevalence of this disease in the last three 
decades. Over this period, the dietary pattern in many developed and developing 
societies has changed. The current high prevalence of asthma may be related to a diet 
characterised by lower consumption of fresh fruits, vegetables and fish, and high 
consumption of foods rich in saturated fatty acids, sugars, and salt [24]. 
One of the earliest hypotheses that changes in diet may be related to changes in 
prevalence of asthma was postulated in the 1980s when Bumey observed that regional 
variations in mortality for asthma in England and Wales were related to purchase of 
table salt [25]. In 1994, Seaton first hypothesised that an insufficient intake of dietary 
antioxidants could be related to asthma [26]. Since then, several researchers have 
proposed that diet may have an impact on either the aetiology or severity of asthma 
[27,281. 
Ecological studies suggest that changes in diet related to a decrease in consumption of 
dietary sources of antioxidants, as well as variation in the type of fatty acids consumed, 
may be contributing to the increase in the prevalence of asthma [28-30]. This 
hypothesis arises from the fact that the inflammatory-immune process that 
characterises asthma involves the permanent production of a series of molecules with 
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oxidative capacity, known as reactive oxidative species (ROS) [311, which if not 
contained could lead to a chain of molecular events that may end in the worsening of 
the asthmatic response [321. 
A higher intake of specific dietary antioxidants has been suggested as a protective 
factor by preventing, or at least modulating, the damage that ROS generate, thus 
attenuating the manifestation of asthma symptoms. In addition, dietary antioxidants 
have anti-inflammatory properties, as they directly prevent the activation of 
inflammatory cells [291. Another component of the diet, polyunsaturated fatty acids 
(PUFA), play a key role in the inflammatory response. When they are oxidized, the 
synthesis of a number of pro-inflammatory molecules takes place, directly stimulating 
the progression of the asthmatic response [32]. Therefore, these fatty acids could also 
have a protective effect. 
The largest epidemiological evidence of an association between dietary antioxidants, 
PUFA and asthma comes from cross-sectional studies, with some evidence from 
randomised controlled trials (RCT) and longitudinal studies that have tested the 
hypothesis that dietary intake may affect the incidence of asthma [27-301. Symptoms of 
asthma in epidemiological studies have been mainly ascertained by questions on 
respiratory symptoms, and more recently have included measurement of BHR. The use 
of standardised questionnaires on asthma in children [33] and adults [34] has facilitated 
the comparison of prevalence of the disease and its symptoms, defining asthma based 
on questions of personal perception of symptoms, which sometimes has the limitation 
of different interpretations given to these questions, due to cultural bias. 
Dietary questionnaires have been the main tool utilised to assess intake of antioxidants, 
with the limitation that they may not measure endogenous levels of antioxidants that 
are effectively absorbed or the effects that antioxidants may or may not exert against 
oxidative damage in the lungs. In spite of these limitations, dietary questionnaires can 
still offer a reliable estimate of the dietary intake in epidemiological settings, especially 
if its validation and reproducibility have been tested, and if it has been carefully 
designed to meet the aims of the research [35,36]. A number of measurements in blood 
of biomarkers have been included in epidemiological studies as complementary tools to 
the information given by dietary questionnaires. 
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Generally, a biomarker is defined as a characteristic that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacological responses to a therapeutic intervention [37]. Nutritional biomarkers 
can provide an estimate of nutrient intake and nutritional status, independent of the 
information given by individuals, allowing for more accurate information of the 
endogenous antioxidant/oxidant status [28,29]. The main limitation is the high cost and 
complexity that may involve their measurement. 
In the study of asthma, two main groups of biomarkers have been used to assess the 
relationship with diet. These are biomarkers of antioxidant status/intake, through the 
assessment of antioxidant enzymes or nutrients in plasma, and biomarkers of oxidative 
stress, where oxidation of molecules such as fatty acids and proteins is assessed [38, 
391. 
Overall, there are several tools to evaluate the possible association between diet and 
asthma in epidemiological studies. A combination contributes to obtaining more 
detailed estimates of the nutritional status of an individual and the relationship with 
asthma. 
1.3 THE CHILEAN PERSPECnVE 
In spite of the increasing epidemiological evidence reported in relation to asthma and 
diet little information has been provided regarding dietary intake pattern as a risk factor 
for asthma in the Chilean population, a country with a similar prevalence in children to 
that reported for developed countries [6,8,9]. In addition, there is little known about 
the prevalence of asthma and the possible aetiological factors responsible for the 
disease in adult population. 
The dietary pattern observed in the country has followed the same evolution as that 
described for America and Western European countries, with an insufficient intake of 
fruits and vegetables and an increase in the intake of saturated fatty acids and vegetable 
oils [40]. This has been mirrored in a concomitant increase in the figures of obesity, 
which currently affects nearly 20% of the population [40]. 
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1.4 HYPOTBESES, AIMS, AND STRUCTURE OF TBE THESIS 
The primary hypothesis of this thesis is that intake of specific dietary antioxidants is 
associated with asthma in a population of Chilean young adults. As an approach to 
define asthma, self-reported respiratory symptoms and bronchial responsiveness (BHR) 
were determined. The main contenders for a beneficial effect should be dietary 
antioxidants with known antioxidant properties that the literature suggests might 
decrease the risk of asthma. 
To address this hypothesis, the specific aims are to: 
I Explore the associations between self-reported asthma symptoms and BFIR, 
with dietary intake of: 
a. Fruits and vegetables rich in antioxidants; antioxidant vitamins C, E and 
total vitamin A 
b. Minerals selenium and zinc and flavonoids 
c. Omega 3 fatty acids, and the ratio omega 6/omega 3 (ratio n6/n3) 
A second hypothesis is that biornarkers of antioxidant status and of oxidative stress in 
plasma would reflect to some extent the association between oxidative stress and 
asthma. For this purpose, the following objectives are to be addressed: 
1. Evaluate the association between asthma symptoms and BHR, with antioxidant 
status assessed through plasma levels of ferric reducing ability of plasma 
(FRAP) and uric acid. 
2. Assess the association between asthma symptoms and BHR with oxidative 
stress as measured through the plasma levels of protein carbonyls and 172- 
Isoprostanes (F2-ip). 
3. Assess the correlation between biomarkers of oxidative stress and of 
antioxidant status with dietary antioxidants and food items. 
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A third hypothesis in this thesis is that intake of dietary antioxidants is associated with 
a better lung function in young adults, as well as with lower levels of oxidative stress. 
For this purpose, the aims are to: 
I Explore the associations between FEVI and the ratio FEVI/FVC with: 
a. Fruits and vegetables rich in antioxidants 
b. Antioxidant vitamins C, E and total vitamin A; minerals selenium and 
zinc and flavonoids 
c. Omega 3 fatty acids, and the ratio omega 6/omega 3 (ratio n6/n3) 
d. Biomarkers of antioxidant status and oxidative stress in plasma 
This thesis is based on a prospective study aimed to assess current and early risk factors 
on asthma in young adults bom between 1974 and 1978 in Limache and its vicinity. 
This study reports a cross-sectionally designed study looking at the dietary intake of 
this population as a risk factor for asthma. 
This thesis is focused on the study of dietary intake as a risk factor for asthma in young 
adults of Chile, a middle-income industrial country. The high rates of asthma in Latin 
America may be similar to those observed in developed countries [41], but they may 
not have the same risk factors and its study may provide epidemiological clues in other 
settings, a need that has been expressed by researchers from developed societies [42]. 
The evidence on the relationship between diet and asthma is scant in Latin America. 
There is some indication that supplementation with antioxidant enzymes may protect 
against moderate or severe asthma in Mexican children living in areas with high ozone 
levels [43], but no studies have been carried out in other countries of this region. 
Similarly, no attempts have been made to evaluate the association between dietary 
intake and asthma in children or adults from South America. Food habits may differ 
greatly from one country to another and local factors may influence the effect of food 
intake on asthma. 
The inclusion in this study of assessment of plasma biornarkers of antioxidant status 
aims to confer more certainty on the relationship, if any, that exists between oxidative 
stress that is present in young adults with asthma symptoms. The assessment of 
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oxidation of lipids and proteins in a population-based study is novel. Although these 
biomarkers have been increasingly used with asthmatics in clinical studies, these 
normally include a small number of participants, and scarce evidence- has been 
provided on their applicability in studies on general population. 
In Chapter 2 the main components of the definition of asthma as used in 
epidemiological studies are described. A brief description is given of the molecular 
pathogenesis of the disease, which is characterised by an inflammatory process 
mediated by oxidative stress. An overview of the prevalence is also presented in order 
to give a picture of the magnitude of the disease in developed societies with a similar 
epidemiological profile to Chile. 
The current knowledge on the mechanisms by which dietary antioxidants are involved 
in asthma is described in Chapter 3. This is covered in two sections, one describing the 
molecular role that these antioxidants have in the pathways of asthma, while the second 
comprises a review of the epidemiological evidence that has been gathered so far for 
each of these antioxidants and asthma. This thesis is concerned with the situation 
regarding dietary intake and asthma in adults so the review is limited mainly to this 
group of people, but a brief overview in children is also provided. 
The role of biomarkers as tools in the assessment of oxidative stress and of antioxidant 
defences against asthma is reviewed in Chapter 4. A description of those included in 
this study is given, and others commonly used in other studies but unfeasible to include 
in this thesis, are also described. 
The methodologies used for the study arc described in Chapter 5. The main 
questionnaire utilised to assess asthma was obtained from the European Community 
Respiratory Health Survey (ECRHS) using the Spanish version adapted to the local 
lexicon. The results are presented in Chapters 6 to 8. In Chapter 6 the general findings 
on prevalence of symptoms and respiratory outcomes are described, as well as results 
for dietary intake. In Chapter 7, the associations between respiratory symptoms and 
BHR with diet, flavonoids and biomarkers are presented. In Chapter 8, the association 
between best FEVI, as well as the ratio FEVI/FVC with dietary intake of antioxidants, 
flavonoids and biomarkers is described. In Chapter 9 the results of the thesis are 
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surnmarised and discussed and their contribution to the current knowledge on dietary 
intake and asthma is presented. 
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CHAPTER2 
The components of asthma and the magnitude of the problem 
This chapter provides a definition of asthma (Section 2.1) and the elements that 
comprise the definition used for epidemiological purposes (Section 2.2). In section 2.3 
the pathogenesis of the disease is outlined. A description of BHR as a more specific 
measurement of asthma is provided in section 2.4, as well as the definition of lung 
function, an indicator of chronic respiratory disease. The last part of the chapter 
summarises the international prevalence of asthma (Section 2.5). 
2.1 DEFINMON OF ASTHMA 
Asthma is one of the commonest illnesses that affects people across the world. In spite 
of this, there is not a universally accepted definition for asthma [441. The World Health 
Organization defined asthma in 1975 as 'a chronic condition characterised by recurrent 
bronchospasm resulting from a tendency to develop reversible narrowing of the 
airways lumina in response to stimuli of a level or intensity not inducing such 
narrowing in most individuals' [45]. 
The American Thoracic Society emphasises that the physiological manifestation of 
asthma is characterised by one or more of the following alterations of respiratory 
function: (1) diminished vital capacity, forced expiratory flow rate, and maximal 
voluntary ventilation; (2) increased airway resistance; (3) increased residual lung 
volume; (4) abnormal intrapulmonary gas mixing; and (5) hypoxemia and hypercarbia. 
According to the ATS, "the degree of functional alteration depends on the severity of 
the bronchial obstruction" [I]. 
The Global Initiative on Asthma (GINA) adds that it is an "'inflammatory disorder of 
eosinophils and T lymphocytes, causing in susceptible individuals breathlessness, chest 
tightness and cough, particularly at night and/or early morning". These symptoms are 
usually associated with widespread but variable airflow limitation that is at least partly 
reversible either spontaneously or with treatment" [2]. 
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2.2 EpiDEmIOLOGICAL DEFINmON OF ASTHMA 
The majority of epidemiological studies have used three main methods to classify 
individuals as having asthma. These are (1) a positive answer to a question on whether 
a person has asthma, usually diagnosed by a doctor; (2) a positive answer to whether 
he/she has a symptom of asthma, usually wheeze; and (3) a measurement of increased 
BHR. 
Questionnaires are regarded as the main tool to obtain information on asthma 
symptoms in the population. Therefore, the diagnosis of asthma has largely relied on 
the answers provided by the subjects themselves, or by parents in the case of children 
[46]. The commonest questions included in a questionnaire are whether the participant 
has ever been diagnosed as having asthma, and the presence of symptoms like 
wheezing or breathlessness [47-49]. A main limitation arises, as the words wheezing, 
chest tightness and breathlessness may mean different things to different people within 
and between societies, therefore leading to bias in comparisons. 
The use of questionnaires has as advantages that they have a relatively low cost and can 
cover a large population in a relatively short period of time. A large number of 
questionnaires can be administered under different conditions, such as person-to-person 
interview, self-administered, or by telephone, saving time and human resources. In 
developed societies, a postal questionnaire has been widely used, with variables rates 
of response. However, this alternative is not always feasible in countries with high or 
partial levels of illiteracy or unreliable postal services. 
The ECRHS, carried out to assess the prevalence of asthma across Europe, included 
both validated questionnaires and objective measurements. Since the publication of its 
protocol in 1994, it has produced data on prevalence of asthma symptoms in adults 
aged 20 to 44 years old. This survey aimed to estimate the variation in the prevalence 
of asthma, and symptoms of asthma across European countries. It also aimed to 
estimate the variation in the exposure to several environmental risk factors and their 
association with asthma, and the extent to which they may explain the variation in 
asthma found between centres in the study. 
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The main questionnaire included a number of questions on symptoms of asthma and 
medical history, as taken from The International Union Against Tuberculosis and Lung 
Disease (IUATLD) questionnaire [34]. It also included questions on social status, 
occupation, smoking, housing conditions, and medication. In addition to this 
questionnaire, measurements of airway obstruction (lung function and responsiveness 
to methacholine) and atopic status (skin prick test and serum IgE) were included in the 
survey. 
The International Study of Asthma and Allergies in Childhood (ISAAC) was the first 
study assessing variations of prevalence in children between countries. As with the 
ECRHS, ISAAC aimed to assess prevalence and its risk factors through the use of a 
questionnaire. It also aimed to describe the severity of asthma, rhinitis and eczema in 
children, and provided baseline measures for assessment of future trends in prevalence, 
thus allowing for comparisons in change of prevalence across time. The survey 
included children aged 6 to 7 years old with questions completed by parents and 13 to 
14 years old who responded to a self-administered questionnaire at school. They were 
also shown a video picturing asthma symptoms after which the children answered 
several questions related to it. 
The survey has been carried in most of the continents, being considered the most 
extensive international survey on prevalence of asthma symptoms so far carried out. 
These two surveys have provided insights in the variations of prevalence of asthma 
symptoms, both in adults and in children. A study comparing the level of agreement 
and correlation between the ECRHS and ISAAC projects showed a strong coffelation 
between the prevalence reported by the two surveys, with generally good agreement 
between them [50]. 
2.3 PATHOGENESIS OF ASTHMA 
The central feature in asthma is airway inflammation. Several pathways lead to the 
inflammatory response that will cause the manifestations of asthma symptoms [51]. 
One of them is represented by the role of leukotrienes. They are synthesised from 
arachidonic acid (AA) released from the cell membranes. Once this occurs, AA can be 
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metabolised through two enzymatic pathways. One is through cyclooxigenase (COX), 
which will lead to formation of prostaglandins, thromboxanes and prostacyclines. 
The second is through lipoxigenase (LOX), which will lead to formation of 
leukotrienes. The first leukotriene synthesised is LA4. considered the precursor of all 
the other families of leukotrienes. Other leukotrienes are also generated, such as LB4, 
LTC4, LD4 and LE4 under the regulation of several enzymes. It has been established 
that LB4 is a potent stimulus for activation of leucocytes, stimulates the secretion of a 
ROS, superoxide anion and can affect the synthesis of IgE. LC4, LD4 and LE4 are 
considered the most potent inducers of bronchoconstriction, related to the functions of 
smooth muscle contractility and vascular permeability [5 11. 
The other main pathway involved in the inflammatory response is that related to the 
immune system, in which lymphocytes and cytokines play a major role. The series of 
events start when T lymphocytes are presented with an antigen by macrophages. This 
results in the production of two subtypes of lymphocytes, namely T helper I (Th I) and 
T helper 2 (M). They produce several cytokines, which will activate a series of 
mediators of inflammation. Interleukines (IL) 4 and 13 are the two cytokines 
suggested to play a central role, as they regulate the synthesis of IgE [52]. IgE binding 
to allergen can link the high-affinity IgE receptor on mast cells, resulting in release of 
mediators that include histamine, prostaglandins, leukotrienes and enzymes [52,53]. 
IL-4 is also involved in the activation of mast cells jointly with IL-9, while IL-3 
activates eosinophils. The sputum of asthmatic patients contains large numbers of 
eosinophils [54], which are considered pivotal cellular mediators of asthma. The 
release of these substances leads to BHR and airway obstruction, and the manifestation 
of clinical symptoms. These include, to different extent of intensity and reversibility, 
wheezing, cough early in the morning, tightness of chest, waking up with cough, and 
attacks of asthma. 
IgE also plays a role in the manifestation of asthma. The development of atopy is 
associated with an increased persistence and severity of asthma. Atopy is defined as an 
abnormally high production of IgE making individuals susceptible to develop allergic 
reaction to several environmental factors. This alteration in the production of IgE has 
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been considered an important component of asthma, as it is present in a large number 
of asthmatic subjects [55]. 
2.4 ASSESSMENT OF LUNG FUNMON AND AIRWAYS OBSTRUCTION. 
2.4.1 Lung function and its measurement 
Lung function can be measured using spirometry. Trained professionals, who need 
patient co-operation to produce a valid result, usually carry them out [561. 
The volume of air expired with each normal respiration constitutes the tidal volume 
(Vt), and can be reduced in painful or limiting processes of the bones or muscles 
involved in respiration [57]. The volume of air left in the lungs after a normal 
expiration represents the functional residual capacity (FRQ; the volume expired in a 
forced expiration starting at a normal inspiration is the expiratory reserve volume 
(ERV). The volume expired from full inspiration (total lung capacity (TLC)) to full 
expiration (residual volume (RV)) regardless of time, is the vital capacity (VC) [58]. 
Dynamic lung function can be explained as the changes in volume vs. time (flow); the 
volume exhaled from full inspiration to full expiration under forced expiration 
constitutes the forced vital capacity (FVQ [59]. The volume expired in the first second 
of forced expiration is the forced expiratory volume in I second (FEVI). Maximal mid 
expiratory flow (FEF 25-75%) represents the mean flow achieved during the middle of 
the FVC (in forced expiration manoeuvre from full inspiration between 25% and 75% 
of FVQ [60]. FEV, and FEV25-75, and to a lesser extent FVC, are reduced during 
obstruction to airflow. 
2.4.2 Bronchial Responsiveness 
Bronchial responsiveness (BHR) can be defined as the tendency for the airways of 
asthmatic subjects to broncho-constrict when exposed to various chemical and physical 
stimuli [61]. Exposure to stimuli, such as allergens, which are specific for an 
individual, produce a different effect, in that the non-specific stimuli generally cause a 
short-lived period of broncho-constriction without inducing significant airway 
inflammation whilst antigenic stimuli cause more prolonged bronchoconstriction with 
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an immediate response lasting for 1-2 hours that may follow a late response at 4-8 
hours, which is characterised by inflammatory cell recruitment to the airways [62]. 
Various broncho-constrictor stimuli can be used to measure the degree of BHR, 
including inhaled histamine or methacholine, inhaled hypertonic saline or distilled 
water, exercise or cold air [63,64]. 
During obstructive processes, the reduction of FEVI is greater than the reduction of 
FVC and the FEVI/FVC ratio is reduced [65]; conversely, in restrictive lung disease 
the reduction in FVC is greater than in FEVI and the ratio is increased or normal. In 
asthma, peak expiratory flow (PEF) variation is closely related to FEVI and can be used 
to monitor asthmatic episodes and treatment responses [66]. 
The assessment of BHR has been done mainly through challenge with histamine and 
more recently methacholine. The first occurs naturally in humans, while the second is 
artificial. The tests of BHR give a measure of the concentration (PC20) or dose (PD20) 
required to produce a 20% fall in FEVI. When normal individuals are challenged with a 
non-specific stimulus there is usually a small degree of bronchoconstriction but the 
FEVI value reaches a plateau before a 20% fall is achieved [67]. In asthmatics, 
bronchoconstriction typically occurs at a much lower concentration and there is no 
plateau, so that increasing the histamine dose further produces greater 
bronchoconstriction [681. 
Asthmatic subjects generally have a PC20 to methacholine or histamine less than 
8mg/mI while most non-asthmatic subjects have a PC20 greater than 16 mg/ml. There is 
some overlap, and defining an exact level of BHR, which would distinguish asthmatic 
from non-asthmatic subjects is not possible. Evidence suggests that the BHR in 
population exhibits a continuous distribution, in which the majority of asthmatic 
subjects have values in one tail [69]. 
2.5 PREVALENCE OF ASTHMA 
There is a strong body of evidence suggesting that asthma is highly prevalent in many 
countries and it has been increasing during the last decades [70,71]. Its prevalence 
shows large variation across the world, being higher in countries with emerging or 
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advanced economies. The highest prevalence of asthma (> 20%) has been found in 
English speaking countries such as Australia [72], and New Zealand [73], while low 
rates have been reported in Eastern European countries (5-15CIO). Countries with the 
lowest reported prevalence of asthma (< 3%) include South Korea, Russia, Uzbekistan, 
Indonesia and Albania [74]. 
The epidemiological evidence of prevalence in Latin America is scant and comes 
mainly from studies in children [33]. The prevalence of a number of asthma symptoms 
shows variations across the countries. Wheeze in the last 12 months varies from 6.8% 
(Punta Arenas, south of Chile) to 26.0% (Lima, Peru) in children aged 13-14 years old, 
with an overall rate of prevalence of 16.9%. Similarly, variations from 6.6% 
(Argentina) to 28.0% (Peru) have been reported for those ever having asthma, with an 
overall rate of 13.4%. In children aged 6-7 years old wheezing in the last 12 months is 
present in a range of 8.6% (Cuernavaca, Mexico) to 32.1% (Costa Rica). 'Ever had 
asthma' has been found in similar proportions to these other symptoms, with an overall 
rate of 12.4%. 
Some researchers have suggested that that there has been an over-reporting of asthma, 
so the increase in its prevalence is only apparent in developed countries [75,76]. They 
believe that between 1970 and 1990 the labelling of wheezing changed in Britain and 
Australia, source of many papers published [77]. These authors suggested that surveys 
should include objective assessments of asthma, including measurement of lung 
function and BHR, which were introduced into surveys in the 1980s. These arguments 
now seem somewhat weak, as several large surveys have introduced the use of such 
instruments, confirming a high and increasing prevalence in children and young adults 
[71]. 
Conclusion 
Asthma is a complex disease, which affects a large proportion of people worldwide. Its 
prevalence is higher in wealthier and more developed countries. The assessment of 
such prevalence has been obtained from questionnaires to elicit the symptoms that 
could be related to asthma. The inclusion of more objective measurements as indicators 
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of atopy or BHR are useful to increase certainty in the estimates of the prevalence and 
impact of the illness in the community. 
In spite of the increasing efforts to describe the prevalence of asthma through 
standardised instruments in different countries, there is still uncertainty about the extent 
to which the prevalence differ in South American countries in comparison to other 
developing and developed countries. 
The explanations for the magnitude of the prevalence of asthma worldwide are being 
centred in the contribution of several environmental factors. In the next chapter, the 




Dietary antioxidants, fatty acids and asthma 
This chapter summarises the relationship between diet and asthma derived from the 
epidemiological literature. The chapter is divided into three sections that describe the 
molecular roles and the epidemiological evidence by which oxidative stress in general 
and specific antioxidants or nutrients in particular are related to asthma. 
In the first section of the chapter, the mechanisms by which oxidative stress is 
generated, particularly in asthmatic subjects, are described. There are a number of 
endogenous antioxidant defences available to constrain the oxidative damage that is 
generated, which are described in this section jointly with their biological role in the 
lung and potentially in asthma. 
The second section describes the dietary antioxidants and minerals thought to play a 
part in lung function and asthma. The molecular mechanisms by which they may 
prevent or attenuate the oxidative damage caused in asthma are mentioned, followed by 
a literature review of the epidemiological evidence so far accumulated in relation to 
each antioxidant and lung function, and asthma, as obtained from studies looking at 
dietary intake, blood biomarkers of nutrient exposure, and RCT. The data reviewed are 
largely limited to adults, as this was the population investigated in the study for this 
thesis. 
The third part of this chapter defines polyunsaturated fatty acids (PUFA) and their 
possible contribution to the pathogenesis of asthma, describing the biological 
mechanisms by which these nutrients are related to the inflammatory response of 
asthma. The epidemiological evidence obtained from observational studies and RCT is 
presented. Finally, conclusions are drawn from the available epidemiological evidence 
of diet and asthma. 
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3.1 OXIDATIVE STRESS AND DIETARY ANTIOXIDANTS: THE MOLECULAR BASIS 
3.1.1. Reactive oxygen species (ROS) and oxidative stress 
The epithelial lining of the respiratory system is highly vulnerable to oxidative damage, 
as a consequence of its large surface area and its role in gas exchanges and host 
defence [78]. The deleterious effect of oxygen, at least as it relates to free radical 
mechanisms, occurs directly through damaging the structure and functionality of 
cellular lipids, proteins, and nucleic acid or indirectly, through activation of 
inflammatory cells able to create additional free radicals. Existing oxidative stress 
appears to prompt the inflammatory response of asthma and also appears to be 
endogenously generated as a consequence of this response, therefore perpetuating the 
manifestation of inflammation [31,79]. 
Oxidation happens in physiological conditions in all the biological systems, resulting in 
the production of small amounts of ROS [31]. When an imbalance is occurring in 
favour of the amount of ROS produced against the scavengers that contain them, a 
stage of oxidative stress takes place. During the inflammatory-immune response that 
characterises asthma, mast cells (macrophages, eosinophils and monocytes) are 
activated. Once this occurs, these cells are able to release high amounts of ROS, mainly 
hydrogen peroxide (H202), hydroxyl radical (-OH) and superoxide radical (02*-). Under 
conditions of chronic inflammation and tissue damage in the airways, high amounts of 
iron are also released. This metal can react with H202 in a reaction known as Fenton's 
reaction, resulting in the production of -OH [52]. 
Another group of cells that contribute to the propagation of ROS is that of pro- 
inflammatory cytokines activated during the asthmatic response [80J. They. induce the 
production of a group of enzymes involved in the production of nitric oxide (NO), 
whose exaggerated production (as that occurring when inflammation is activated) 
facilitates its reaction with superoxide, resulting in the synthesis of peroxynitrite, a 
powerful oxidant able to react with several proteins and lipids leading to their oxidation 
[81]. 
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The deleterious effects that ROS can generate include oxidation of PUFA, proteins and 
enzymes [82]. ROS are also capable of modulating the expression of a variety of 
immune and inflammatory molecules, perpetuating and exacerbating inflammation. 
PUFA are the molecules most vulnerable to be oxidised due to their large number of 
double binds. Thus, a large number of molecules of lipid peroxides ýCould be produced 
if a single -OH attacks PUFA (located in the membrane cell). The process may 
continue as a chain reaction depending on the level of oxidative stress taking place. The 
peroxidation of PUFA generates the synthesis of pro-inflammatory compounds, thus 
worsening the asthma response [83]. 
The ROS can usually be contained by the action of several biological systems known 
as antioxidants, which act as 'scavengers' in the intra- and extra- cellular space, thus 
protecting the cells from radical-mediated damage. One of them consists of the 
antioxidant enzymes catalase (CAT), superoxide dismutase (SOD) and glutathione 
peroxidase (GSH-Px), which through a sequence of reactions transform ROS into water 
and other non-toxic molecules as final products. Another group is represented by 
antioxidant vitamins and minerals, which can also react with ROS, thus reducing them 
and preventing the damage to vulnerable molecules [3 1 ]. 
3.2 DIETARY ANTIOXIDANTS AND ASTHMA 
There are several antioxidants in the diet that represent the exogenous antioxidant 
defence against oxidative damage. They can be grouped into vitamins, minerals and 
polyphenols. Amongst the first group the most well recognized as antioxidants are: 
vitamin A and its precursors (i. e. (x and P-carotene, lycopene, retinol), found in carrots, 
tomato and dark green leafy vegetables; vitamin C, abundant in citrus fruits; and 
vitamin E (y-tocopherol), abundant in almonds, peanuts, sunflower seeds, and 
vegetable oils. Amongst minerals, selenium, zinc and to a lesser extent magnesium, 
widely distributed in red meat, seafood, dairy products and some vegetables, have been 
described as having antioxidant activity. Flavonoids, a family of polyphenols, are 
widely found in onion, apples, red wine and tea, and have been described as potent 
antioxidants [84]. 
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3.2.1 Vitamins and the experimental evidence 
Antioxidant vitamins are strong scavengers, reducing many of the circulating ROS. 
Vitamin E, a lipophilic molecule is concentrated inside the membranes and in blood 
lipoproteins. Its two main antioxidant actions are its capacity to act as a scavenger of 
-OH, (thus protecting membranes of oxidation) and its ability to act as a chain breaking 
antioxidant, by donating hydrogen to peroxy-radicals, making ROS and lipid peroxides 
less-reactive molecules. In the extra-cellular environment, vitamins C and 0-carotene 
(a precursor of vitamin A) also act as potent scavengers [851. 
These three antioxidant vitamins are directly involved with the prevention of oxidative 
damage in the lung. They are supporters of maintenance of the alveolar -surfactant, 
whose integrity is a deten-ninant of a normal lung function. It is estimated that 
approximately 90% of the alveolar surfactant corresponds to lipids (mainly PUFA and 
cholesterol) that are highly vulnerable to undergo oxidation due to the permanent 
interchange Of 02 and C02 that takes place in the alveolus. According to these 
findings P-carotene, vitamin C and E are closely involved with the prevention of liPid 
peroxidation and tissue damage [86,87]. 
A specific group of alveolar cells, namely type Il cells, are responsible for the synthesis 
of surfactant lipids and of the alveolar surfactant and its assemblage. Vitamin E appears 
to be one of the most important antioxidants at this level, preventing these lipids from 
oxidation. There is evidence that after being recruited by specific receptors from the 
HDL circulating in the interstitial tissue, vitamin E is secreted from type 11 cells jointly 
with the surfactant [86]. 
Vitamin A (retinol) is found in foods of animal origin such as meat, liver, eggs and 
dairy products. Vitamin A plays a central role in the development of respiratory 
epithelium, as it is involved in the synthesis of phospholipids of the alveolar surfactant, 
particularly in newborns [88]. At this stage, this vitamin is essential in the regulation of 
cellular differentiation of the respiratory epithelium and lung epithelium, therefore 
facilitating a normal respiratory epithelia] differentiation, lung function and pulmonary 
immune function in later life [87]. 
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In vitro studies on human lung cells have demonstrated that P-carotene, both separated 
and jointly with vitamins E and C, has antioxidant capacity [89]. This has been 
reflected in a lower production of products of oxidative stress (protein carbonyls and 
isoprostanes) in cells exposed to varying concentrations of vitamins and Of 02 when 
compared to cells that were not exposed to antioxidants [89]. This suggests that a 
deficient amount of these vitamins results in oxidative damage and ultimately in tissue 
damage in the airways. Kelly et A tested this hypothesis in a clinical study carried out 
in mild asthmatic subjects, finding that asthmatics had significantly lower 
concentrations of vitamins C and E in bronchoalveolar lavage compared to healthy 
controls [90]. 
The beneficial relationship between antioxidants and containment of the oxidative 
damage that takes place in the pathophysiology of asthma has motivated an increasing 
interest into whether these associations could be seen in epidemiological studies. 
3.2.2. Vitamins and the epidemiological evidence 
Vitamins C, E, A and P-carotene are the antioxidant vitamins most widely investigated 
in relation to their effect on lung function and asthma symptoms. The epidemiological 
evidence on the association between lung function, symptoms of asthma, BHR and 
atopy is presented for each vitamin, grouping studies according to the respiratory 
outcome studied and to whether vitamins were studied from dietary intake or blood 
levels. 
3.2.2.1 Vitamin C and lungfunction 
The association between dietary intake of vitamin C and lung function has been 
extensively investigated in cross-sectional studies. A summary of their main results is 
presented in Table 3.1. These surveys were large population-based studies in adults, 
that obtained information about dietary intake of vitamin C from self-administered 
dietary questionnaires. Most of them assessed lung function based on net changes in 
FEVI and FVC, the exception being Schunemann et al. who analysed these outcomes 
as percentages of predicted values [9 1 ]. 
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In 1995, Britton et A reported a positive association between aI SD increase in intake 
of vitamin C and greater FEVI and FVC in a sample of 2,633 adults from Nottingham 
[92]. A9 years follow-up in -these adults carried out by McKeever et A reported that a 
higher average intake of vitamin C was related to a 50.8 (95% CI 3.8 to 97.7) smaller 
decrease of FEVI during that period. The authors confirmed the previous cross- 
sectional observation of a greater FEVI associated to a higher intake of vitamin C 
[93)(Table 3.1). These results are in keeping with those of the MORGEN study, a large 
cross-sectional survey of the prevalence of risk factors for chronic diseases, carried out 
in 6,555 adults aged 20 to 59 years from The Netherlands. The intake of vitamin C was 
in average well above recommended values in this population, and was associated with 
a greater FEVI and FVC when comparing the 90'h versus the I 01h percentile of intake 
[94]. 
Chcn et al. assessed the relation between waist circumference, lung function and 
dietary intake of antioxidants in 1,804 men and women separately [95]. They reported 
a statistically significant greater FEVI in men but not in women with increasing intake 
of vitamin C, the effect size being half in women compared to that of men in the single 
linear regression (Table 3.1). In both groups, lung function showed a statistically 
significant negative association with waist circumference, possibly explained on the 
grounds that a large waist circumference could affect the movement of the diaphragm 
and the chest wall. In the multivariable model, where other antioxidants and waist 
circumference were added as potential confounders, the association between FEVI and 
vitamin C only remained in men. The authors hypothesised that the fact that energy 
was a strong predictor of lung function in women but no in men, and the higher vitamin 
C observed in women, could have partly explained the lack of association found in 
women. 
Another cross-sectional study that included a sample of 1,616 Caucasian and Afro 
American adults, reported than FEVI% and FVC values were greater with higher 
quartiles of vitamin C intake. The multivariable analyses showed that vitamin C was 
positively associated with both FEVI% and FVC when added separately, but not 
simultaneously with vitamin E and several carotenoids [91]. Similarly, Hu and 
colleagues [96] reported that adults from the Third National Health and Nutrition 
Examination Survey (NHANES) had a small but not statistically significant increase in 
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FEVI as the intake of vitamin C increased, which disappeared when this antioxidant 
was simultaneously included with vitamin E and carotene in the multivariable model 
(Table 3.1). 
Table 3.1: Association between dietary intake of vitamin C and lung function in 
adults in cross- sectional studies 
First Intake Outcome measurement Difference observed in Adjustment 
Author analysed of lung function n-d (95% CI) except* 
Britton J [921 1 SD increase FEVI 25 (5.2 to 44.8) Age, sex, height, mean 
in intake FVC 23.3 (0.9 to 45.7) allergen skin wheal 
diameter, and pack- 
years smoking history 
Grievink L go,, vs. 1011 FEVI 52.9 (23.0 to 82.3) 
2 Age, age , sex, smoking [94] percentile of FVC 79.0 (42.3 to H 5.7) status, pack years of 
intake smoking, and TEI 
McKeever TM 100 mg /day Cross-sectional study: Age, age 2, height sex, 
[93] intake increase FEVI 66.8 (12.2 to 121.4) BMI, atopy, TEI, 
smoking and social 
class 
Chen R [95] 100 mg intake Men Age, height, weight, 
increase FEV, 10.2 (0.8 to 19.6) working status, TEI, 
FVC 7.4 (4.0 to 18.0) smoking pack years, 
Women and serum cotinine, 
FEVI - 1.9 (4.0 to 7.8) 
waist circumference, 
FVC -0.4 (-6.0 to 7.0) 
and vitamin E, retinol 
and P-carotene. 
Schunemann I SD increase Smoking status, total 
HJ [91 in intake FEVI%* 1.04 (0.18 to 1.90) pack-years of smoking, 
FVC%* 0.85 (0.03 to 1.66) weight, education, - 
eosinophil count, and 
FEVI%* 0.40 (-0.62 to 1.41) TEI 
FVC%* -0.24 (-1.21 to 0.72) All above + vitamin E 
and carotenoids 
Hu G [96] 1 SD increase Age, age 2, sex, height, 
in intake 9.5 (-0.2 to 19.2) race, BMI, income, 
FEVI smoking, and TEI 
(vitamin C as only 
nutrient in the model) 
-3.0 (-15.5 to 9.4) All above + vitamin E 
and carotene 
Tabak C [97] Above vs. FEVI: Age, height, smoking, 
below median Finland 5.0 (-76.0 to 85.0) BMI, alcohol 
intake Italy 10.0 (-6 1.0 to 8 1.0) consumption, and TEI 
The Netherlands 7.0 (-8 1.0 to 94.0) 
Butland B I SD increase FEV, 26.2 (-2.0 to 54.4) Age, height, age 2 
2 [100] in intake height , BMI, smoking history, social class, 
work exercise and 
leisure exercise, and 
TEI 
Hu G [98] 100 mg intake FEVI 21.6 (-0.4 to 43.5) Sex, age, height, 
increase FVC 24.9 (0.2 to 49.6) weight, TEI, tobacco 
smoking, and education 
Dow L [99] 100 mg intake FEVI 0.07 (41 to 0.3) Age, sex, height, 
increase FVC 0.1 (40 1 to 0.3) cuffent/ex-smoker, and 
I I TEI 
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The evidence on the possible benefit of dietary vitamin C on lung function is 
contentious, as the findings of greater FEVI or FVC related to a higher intake of 
vitamin C have not been confirmed in at least four large cross-sectional studies. These 
describe different levels of intake, and different adjustments for potential confounders, 
showing some, but statistically and biologically weak indication of a greater lung 
function with higher intakes of vitamin C. Tabak and colleagues found no statistically 
significant increase in FEVI in men from Finland, Italy and The Netherlands when 
comparing those above versus below the median intake, after controlling for several 
potential confounders including BMI, smoking, alcohol and energy intake [97]. 
Butland et al. found that FEVI was positively associated with vitamin C in a sample of 
2,136 men aged 45 to 59 years old before, but not after controlling for social class, and 
TEL Adults from rural China have shown an association between FVC but not FEVI 
and dietary intake of vitamin C [98], while in individuals aged 65 or over it has been 
observed a very small size effect in the intake of this vitamin and measurements of lung 
function [99] (Table 3.1). 
Most of the available evidence on the relation between serum and plasma levels of 
vitamin C with lung function is suggestive of a positive association (Table 3.2). Two 
large cross-sectional studies, one from Scottish adults [ 10 1] and the other on American 
adults from the NHANES III survey [96], have reported a statistically significant 
positive association between FEVI and plasma [101] and serum [101] levels of vitamin 
C. In the NHANES III the authors found that after controlling for vitamins E and A, 
and selenium in the multivariable analyses, the effect size was smaller but still 
statistically significant. 
Schunemann et al. found that aI SD increase in vitamin C was positively and 
statistically significantly related to FEVI%. They also reported some increase in FVC% 
but this did not reach statistical significance [102]. Ness and colleagues found that 
higher plasma levels of vitamin C were associated with a greater FEV, in men but not 
in women selected from the European Prospective Investigation into Cancer (EPIC) 
[103] (Table 3.2). 
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Table 3.2: Association between blood levels of vitamin C and lung function in 
cross-sectional studies 
First author Blood level Outcome Difference observed in Adjustment 
compared measurement nil (95% CI) except 
of lung function 
Kelly Y [101] Increase of I FEVI 49.0 (13.0 to 85.0) Age, height, age 2 
SD (as Z height2 , BMI, sex, 
score) in smoking, social 
plasma levels class, activity 
level, and other 
plasma analytes 
(vitamins A, E and 
P-carotene) 
Hu G [96] Increase of I FEVI 28.1 (18.7 to 37.6) Height, sex, age, 
SD in serum race, BMI, income, 
level and smoking 
(vitamin C as only 
nutrient in the 
model) 
16.6 (7.3 to 26.0) All above + 
vitamins E and A, 
and selenium 
included in model 
simultaneously 
Schunemann HJ I SD FEV1% 0.77 (0.01 to 1.53)* Weight, blood 
[1021 increase in FVC% 0.49 (-0.24 to 1.22)* eosinophils count, 





Ness AR [103] Increase in Men 
50[tmol/L FEVI 22.0 (10.0 to 33.0) Age, height and 
FVC 23.0 (9.0 to 37.0) packet years of 
Women cigarette smoking 
FEVI 4.0 (-2.0 to 10.0) 
FVC 6.0(-I. Otol3.0) 
* Results expressed as regression coellicient of the FEV, and FVC as percentages of predicted value 
(95% CI) 
3.2.2.2 Vitamin C and Respiratory Symptoms 
Evidence that vitamin C could be related to asthma was initially reported by Puglisi in 
the 1970s after a experimental model in guinea pigs demonstrated that insufficient 
intake of a fon-n. of vitamin C, L-ascorbic acid, led to a higher contraction of the trachea 
explained by a reduction of PGE2 and increased formation of PGF2,, [104]. One of the 
earliest clinical studies examining the relation between vitamin C and asthma was 
conducted by Olusi et A, who reported that adults with untreated and salbutamol- 
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treated asthma had significantly lower levels of plasma concentration of vitamin C 
when compared to controls [105]. 
Table 3.3 summarizes the current evidence of association between asthma, BHR and 
atopy, with dietary intake of vitamin C. These results come largely from cross-sectional 
[94,106-108], case-control studies [109-113] and one longitudinal study [1141. 
Grievink and colleagues assessed the association between several respiratory outcomes 
and intake of vitamin C in Dutch adults. They found that cough was the symptom for 
which a statistically significant association was reported in those in the 90'h percentile 
of vitamin C intake compared to those in the IO'h percentile. For the other four 
symptoms there was a lack of association [94]. 
A study on adult Norwegians found that those in the highest tertile of intake per week 
had a lower prevalence of morning cough, but such intake was unrelated to other four 
respiratory symptoms, including chest tightness and asthma attack when the whole 
population was included in the multivariable analyses (Table 3.3). When stratifying by 
smoking (current/ex/never smoker), current smokers tended to have a lower prevalence 
of morning cough and chronic cough, while ex smoker in the highest tertile of vitamin 
C intake had a lower prevalence of wheeze (OR 0.56; 95% CI 0.35-0.88) [107]. 
Other two cross-sectional studies and one longitudinal survey have found a lack of 
association between prevalence of asthma, BHR, and atopy [106], wheezing in the last 
12 months [ 108], and incidence of asthma [ 114]. Schwartz and colleagues examined 
the relation between several respiratory symptoms and dietary intake of vitamin C, 
bronchitis being the only symptom negatively associated with vitamin C after 
controlling for potential confounders [108]. Troisi et al. reported a statistically 
significant negative association between incidence of asthma in women only when 
intake of vitamin C included consumption of supplements [114] (Table 3.3). 
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Table 3.3: Association between dietary intake of vitamin C and symptoms of 
asthma, BHR or atopy in adults 
First Typeof Dietary intake Respiratory outcome OR (95% confidence 
author study compared interval) 
[Adjusted for], except* 
Grievink L Cross- gy, vs. 1011 -Cough 0.66 (0.50 to 0.87) 
[941 sectional percentile -Phlegm 0.77 (0.59 to 1.02) 
6,555 adults -Productive cough 1.09 (0.93 to 1.28) 
The -Wheeze 1.04 (0.83 to 1.30) Netherlands 
-Shortness of breath 0.81 (0.61 to 1.07) 
[Age, sex, smoking status, 
pack years of smoking, and 
energy intake] 
Omenaas E Cross- Highest vs. -Morning cough 0.70 (0.55 to 0.90) 
[1071 sectional lowest tertile of -Chronic cough 0.76 (0.52 to 1.01) 
3,450 adults intake -Wheeze in the last 12 0.86 (0.67 to 1.12) 
Norway (mg/week) months 
-Breathless at night 0.93 (0.59 to 1.5 1 
-Chest tightness 1.13 (0.81 to 1.56) 
-Asthma attack 1.47 (0.76 to 2.77) 
[Age, sex, BMI, occupational 
exposure, and smoking habits] 
Woods RK Cross- Increase per -Current asthma 0.93 (0.65 to 1.32) 
[1061 sectional mg/day -Asthma 1.19 (0.88 to 1.60) 
1,601 adults -BHR 0.96 (0.71 to 1.3 1) 
Australia -Atopy 0.97 (0.74 to 1.27) 
[Age, sex, smoking, BMI, 
region of birth, family history 
of asthma, and TEI] 
Schwartz J Cross- 2 SD change in -Bronchitis 0.70 (0.54 to 0.92) 
[1081 sectional intake [Age, sex, race, pack-years of 
9,074 adults cigarette smoking, family 
USA income, and TEII 
Troisi RJ Prospective Highest vs. -Incidence of asthma 1.69 (1.28 to 2.23) 
[114] cohort lowest quintile (RR including vitamin [Age, smoking, BMI, area of 
(Over a 10- C supplements) residence, quintiles of energy 
yr period) intake, vitamin C and E 
77,866 simultaneously (including 
women supplements)] 
-Incidence of asthma 
USA (RR excluding vitamin 1.11 (0.69 to 1.77) 
C supplements) [Age, smoking, BMI, area of 
residence, quintiles of energy 
intake, vitamin C and E 
simultaneously (excluding 
supplements)] 
JýCurrent asthma defined as having wheeze in the last 12 months and BHR. "Asthma" defined as 
answering 'yes' to the questions 'Have you had an attack of asthma in the last 12 months?, 'Have you 
been woken by an attack of shortness of breath any time in the last12 monthsT, or 'Are you currently 
taking any medicine for asthma?. 
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Continuation Table 3.3 
First Type of study Dietary intake Respiratory OR (95% confidence 
author compared outcome interval) 
[Adjusted for] except* 
Bodner C Nested case- Lowest vs. -Wheezing 
[109] control (30- highest tertile 1.45 (0.71 to 2.97) 
years follow [Smoking habit, atopy, family 
up) history, social class, sex, and 
94 cases/ 203 TEII 
controls 
Scotland 
Shaheen S Case-control Highest vs. -Asthma 0.92 (0.64 to 1.34) 
[110] 607 cases/864 lowest quintile (Defined according [Age, sex, BMI, social class, 
controls to questions from housing tenure, employment 
England ECRHS) status, whether a single 
parent, smoking, passive 
smoke exposure at home, and 
TEII 
Soutar A Case-control Lowest vs. -History of seasonal 0.95 (0.32 to 2.77) 
[111] 51 cases/38 highest tertile symptoms [Age, sex, and smoking] 
controls (Included allergy, 
atopy, eczema, 
Reactors/Non diagnose of asthma) 
reactors to 7.13 (1.91 to 26.7 1) 
BHR=29/58 -Positive response [Age, sex, and smoking] Scotland to BHR 
Picado C Case-control *Mean intake -Severity of asthma 152.0 (74.0) vs. 177.0 (76.0); 
[1121 118 cases/l 21 in those with (Established (P>0.05) 
controls severity 4 according to GINA) [Energy intake, sex, and age] 
Spain compared to I 1= intermittent 
4= severe 
De Luis Case-control *Mean intake -Allergenic asthma 93.1 (63.9) vs. ] 24.0 (70.0); 
[1131 54 cases /54 (SD) in cases (regular follow up p<0.05 
controls vs. controls patients) [No adjustments] 
Spain I I I I 
Case-control studies have shown no association when dietary intake of vitamin C in 
cases with wheezing [ 109], asthma [I 10], seasonal symptoms [III], severity of asthma 
[ 112], and allergenic asthma [ 1131 has been compared to healthy controls. In a sub- 
sample, Soutar and colleagues reported than those cases with positive response to BHR 
were more likely to have a low intake of vitamin C [I I I] (Table 3.3). 
As presented in Table 3.4, at present there are a number of cross-sectional and case- 
control studies that have examined the relation between vitamin C in blood and 
respiratory symptoms. A large cross-sectional American study reported that those 
having a 2SD higher plasma concentration of vitamin C were at lower risk of having 
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wheeze and bronchitis [108]. Contrary, Kelly and colleagues found no association 
between several respiratory symptoms and plasma vitamin C when adults were asked 
abut wheezing attacks with shortness of breath and another two respiratory symptoms 
[101]. 
Table 3.4: Association between blood levels of vitamin C and asthma symptoms or 
atopy in adults 
First Typeof Level of vitamin Respiratory Mean differences, 
author study C compared outcome except* [Adjustment] 
Schwartz J Cross- 2 SD change in -Bronchitis 0.65 (0.48 to 0.88) 
[108] sectional serum level -Wheezinc, cp 0.56 (0.46 to 0.67) 9,017 adults *OR (95% Cl) [Age, sex, race, pack- 
USA years of cigarette 
smoking, family income] 
Kelly Y Cross- I SD (Z score) -Phlegm in the 1.02 (0.84 to 1.25) 
[101) sectional change in plasma morning in winter 
7,932 adults level -Phlegm 2t 3 0.94 (0.74 to 1.20) 
Scotland *OR (95% Cl) months/year 
-Wheezing attacks C, 1.02 (0.84 to 1.24) 
with shortness of 
breath [Adjusted by age, sex, C 
social class, smoking, 
activity level, and other 
plasma analytes (vitamin 
E and A)] 
Ford ES Cross- Mean (SD) serum -Current, former, 34.0 (1.32), 32.9 (2.6), and 
[1151 sectional level in each and never asthma 37.3 (0.82); p>0.05 [No 
16,541 adults group adjustments] 
USA -Mild, moderate, 
severe asthma 41.1 (1.77), 41.2 (3.1), and 
39.6 (3.1); p>0.05 
[Age, sex, race, education, 
smoking status, cotinine, 
non-high-density 
lipoprotein, HDL, BMI, 
physical activity, alcohol 
consumption] 
Mainous A Cross- Mean (SD) serum Number of 0 42.6± 25.0 pM /L 
[1161 sectional level of vitamin C ambulatory visits 1 43.2± 28.4gM /L 
19,760 adults for wheezing in last >1 42.6± 27.8 gM /L 
USA 12 months (p= 0.95) 
McKeever Cross- 1 SD difference Skin allergen 0.98 (0.92 to 1.04) 
TM [117] sectional in serum level sensitization [Age, sex, smoking status, 
5,858 adults BMI, poverty, race/ethnicity, 
USA total cholesterol, and tryglicerides] 
Vural H Case-control Mean (SD) serum -Bronchial asthma 36.9 (12.5) vs. 53.4 (13.1) 
[1181 40 cases/43 level (pM/L) in (P<0.001) 
healthy each group 
controls 
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Three groups investigated prevalence of asthma [ 1151, number of ambulatory visits to 
healthcare units as consequence of episodes of wheeze in the last 12 months [116], and 
allergen sensitisation [117], and their association with serum levels of vitamin C in the 
participants of the NHANES 111. They found no evidence for an association with any of 
the outcomes studied (Table 3.4). 
Vural et A reported that individuals with asthma had significantly lower serum levels 
of vitamin C when compared to healthy controls [118]. 
Overall, this epidemiological evidence suggests that vitamin C may be related to a 
greater lung function as gathered from studies on its blood level but the evidence from 
dietary intake is suggestive of a lack of association. Regarding symptoms of asthma, 
the results from case-control studies and some cross-sectional studies suggest that there 
is no association between intake of this vitamin with several symptoms of asthma, 
while the studies on blood levels of vitamin C report mixing results to strengthen a 
more definitive role of the vitamin in asthma. 
3.2.2.3 Vitamits E and Lung Function 
Table 3.5 summarises the differences in FEVI and FVC according to vitamin E intake 
in adults. A large cross-sectional study based on a cohort of men aged 50-64 years 
(n=2,519) from Finland, Italy and The Netherlands, assessed dietary intake of 
antioxidant vitamins C, E and A and fruits and vegetables. They reported a positive 
significant association between intake of vitamin E and a greater FEVI in men from 
Finland when controlling for age, height, smoking, BMI, and alcohol consumption. 
After subsequent adjustment for energy intake, FEV, was not associated with intake of 
vitamin E in any of the countries [97]. The MORGEN study found that intake of 
vitamin E in this population was not associated with FEVI or FVC (Table 3.5) [94]. 
A cross-sectional analysis by Butland et al. of the association between intake of 
antioxidants and FEVI in 2,136 Welsh men aged 45-59 years old that were part of a 
cohort study showed that intake of vitamin E was associated with maximum FEVI in 
this population. However, such association was present in models that included as 
confounders BMI, age 2, height2 , age, but lost statistical significance when controlled 
for social class and smoking. When energy intake was subsequently added as 
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confounder, the size of the association was restored. These authors also added as 
confounders vitamin C and apple intake, which tended to decrease the size of the 
association slightly but was still significant [100] (Table 3.5). 
Another study in a population of 2,633 adults from UK found that an increase in I SD 
of vitamin E intake was related to a 20. ImI increase in FEVI after adjustment for 
several confounders including smoking but not socio-economic level. In this study, 
after controlling for vitamin C intake, the association between vitamin E and FEVI or 
FVC was no longer observed [92]. These findings are in agreement with those of the 
NHANES study, a large cross-sectional survey, which found that dietary intake of 
vitamin E was associated with a greater FEVI in these adults after adjusting for several 
confounders. However, such association was no longer observed when vitamin C was 
also included in the multivariable analysis [96] (Table 3.5) 
Other two studies have reported a greater lung function in adults with higher intake of 
vitamin E. A cross-sectional study on 1,616 individuals aged 59.6±10.8 years 
examining lung function and intake of specific antioxidants found a statistically 
significant difference in the FEVI% and FVC% in those with the highest quartile intake 
of vitamin E compared to those with the lowest [102]. A study in a sample of 188 
adults found an independent association between intake of vitamin E and FEVI and 
FVC [99] (Table 3.5). 
Studies assessing association between antioxidants in blood and lung function provide 
are shown in Table 3.6. A non-statistically significant increase in FEVI in plasma of 
367 Dutch men and women was reported by Grievink et al. [119]. More recently, in 
another population, Grievink et al. found a greater FEVI in 528 elderly adults with a 
higher serum level of (x-tocopherol but did not reach statistical significance [120]. Hu 
et al. reported that increasing serum levels of vitamin E were statistically significantly 
associated with a greater FEVI in the NHANES III study [96]. These results are in 
keeping with those reported by Schunemann et al. who found a positive association 
between serum levels of vitamin E and FEV1% and FVC% in a sample of 1,616 adults 
[102]. 
Recently, a study on a cohort of workers and residents highly exposed to asbestos in 
Australia looking at serum antioxidants and lung function has been published [121]. 
54 
The study included an average of 5.4 simultaneous (same day) measures of serum 
antioxidants and spirometry over a period of 6 years. The authors found that serum 
levels of vitamin E were positively associated with a greater-FEV, and FVC at the 
entry of the study, but in contrast, it was observed that the increase in serum vitamin E 
was related to an annual decline in lung function in this population. 
Table 3.5: Association between dietary intake of vitamin E and lung function in 
adults in cross-sectional studies 
First author Intake Outcome Difference Adjustment 
analysed measurement of observed in nil 
lung function except* 
(95% CI) 
Tabak C Above VS. FEVI: Age, height, smoking, 
[971 below median Finland 23 (-67 to 1] 2) BMI, alcohol consumption, 
intake Italy -62 (443 to 18) and energy 
intake 
The Netherlands -92 (-189 to 5) 
Grievink L goth percentile FEVI 27.9 (42.9 to 68.7) Age, age 2, sex. energy C 1941 of consumption FVC 18.2 (-32.2 to 68.6) intake, smoking status, and 
vs. I 0'h pack years of smoking 
Butland B FEVI 19.7 (-7.8 to 47.2) Age, height, acye 2, height2, 
[100] Increase per SD BMI, smoking, and social 
class 
FEVI 39.1 (9.4 to 68.8) All above + energy intake 
FEV, 31.7 (0.9 to 62.5) All above + vitamin C and 
apple 
Britton J Increase per SD FEVI 20.1 (1.3 to 40.4) Age, sex, height, mean 
[921 FVC 23.1 (1.0 to 45.0) allergen skin wheal 
diameter, and pack-years 
smoking history 
Dow L [99] 100 mg intake FEV, 4.2 (1.0 to 7.4) Age, sex, height, 
increase FVC 5.3 (1.8 to 8.8) current/ex-smoker, energy 
intake 
Schunemann Highest VS. FEV1% 4.0 (1.0 to 6.9)* Smoking status, total pack- 
HJ [91 lowest quartile FVC% 3.4 (0.6 to 6.2)* years of smoking, weight, 
education, eosinophil 
count, total daily energy 
intake 
Hu G [961 Increase per SD FEVI 
- Nutrient alone 16.4 (5.5 to 27.4) Height, sex, age, age 
2, race 
in the model BMI, income, smoking, 
TEL total fat intake 
- Nutrient 113 (4.4 to 24.5) 
included 
simultaneously 
with vitamin C 
and carotene 
w Kcsults expressed as dillcrence in FEV 117b and FVC17c of predicted values 
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Table 3.6: Association between blood levels of vitamin E and lung function in 
adults in cross-sectional studies 
First Blood level Outcome Difference observed Adjustment 
author analysed measurement of in n-d except 
lung function (95% CI) 
Grievink L 901h percentile FEVI 23.2 (-91.3 to 137.7) Age, sex, height, 
119] VS. I 01h in FVC 35.6 (411.2 to 182.4) smoking, alcohol 
plasma consumption 
Grievink L 5 1h VS. FEVI 94 (-63 to 25 1 Age, height, sex, pack- 
[1201 1 slquintile in years of smoking 
serum 
Hu G [96] Increase in I FEVI 49.1 (37.4 to 60.7) Age, height, sex, race, 
SD in serum BMI, income, smoking, 
serum triglycerides and 
total cholesterol 
Schunemann Increase in I FEV1% 1.12 (0.34 to 1.90) * Weight, blood 
HJ [102] SD in serum cosinophils count, 
FVC% 1.66 (0.91 to 2.4 1) * education, smoking 
status, cumulative 
tobacco smoke exposure. 
Alfonso S Highest vs. Levels at entry of Age, sex, height, 
[1211 lowest study 35.9 (8.1 to 63.7) asbestos exposure and 




-7.9 (4.3 to - 1.6) FEVI 13.9 (-21.9 to -6.0) FVC 
* Results expressed as regression coefficient (95% Cl) 
3.2.2.4 Vitamin E and respiratory symptoms, BHR and atopy 
Several studies have explored the association bet%ýýen vitamin E and respiratory 
symptoms (Table 3.7). Four case-control studies failed to find any beneficial 
association between dietary intake of this vitamin and wheezing [ 109], asthma [I 10], 
seasonal symptoms [111], and severity of asthma [112]. Similarly, a large cross- 
sectional study in 6,555 Dutch adults found no association between the highest 
percentile of intake of vitamin E and any of five respiratory symptoms [941. 
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Table 3.7: Association between dietary intake of vitamin E and asthma symptoms, 
atopy or BHR in adults 
First Type of Level of Respiratory outcome OR (95% Cl) 
author study vitamin E [Adjusted for], except* 
compared 
Grievink L Cross-sectional 9Yhpercentile -Cough 0.85 (0.61 to 1.18) [94] 6,555 adults vs. 10, -Phlegm 1.06 (0.76 to 1.47) 
The Netherlands -Productive cough 1.26 (1.02 to 1.56) 
-Wheeze 1.13 (0.85 to 1.52) 
-Shortness of breath 1.24 (0.87 to 1.77) 
[Age, sex, TEI, smoking status, 
and pack years of smoking] 
Woods RK Cross-sectional Increase per ing -Current asthma 0.89 (0.43 to 1.85) 11061 1,601 adults -Asthma 0.62 (0.33 to 1.15) 
Australia -BHR 1.26 (0.67 to 2.38) 
-Atopy 1.01 (0.58 to 1.77) 
[Age, sex, smoking, BMI, region 
of birth, family history of 
asthma, and TEI] 
Fogarty A Cross-sectional Increase per mg -Atopy 0.95 (0.92 to 0.99) [1221 2,633 adults [Age, sex, and smoking] 
England 
Troisi RJ Prospective Highest vs. -Incidence of asthma (RR including 0.83 (0.64 to 1.08) [114] cohort lowest quintile use of vitamin E supplements) [Age, smoking, BMI, area of 
77,866 women of intake residence, quintiles of energy 
USA intake, vitamin C and E 
simultaneously (including 
supplements)] 
-Incidence of asthma 
(RR including only vitamin E from 0.53 (0.33 to 0.86) diet) 
[Age, smoking, BM I, area of 
residence, quintiles of TEI, 
vitamin C and E simultaneously 
(excluding supplements)] 
Bodner C Nested case- Low vs. highest -Wheezing 1.93 (0.79 to 4.72) [109] control (30- tertilc [Smoking habit, atopy, family 
years follow up) history, social class, sex, and 
94 cases/ 203 TEU 
controls 
Scotland 
Shaheen S Case-control Highest vs. -Asthma 0.76 (0.48 to 1.20) 
1110] 607 cases/864 lowest quintile (Using questions from ECRHS) [Age, sex, BMI, social class, 
controls housing tenure, employment 
England status, whether a single parent, 
smoking, passive smoke 
exposure at home, and TEII 
Soutar A Case-control Low vs. high -History of seasonal symptoms 1.50 (0.51 to 4.4 1) [111] 51 cases/38 tertile (Included allergy, atopy, eczema, [Age, sex, and smoking] 
controls diagnose of asthma) 
Reactors/non- 
reactors to -Reactors to BHR vs. non-reactor 1.89 (0.59 to 6.11) BHR=29/58 
Scotland [Age, sex, and smoking] 
Picado C Case-control *Mean intake -Severity of asthma 6.4 (2.1) vs. 7.6 (1.8); p>0.05 [1121 118 cases/I 21 (SD) in those (Established according to GINA) I= (Age, sex, and TEU 
controls with severity 4 intermittent 
Spain compared to 1 4= severe 




Woods et A reported lack of association between higher levels of vitamin E intake 
with current asthma, asthma ever, and BHR in a cross-sectional study [106]. A large 
prospective cohort study in women reported that a higher intake of vitamin E 
(excluding or including supplement intake) was associated with a lower risk of 
incidence of asthma over a period of 10 years [ 114] (Table 3.7). 
In relation to atopy, two cross-sectional surveys have reported different findings. 
Woods et al. found no association between atopy and increase per mg of dietary intake 
of vitamin E in a sample of 1,601 Australian adults, with a prevalence of atopy of 
62.8% defined as a 2: 3mm wheal diameter in response to any out of eight allergens 
[1061. Contrary, Fogarty et al. reported a reduction in the risk of being atopic as daily 
intake of vitamin E increased in a sample of 2,633 adults from Nottingham. They 
defined atopy as a 2: Imm wheal diameter in response to any of three allergens. This 
study also found that intake of vitamin E was independently associated with a reduction 
in the serum levels of IgE, and they suggested that atopic responses mediated by IgE 
might be reduced by the effect of vitamin E[ 122]. 
Evidence of association between asthma symptoms and blood levels of vitamin E is 
presented in Table 3.8. A large cross-sectional study on Scottish individuals aged 16 to 
64 years found a negative association of statistical significance between aI SD change 
in plasma vitamin E and phlegm in morning in winter in the multivariable analysis, but 
found no association with the other two respiratory symptoms studied [101] (Table 
3.8). 
Another two cross-sectional studies on adults recruited from the Third National Health 
and Nutrition Examination Survey (NHANES III) and studied serum levels of vitamin 
E in relation to atopy [ 117] and asthma prevalence and severity [ 115]. In the first, 
McKeever et al. found that serum vitamin E was statistically significantly associated 
with positive sensitisation in a sample of over 5,000 adults of whom 57.6% had a 
positive response to any of ten skin prick tested allergens. However, they did not find it 
in a sample of over 4,000 children analysed in parallel, with a similar prevalence of 
atopy [117]. The study by Ford et al. assessed whether serum vitamin E in adults was 
related to self-reported current doctor-diagnosed asthma or former asthma (answering 
no to the question 'Do you still have asthma'? ), as well as to severity. Vitamin E levels 
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were similar in all the groups compared (Table 3.8) and were not related to prevalence 
of asthma or its severity in the multiple linear regressions (data not shown in the paper) 
[1151. 
Table 3.8: Association between blood levels of vitamin E and asthma symptoms or 
atopy in adults 
First Type of study Level of vitamin Respiratory OR (95% Q 
author E compared outcome [adjustment] except* 
Kelly Y Cross-sectional I SD score (Z - Phlegm in the 0.80 (0.65 to 0.99) 
[101] 7,932 adults score) change in morning in winter 
Scotland plasma 
concentration - Wheezing attacks 0.93 (0.77 to 1.13) 
with shortness of 
breath 
- Phlegm 2: 3 0.87 (0.68 to 1.11) 
months per year [All three analyses adjusted 
for age, social class of head 
of household, smoking C, 
status, activity level, and 
vitamin A and Q 
McKeever Cross-scctional I SD difference Skin allergen 0.93 (0.87 to 0.99) 
TM [ 1171 5,858 adults in serum level sensitization [Age, sex, smoking status, 
USA BM I, poverty, race/ethnicity, 
total cholesterol, and 
trygliccrides] 
Ford Cross-sectional *Mean (SD) of -Current, former, 24.3 (0.38), 27.3 (1.72), and 
[1151 16,541 adults serum level in and never asthma 24.4 (0.19); p>0.05 
USA each group [unadjusted] 
-Mild, moderate, 
severe asthma 28.2 (0.95), 27.3 (1.23), 
25.9 (1.11); p>0.05 
[Age, sex, race, education, 
smoking status, cotinine, 
non-high-density 
lipoprotein, HDL, BMI, 
physical activity, alcohol 
consumption] 
Bodner C Nested case- I unit increase in Current wheezing 1.03 (0.99 to 1.07) 
[1091 control (30- plasma [Age, sex, smoking habit, 
years follow concentration atopy, family history, and 
up) social class] 
86 cases/ 194 
controls 
Scotland 
Gazdik F Case-control *Median (IQR) - Mild to moderate 24.1 (19.8 to 30.5) vs. 33.2 
[1231 56 cases/25 plasma persistent asthma as (28.25 to 38.05) 
controls concentration in defined by GINA p=0.006 
Slovak cases vs. controls vs. healthy controls. 
Republic (gm/L) 
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Evidence from a case-control study in Scotland found that plasma concentration of 
vitamin E was unrelated to current wheezing. They found no association between 
vitamin E and prevalence of current wheezing when analyses included all 86 cases 
(those having responded yes to the question 'Have you had an attack of wheezing after 
the age of 15 yearsT, or those with current wheezing were considered as cases (n=59) 
[109]. A smaller clinical case-control study assessing levels of the antioxidant 
coenzyme Q10 in asthmatics, also measured a number of antioxidant nutrients, and 
reported no differences between levels of vitamin E in plasma in those with mild to 
moderate persistent asthma versus healthy controls [ 123]. 
Overafl, the evidence for an association between vitamin E seems to suggest some 
consistent beneficial association between lung function and dietary vitamin E. Such an 
association did not occur between lung function and blood vitamin E level. There is 
lack of supportive evidence for an association between dietary intake or blood levels of 
vitamin E and asthma. Evidence for an association between atopy and dietary intake of 
blood levels of vitamin E is still limited and inconsistent. 
3.2.2.5 Vitamin A and lungfunction 
Intake of P-carotene was positively associated with better lung function in several 
studies. In a cohort study on men from three countries, Tabak et A found a positive 
association between intake of P-carotene and FEVI in those from The Netherlands, but 
not in the men from Italy and Finland [97]. In agreement with these findings, a positive 
association was found in a sample of Dutch adults aged 20-59 [94]. Butland et aL also 
reported a positive association but it disappeared after controlling for smoking history 
in Welshmen of a similar range of age [100] (Table 3.9). 
Observational studies assessing the association between blood levels of carotenoids and 
lung function offer further support to a possible protective effect of these antioxidants 
in respiratory health. Two cross-sectional studies in Dutch adult [1191 and elderly 
population [1201 reported that plasma and serum levels of several carotenoids were 
related to a greater lung function (Table 3.10). This positive association was also 
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confirmed by Hu and colleagues in adults from the NHANES III survey [961, but not 
by others [ 10 1 ]. 
Table 3.9: Association between dietary intake of vitamin A and its precursors and 
lung function in adults 
First Intake Outcome Difference Adjustment 
Author analysed measurement observed in ml 
of lung function (95% CI) except* 
Tabak C Above vs. FEVI: Age, height, smoking, 
[971 below Finland - 15.8 (-35.5 to 3.9) 
BMI, alcohol 
median Italy 1.1 (-55.6 to 57.9) consumption, and 
TEI 
intake 
P-carotene The Netherlands 141.1 (27.4 to 254.7) 
Grievink L 901h VS. I oth FEVI 60.0 (31.4 to 88.6) Age, age 2, sex, 
[94] percentile of FVC 75.2 (40.2 to 110.2) smoking status, pack 
intake years of smoking, and 
P-carotene TEI 
Butland B I SD FEVI 14.1 (-13.9 to 42.1 Age, height, age 2 
[100] increase in height2 , BMI, smoking 
intake history, social class, 
P-carotene work exercise and 
leisure exercise, and 
TEI 
Hu G [96] 1 SD Age, age 2, sex, height, 
increase in 18.2 (8.7 to 27.6) race, BMI, income, 
intake smoking, and TEI FEVI (vitamin C as only 
nutrient in the model) P-carotene 
16.1 (4.2 to 28.1 All above + vitamin E 
and carotene 
A cross-sectional study on American adults looked at the association between blood 
levels of six different carotenoids (including P-carotene) and FEVI% and FVC%, 
finding a positive association onlY with lutein, a carotenoid with lower antioxidant 
capacity than P-carotene. An increase in both spirometric measurements was observed 
as the intake lutein increased (difference between highest vs. lowest quartile 2.8%, 
p=0.016 and 4.4%, p<0.001, respectively) [911. Finally, Chewers and colleagues 
reported that higher serum levels of P-carotene and to a lesser extent retinol, were 
positively related to a greater lung function in a population of adults exposed to high 
levels of asbestos [ 124] (Table 3.10). 
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Table 3.10: Association between lung function and blood levels of vitamin A 
(retinol) or its precursors 
First Blood level Outcome Main results Adjustment 
author compared of lung 
function 
Grievink L Plasma level Age, height, 
[119] difference (gmol/L) FEVI b-- 73.0 (59.9) sex, pack-years 
between the 9Uh vs. FVC b--147.4 (75.6) of smoking, and 
the 10'h percentile of alcohol 
0-carotene consumption 
Grievink L Highest vs. lowest Age, height, 
[1201 serum quintile Difference in FEVI: sex, and pack- 
(gmol/L): years of 
-Total carotenoids FEVI 210 (56 to 365) (p=0.004) smoking a-- 
-a-carotene 257 (99 to 414) (p=0.02) 
-0-carotene 195 (40 to 35 1) (p=0.0 1) 
-Lycopene 171 (16 to 325) (p=0.004) 
Hu G [96] 1 SD increase in Difference in FEVI: Height, sex, 
serum level (gg/dL) FEVI 27.5 (16.1 to 39.0) age, race, BMI, 





Kelly Y I SD(limol/L) change Difference in FEVI: Age, social 
[1011 in plasma level of- class, smoking 
Vitamin A FEVI 22 (44 to 58) status, activity 
0-carotene 11 (-23 to 45) level and other 
plasma analytes 
Schunemann 1 SD (jig/mL) serum FEVI% FVC% Weight, blood 
HJ [102] levelchange: cosinophil 
FEVI% count, 
-0-cryptoxanthin FVC% b-- 1.52 (0.4 1) b=1.63 (0.39) education, 
-Lutein/zeaxanthin b--0.90 (0.39) b--1.38 (0.38) smokinc, status. 
-0-carotene b--0.67 (0.40) b--1.02 (0.38) 
-Lycopene b=0.21 (0.39) b=0.08 (0.37) 
-Retinol b=0.92 (0.39) 1 b=0.66 (0.37) 
Chuwers P 75"' vs. 25'h percentile Asbestos 
[124] of serum level exposure, and 
(ng/mL): smoking 
-p-carotene FEVI b=0.06 (0.03) (p<0.05)* FVC b---0.09 (0.04) (p<0.05)* 
-Retinol FEVI b=0.17 (0.09) (p=0.08)* FVC b--0.23 (0-11) (p--0.05)* 
* Results expressed as regression coefficients (standard error) of multiple linear regression 
3.2.2.6 Vitamin A and respiratory symptoms, BHR or atopy 
Almost all the data collected to date from observational studies have shown no 
association between intake of retinol, P-carotene and various respiratory symptoms of 
asthma, BHR and physician-diagnosed asthma [94,106,109,110,112,1141 (Table 
3.11). Some authors have found a positive association between intake of P-carotene 
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and wheeze [94], hay fever [125], as well as a higher intake of retinol in asthmatic 
subjects [ 113]. Woods et a] reported a negative association between retinol intake and 
asthma [ 106] (Table 3.11). 
Table 3.11: Association between dietary intake of vitamin A and carotenoids and 
respiratory symptoms of asthma, BHR or atopy in adults 
First Type of study Level of Respiratory outcome OR (95% CI) 
author vitamin/carotenoid [Adjusted for], except* 
compared 
Grievink Cross- goth percentile vs. I Uh -Cough 0.86 (0.67 to LI 0) 
L [94] sectional P-carotene (pg/day) -Phlegm 1.11 (0.87 to 1.40) 
6,555 adults -Productive cough 1.14 (0.99 to 1.33) 
The 
-Wheeze 1.27 (1.04 to 1.55) Netherlands 
-Shortness of breath 1.00 (0.77 to 1.29) 
[Age, sex, smoking status, 
pack years of smoking, and 
TEII 
Woods Cross- Increase per mg -Current asthma 0.77 (0.54 to 1.10) 
RK [106] sectional Retinol (pg1day) -Asthma 0.71 (0.53 to 0.96) 
1,601 adults -BHR 0.96 (0.70 to 1.3 1) 
Australia -Atopy 1.01 (0.76 to 1.33) 
[Age, sex, smoking, BMI, 
region of birth, family 
history of asthma, and TEII 
Troisi RJ Prospective Highest vs. lowest -incidence of asthma Relative risk: 0.82 (0.65 to 
[114] cohort quintile of 0-carotene 1.05) 
77,866 women OU) [Age, smoking, BM I, area of 
USA residence, quintiles of TEI, 
intake of vitamin C and El 
Bodner C Nested case- Low vs. highest tertile -Wheezing 0.88 (0.45 to 1.75) 
[109] control (30- P-carotene (pg/day) [Smoking habit, atopy, 
years follow family history, social class, 
up) sex, and TEI] 
94 cases/ 203 
controls 
Scotland 
Shaheen Case-control Highest vs. lowest -Asthma 1.43 (0.98 to 2.09) 
S [I 10] 607 cases/864 quintile (Using questions from [Age, sex, BMI, social class, 
controls P-carotene (Vg/day) ECRHS) housing tenure, employment 
England status, whether a single 
parent, smoking, passive 
smoke exposure at home, 
and TEII 
Soutar A Case-control Low vs. high tertile -History of seasonal Retinol: 0.64 (0.23 to 1.80) 
51 cases/38 Retinol (pg1day) symptoms 0-carotene : 1.53 (0.52 to 
controls P-carotene (pg/day) (Included allergy, atopy, 4.53) 
eczema, diagnose of [Age, sex, and smoking] 
Reactors/non- asthma) 
reactors to 
BHR=29/58 -Reactors to BHR vs. Retinol: 1.13 (0.35 to 3.64) 
Scotland non-reactor 0-carotene : 2.00 (0.63 to 
6.33) 
[Age, sex, and smoking] 
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Continuation Table 3.11 
First Type of study Level of Respiratory outcome OR (95% CI) 
author vitamin/carotenoid [Adjusted for], except* 
compared 
Picado C Case-control *Mean intake (SD) in -Severity of asthma 968.0 (658) vs. 1005.0 (98 1 
[1121 118 cases/] 21 those with severity 4 (Established according to P>0-05 
controls compared to I GINA) I= intermittent [Age, sex, and TEII 
Spain Retinol (pg/day) 4= severe 
De Luis Case-control *Mean intake (SD) of -Allergenic asthma 459 (242) vs. 642 (399) 
DA [1131 54 cases /54 retinol (gg/day) (regular follow up p<0.05 
controls in cases vs. controls patients) [No adjustments] 
Spain 
Nagel G Case-control Highest vs. lowest HaY fever 
11251 334 quartile intake of 
cases/1,336 P-carotene (Vg1day) -1.69 (1.69 to 2.63) controls [Age, sex, educational level, Germany sports activity, smoking 
status, BMI, TEI] 
The evidence from studies assessing blood levels of vitamin A or carotenoids, although 
limited to few studies, suggests that there is no association between these nutrients and 
current wheeze [ 109], skin allergen sensitisation [ 117], and the serum levels found in 
asthmatic subjects do not differ from those without asthma [ 115] (Table 3.12). 
Overall, the current evidence is suggestive of some beneficial effect of vitamin A and 
carotene on lung function, but not on asthma. Further studies are needed to elucidate 
whether the effect of vitamin A is limited onlY to lung function. 
3.2.3. Randomised controlled trials on vitamins and lung function or asthma 
symptoms 
The issue of whether supplementation with antioxidants may have a beneficial effect 
on asthma has received growing attention, mainly based on the assumption that a pro- 
oxidant stage co-exists with this disease. There are a number of clinical trials 
developed and discussed in the literature, regarding the use and possible advantages of 
supplementation with antioxidant vitamins, vitamin C being one of the earliest and 
most studied (Table 3.13). One of the first studies published in 1979 showed no 
benefits after short-term administration of this vitamin to adults [126]. Another two 
studies in larger samples of individuals confirmed the lack of effect [127,128]. These 
studies suggested that vitamin C has no acute bronchodilator effect and does not alter 
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BHR in asthmatic subjects. However, two studies published in the 1990s found a 
favourable effect of long term [129] and double dose-only [130] administration of 
vitamin C in asthmatic subjects, opening a new debate. 
Table 3.12: Association between blood levels of vitamin A and carotenoids and 
asthma sYmptoms or atopy in adults 
First Type of study Level of Respiratory OR (95 % Cl) 
author vitarnin/carotenoid outcome [adjustment] except* 
compared 
Bodner C Nested case- I unit increase in Current wheezing 
[109] control (30- plasma concentration 
years follow of 
up) -Retinol (gmoVL) 1.29 (0.95 to 1.74) 86 cases/ 194 -0-carotene(gmol/L) 0.35 (0.12 to 1.0 1) controls 
Scotland [Age, sex, smoking habit, 
atopy, family history, and 
social class] 
McKeever Cross-sectional I SD difference in Skin allergen 
TM [117] 5,858adults serum level of sensitization 
USA -Retinol (gg/dL) 1.03 (0.97 to 1.09) 
-P-carotene(gg/dL) 
0.96 (0.91 to 1.01) 
[Age, sex, smoking status, 
BMI, poverty, race/ethnicity, 
total cholesterol, and 
tryglicerides] 
Ford ES Cross-sectional *Mean serum level -Current asthma Retinol: 2.01 vs. 2.0 
[1151 16,541 adults (gmoIAL) vs. never asthma P-carotene: 0.31 vs. 0.32 
USA Lycopene: 0.44 vs. 0.44 
-Retinol 
[unadjusted] 
-0-carotene Retinol: 2.08,2.08 and 
-Lycopene -Mild, moderate 2.06 
or severe asthma P-carotene: 0.40,0.36 
and 0.32 
Lycopene: 0.43,0.44, and 
0.40 
[Age, sex, race, 
education, smoking 
status, cotinine, non-high- 
density lipoprotein, HDL, 
BMI, physical activity, 
I alcohol consumption] I 
The hypothesis of whether a combined dose of antioxidant vitamins could better show 
a beneficial effect in lung function and asthma outcomes has also been explored (Table 
3.14). Two studies carried out in adults suggest that supplementation with the three 
antioxidant vitamins promotes a well maintained lung function in adults exposed to air 
pollutants [ 13 1] or to intense exercise [ 132] when compared to those receiving placebo. 
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Contrary, the largest randomised controlled trial so far carried out, which included 300 
asthmatic subjects allocated to three different types of supplementation treatment, 
reported a lack of association in relation to lung function measurements and BHR 
[1331. 
Neuman et A found that subjects supplemented with lycopene [134] or P-carotene 
[135] for 7 days had a lower reduction of FEVI after exercise-induced asthma. Trenga 
and colleagues studied BHR to sulphur dioxide (S02) and lung function measures in a 
sample of 17 asthmatic subjects supplemented with vitamin E and vitamin C in a 
double-blind cross-over design, finding that those receiving the supplement responded 
less severely to S02 and had lower changes in their lung function measurements when 
compared to the placebo group [136]. 
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Table 3.14: Effect of supplementation of combined antioxidants on lung function 
and asthma in adults 




I I I 
Lung function 
Vitamin C, E Romieu 1 47 shoe- 650 mg vitamin Phase I and 2: In 
and 1131) cleaners (Street C+ 75 mg -FEVI supplemented group no 0-carotene workers) vitamin E+ 15 
-FVC 
association between any 
exposed to high mg P-carotene -FEF25-75 parameter of 
lung function 
Randomised, levels of ozone and ozone or N02 exposure. 
double blind and N02 in air Two phases 
Significant inverse 
placebo, cross (10/8 weeks association with most of 
over each) them 
(except FVC) in 
I placebo 
Vitamin C, E Grievink Healthy cyclists 650 mg vitamin -FEVI Significant difference in 
and L [132] 12 C+ 75 Ing -FVC FVC 
in supplemented vs. 
0-carotene supplemented vitamin E+ 15 -PEF 
controls. 
14 control mg 
0-carotene Lung function in 
Randomised, supplemented group was no 
controlled trial 3 months association with ozone 
exposure 
Asthmatic subjects 
Vitamin C& Fogarty 300 individuals I g/d vit. C+ -FEVI No significant changes in 
Magnesium A [1331 Physician- Mg placebo -FVC any of the groups (Alg) diagnosed 450 mg/d Mg + -PD20 
asthma vit C placebo 
Randomised, Vit C+ Mg 
double blind placebo 
placebo 
16 weeks 
Lycopene Neuman 1 11 30 mg/d FEV I Supplemented group had a 
[134] supplemented lycopene mean reduction after 
Randomised, 9 placebo exercise of -14.7% AFEV, 
double blind Exercise- 7 days/4 weeks vs. -26.5% 
in placebo 
placebo induced-asthma washoutf7days 
P-carotene Neuman 38 64 mg1d Higher reduction in post- 
1 [135] supplemented P-carotene FEV, exercise FEV, in placebo 
Randomised, 20 placebo group. 
double blind 7 days 
placebo Exercise- 
induced-astbma 
Vitamin C& Trenga C 17 non-smokers 400 Ul Vitamin FEV, Treated vs. placebo: 
E [136] Physician- E+ 500 mg FVC FEV, -1.2% vs. 4.4% 
diagnosed Vitamin C FEF25-73 PEF +2.2% vs. -3.0% 
Randomised, asthma 5 weeks (before PEF FEF25-75 +2.0% vs. -4.3% 
double blind exposure to S02 
placebo /exercise 
challenge) 
The studies on supplementation with antioxidant vitamins arise two issues. Firstly, the 
small sample size of these studies may have had insufficient statistical power to assess 
the hypothesis. Secondly, it is unclear whether a dose well above the daily 
requirements may be needed for a long period of time to produce a favourable effect, or 
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at the contrary, whether once a single high dose is given, it will provide sufficient 
protection against oxidative imbalance in the individual. 
3.2.4. Antioxidant-related minerals and the experimental evidence 
A number of minerals participate in the endogenous antioxidant system. Their presence 
contributes to maintain the antioxidant capacity of the endogenous antioxidant enzymes 
CAT, GSH-Px and SOD, which play a central role in the antioxidant-oxidant balance. 
Selenium is an essential trace mineral that is part of the antioxidant enzyme GSH-Px. 
In relation to magnesium, there is evidence that deficiency of magnesium is related to 
oxidative stress, as it increases histamine production and synthesis of NO [1371. 
Deficiency of magnesium also stimulates the phagocytes, which produce ROS [138]. 
Although the precise mechanisms of these responses to deficiency of magnesium are 
not well understood, it has been suggested that deprivation of magnesium may increase 
cellular vulnerability to oxidation by depleting reduced glutathion (GSH) [139]. 
Another effect of deficiency of magnesium has been explained by its interaction with 
calcium, as lower concentrations of the former leads to a higher influx of intra-cellular 
calcium facilitating bronchial smooth-muscle contraction, thereby being a risk factor 
for airway obstruction [ 140]. 
Zinc is a mineral with at least four antioxidant-related properties: (1) preventing protein 
oxidation; (2) removing iron and copper from the cell membrane (therefore preventing 
lipid peroxidation); (3) directly neutralizing ROS by accepting their spare electrons; (4) 
as a component of the antioxidant enzyme Cu-Zn SOD. In addition to these antioxidant 
properties it has been postulated that zinc may be related to anti-inflammatory 
properties, as its deficiency has been related to an exacerbation of eosinophils and 
neutrophils activation and to a release of interleukins 4 and 5 (IL-4 and IL-5, 
respectively), leukotrienes B4 and prostaglandin E2. components of the inflammatory 
response of asthma [141]. 
3.2.5 Minerals and the epidemiological evidence 
Most of the evidence currently available from observational studies in relation to lung 
function or asthma symptoms and minerals with some antioxidant role, has included 
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Several studies have assessed blood levels of selenium in asthmatic subjects, reporting 
lower selenium levels in plasma [145,146] and whole blood [147] of asthmatic 
subjects compared to healthy controls. In addition, there is also some evidence of 
reduced activity of GSH-Px in subjects with aspirin-sensitive asthma [148,149]. No 
association was found between serum selenium and atopy in a large community-based 
study [117]. 
b) Magnesium 
Most of the evidence available from observational studies, suggests that intake of 
magnesium was not associated with seasonal symptoms of asthma [I I I], severity of 
asthma [ 112], current asthma and asthma ever [ 106]. In relation to BHR there is 
insufficient and mixed evidence as one study reported an association between a low 
consumption of the mineral and being reactive to methacholine [I I I] but this was not 
confirmed in the study of Woods and colleagues [ 106] (Table 3.15). 
c) Zinc 
A low intake of zinc has been related to a higher prevalence of seasonal symptoms but 
not BHR in one cross-sectional study [1111, while Shaheen and colleagues found a 
weak negative association between high intake of zinc and asthma [I 10]. Another two 
observational studies have found no association between intake of this nutrient and 
severity of asthma [ 112], current asthma, asthma ever, and BHR [ 106] (Table 3.15). 
Overall, there are some indications for a beneficial effect of magnesium in lung 
function, although the number of studies is small. There is yet not enough evidence to 
suggest that selenium has a beneficial effect on lung function or symptoms of asthma. 
For zinc, the evidence available provides inconsistent results and due to the small 
number of studies, more research is needed to estimate the potentially beneficial role of 
this antioxidant. To conclude, there is limited epidemiological evidence to suggest that 
selenium, magnesium and zinc may have a beneficial role in lung function and asthma 
outcomes. 
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Table 3.15: Association between dietary intake of antioxidant minerals and 
symptoms of asthma and BHR in adults 
Mineral First Intake compared Respiratory outcome OR (95% Confidence 
author/Type of interval) 
study [Adjustment] 
Selenium Shaheen [110] Highest vs. lowest -Asthma 0.56 (0.35 to 0.89) 
Case-control quintile (pg/d) [Age, sex, BMI, social 
class, housing tenure, 
employment status, 
whether a single parent, 
smoking, passive smoke 
exposure at home, and 
TEI] 
Soutar [I 11] Lowest vs. highest -Seasonal symptoms 1.64 (0.56 to 4.84) 
Cross-sectional tertile (pg/d) -BHR 1.61 (0.51 to 5.08) 
[Age, sex, and smoking] 
Picado [ 112] Mean intake (mg/d) -Severity of asthma 75.5± 27 vs. 79±. O. 7 
Case-control (p>0.05) 
[Age, sex, and TE11 
Magnesium Soutar [I 11] Lowest vs. highest -Seasonal symptoms 1.68 (0.57 to 4.94) 
Cross-sectional tertile (mg) -BHR 5.63 (1.42 to 22.33) 
[Age, sex, and smoking] 
Picado [112] Mean intake (mg) -Severity of asthma 328.0± 69 vs. 358.0 ± 155 
Case-control (p>0.05) 
[Age, sex, and TE11 
Woods 1106] Mean intake (mg) -Current asthma 1.46 (0.54 to 3.96) 
Cross-sectional 
-Asthma ever 0.98 (0.42 to 2.25) 
-BHR 1.39 (0.58 to 3.30) 
[Age, sex, smoking, BMI, 
region of birth, family 
history of asthma, and 
TEII 
Zinc Soutar[Ill] Lowest vs. highest -Seasonal symptoms 4.70 (1.33 to 16.53) 
Cross-sectional tertile (mg) -BHR 1.90 (0.53 to 6.82) 
[Age, sex, and smoking] 
Shaheen II 10] Highest vs. lowest -Asthma 0.60 (0.36 to 1.02) 
Case-control quintile [Age, sex, BMI, social 
class, housing tenure, 
employment status, 
whether a single parent, 
smoking, passive smoke 
exposure at home, and 
TEII 
Picado, [112] Mean intake (mg/d) -Severity of asthma 10.3±. 3.4 vs. 11.3±. 3.6 
Case-control (p>0.05) 
[Age, sex, and TEI] 
Woods [ 106] -Current asthma 1.28 (0.47 to 3.45) 
Cross-sectional Mean intake (mg) -Asthma ever 1.0 1 (0.44 to 2.36) 
-BHR 1.43 (0.60 to 3.41) 
[Age, sex, smoking, BMI, 
region of birth, family 
history of asthma, and 
TE11 
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3.2.6 Flavonoids and the molecular basis 
Flavonoids are powerful antioxidants widely distributed in fruits and vegetables- (Table 
3.16) [1501. They can act in three ways to prevent oxidative stress. Firstly, they have 
the capacity to be direct scavengers of free radicals, transforming ROS into more 
stable, less-reactive radicals, the subclasses flavones and catechins being those with the 
highest antioxidant capacity. Secondly, some of them (e. g. quercetin) are able to 
chelate iron, thereby inactivating this metal from participating in reactions leading to 
formation of free radicals and peroxidation (Fenton's Reaction). Thirdly, several 
flavonoids, but mainly quercetin, are able to affect the activity of one of the enzymes 
involved in the production of NO, preventing its reaction with ROS and further 
formation of peroxynitrite, another powerful free radical [ 150,15 1 ]. 
It has also been suggested that flavonoids have anti-inflammatory properties, as they 
are able to inhibit pro-oxidant enzymes that participate in the synthesis of leukotrienes. 
Specific flavonoids have been shown to reduce complement activation, decreasing the 
adhesion of inflammatory cells to the endothelium, thus attenuating the inflammatory 
response [152,153]. 
Table 3.16: Main groups of flavonoids and their dietary sources 
Class Compound Dietary sources 
Flavonols Quercetin Onion, apple skin, berries, endive, leek, 
Kaempferol broccoli, grapefruit 
Flavanols Catechin Red wine, tea, apple 
Epicatechin 
Epigallocatechin gallate 
Flavones Apigenin, chrysin, luteolin Apple skins, berries, broccoli, celery, fruit peels, 
syricetin, rutin cranberries, grapes, lettuce, olive, onion, 
sibelin parsley, red wine 
Flavanones Hesperitin, fisetin, narigin, naringenin, Citrus fruit 
I 
taxifolin Citrus peel 
ýhocyanins Cyanindin, delphinidin, malvidin Berries, cherries, grapes, red wine, tea, apple 
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3.2.7 Flavonoids and the epidemiological evidence 
3.2.7.1 Flavonoids and lungfunction 
Only one large population-based cohort study has been carried out, showing a positive 
association between total intake of catechin, flavonol, and flavones and increase in 
FEVI (regression coefficient 44; 95% CI 18 to 59) in adults who had the highest 
quintile of intake when compared to those in the lowest [154]. 
3.2.7.2 Flavonoids and respiratory symptoms 
An interest in the effect of flavonoids in relation to their possible protective effect 
against asthma comes from the evidence of their effects on cardiovascular and 
oncologic diseases. As the principle is the same, prevention and attenuation of 
oxidative stress, it may be possible that flavonoids effectively attenuate the 
inflammatory response seen in asthma. Also, part of the interest comes from the 
observation that hard fruit consumption (rich in flavonoids) has been negatively 
associated with prevalence of COPD symptoms and positively associated with lung 
function [155]. The evidence available so far suggests that intake of apples (rich in 
flavonoids) is negatively associated with prevalence of asthma [I 10]. In addition, one 
study in Finland has examined associations between intake of specific flavonoid groups 
and asthma suggesting possible protective effects of quercetin, hesperetin and 
naringenin on asthma [154]. We have recently reported that intake of three major 
classes of flavonoids was unrelated to asthma or chronic sputum in adults [156]. 
3.2.8 Food intake and its relation to lung function and asthma 
3.2.8.1 Food items and lungfunction 
Fresh fruits and vegetables are common sources of antioxidant vitamins C and E and 
flavonoids. Several large epidemiological studies have demonstrated that consumption 
of fresh fruit, fresh squeezed fruit juice and apples has a beneficial impact on FEVI 
[101,157-1591. Similarly, intake of green vegetables alone or combined with intake of 
fresh fruit is positively associated with lung function [97,101,153] (Table 3.17). 
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Table 3.17: Association between intake of foods rich in antioxidants and lung 
function in adults 
Food Food item Intake Outcome of Difference Adjustment 
(Ref) compared lung function observed in n-d 
(95% CI) 
Fresh Fresh fruit I unit /day Age, height, age 
2, 
Fruits [1011 vs. less than I FEVI 132 (77 to 188) height?, BMI, sex, 
per month smoking, social class, 
activity level, and 
other dietary intakes 
Fresh fruit [ 158] Daily Region, social class, 
consumption FEVI 188 pack-years 
vs. rare 
consumption 
Apples ý: 5 units per Age, height, age 
[1571 week vs. none FEVI 138.1 (58.1 to 218.1) height? BM 1, smoking, 
per week and TEI 
Citric fruit: ýt 5 units per Age, height, age 
2, 
orange and week vs. none FEVI 105.4 (45.6 to 226.4) heighe BM 1, smoking, 
grapefruit 11571 per week and TEI 
Intake of fresh a3 glasses per Sex, age, height, 
fruitjuice and week vs. never FEVI 78 (24 to 132) cigarette fresh fruit in drink fruit consumption, region 
winter [159] juice of residence, 
household social 
group 
Vegetables Green leafy I portion per Age, height, age2, 
vegetables day vs. none FEVI 91 (32 to 150) height', BMI, sex, 
1101] per week smoking, social class, 
activity level, and 
other dietary intakes 
Combined Healthy diet* Daily vs. less Age, sex, sex, height, 
items [153] than daily FEVI 139 (108 to 170) pack year of smoking, BMI, energy intake 
Fruits & Above VS. FEVI Finland 53 00 to 156) Height, age, s 
vegetables below the Italy 118 (4 to 232) BMI, 
[97] median intake The Netherlands I 10 (4 to 224) consumption, energy intake 
C1 not given 
** Healthy diet according to Dutch recommendation: intake of 2: 189g/d fruit + ý: 45g/d whole grain + I- 
30 g1d alcohol vs.: 5189g/d fruit + -<45g/d whole grain + Z-30 g/d alcohol 
Two studies have explored whether these associations are observed longitudinally. The 
first one looked at the consumption of fruits and lung function at two time points over a 
period of seven years, finding that a decrease in the consumption of fresh fruit was 
related to a decline in lung function, while a regular intake did not affect this outcome 
[158]. The second study reported that an increase in the number of apples eaten in the 
week over time did not significantly improve lung function when compared with a 
regular consumption [100]. It may be possible that the beneficial temporal association 
between fruits rich in antioxidants and lung function is stronger when the subjects keep 
a regular intake of these foods, and that an increase would not necessarily have an 
impact in improving a value of FEVI. 
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3.2.8.2 Food items and respiratory symptoms 
The dietary intake of different types and groups of foods may provide some insights in 
their relationship with asthma. Some foods are particularly good sources of one specific 
antioxidant (for example tomato is a good source of P-carotene), while others offer a 
combination of them (fish are rich sources of vitamins and minerals), so the 
associations may correspond to different antioxidants. The strongest evidence available 
comes from fruits and vegetables, as they are well known sources of antioxidants. 
Two studies have suggested that an intake of one fresh fruit a day is significantly 
associated with less risk of wheezing in adults [157,160]. Similarly, consumption of a 
regular amount of apples (2-4 units per week) [143] or hard fruits [106] has been 
negatively associated with current asthma. Positive associations have also been found 
between intake of vegetables and asthma [106,161] (Table 3.18). 
Limited information is available regarding other food items and asthma. Negative 
associations have been found between fish, red meat and asthma [1061. Negative 
associations have been found between intake of rice and bread with BHR and doctor- 
diagnosed asthma, explained partly by the vitamins contained in the wheat flour [106]. 
The epidemiological evidence reviewed in this study suggested that a higher intake of 
vitamin E is associated with greater FEVI and FVC as indicators of lung function in the 
general population, while there is little cross-sectional evidence of an association with 
respiratory symptoms of asthma. In relation to vitamin C and its dietary sources, there 
was a consistent epiderniologic evidence of a positive association with a greater lung 
function. The evidence was far less conclusive in relation to respiratory symptoms of 
asthma. The epidemiological evidence on total vitamin A, carotenes, or retinol, was 
suggestive of a positive association with higher FEVI in healthy adults, but there is 
very weak indication of any association with respiratory symptoms or asthma [94,106, 
109,110,1141. 
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Table 3.18: Association between intake of fruits and vegetables rich in 
antioxidants and respiratory symptoms in observational studies 
Food First Food or antioxidant Respiratory outcome OR (95% confidence interval) 
author [Adjusted for] 
Butland Intake of one fresh fruit -Frequent wheezing 0.59 (0.42-0.83) 
BK[157] per day versus <1 a [Sex, smoking habit, social class 
week and salad/ raw vegetable 
consumption] 
Forastiere 5-7 fruits per week -Wheeze 0.66 (0.55-0.78) 
F [160] versus less than one per -Shortness of breath with 0.68 (0.56-0.84) 
week wheeze 
-Severe wheeze 0.59 (0.40-0.85) 
[Sex, study area, father's 
education, household density, 
parental smoking, dampness or 
mould, parental asthma] 
Shaheen Consumption of 24 -Current asthma 0.68 (0.47-0.98) 
SO [1101 apples per week versus [Age, sex, BMI, social class, 
< once per month housing tenure, employment 
status, whether a single parent, 
smoking, passive smoke exposure 
at home, TEI) 
Woods RK Mean intake of apples -Current asthma 0.83 (0.71 to 0.98) 
[106] and pears [Age, sex, smoking, BMI, region 
of birth, family history of asthma] 
Hijazi N Less than two portions -Current asthma 2.83 (0.98-8.09) 
[1611 of vegetables per day [Place of residence, nationality, 
versus ý! 2 portions per sex, mother's education, family 
day history of asthma, positive skin 
test, social class] 
Woods RK Mean intake of green -Current asthma 0.82 (0.67 to 1.00) 
11061 leafy vegetables 
-Atopy 0.84 (0.71 to 0.99) 
Mean intake of [Age, sex, smoking, BMI, region 
tomatoes of birth, family history of asthma] 
In relation to vegetables rich in antioxidant vitamins, it has been found that mean intake 
of green leafy vegetables was inversely related to atopy [1061, and that eating less than 
two portion per day of green vegetables would be associated with current asthma in 
children [161]. 
3.3 POLYUNSATURATED FATTY ACIDS (PUFA) AND ASTUMA 
3.3.1 The biological aspects 
PUFA are long chain fatty acids found in some foods, fish and vegetable oils being the 
richest sources. Diet also provides several fatty acids denoted essentials, as they cannot 
be synthesised endogenously. They are linoleic acid (LA; ornega-6), and linolenic acid; 
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(ALA; omega-3). From them, several PUFA are synthesised endogenously, which have 
structural, metabolic and regulatory functions related to the pathophysiology of asthma 
[162,1631. 
Over the last two decades there has been a change in the type of fats consumed, moving 
towards an increased consumption of vegetable oils (rich in omega 6 PUFA) and a 
decrease in the consumption of saturated fats and oily fish [ 164], the latter being the 
major source of omega 3 PUFA. In addition, there has been an increase in the 
consumption of hydrogenated vegetable oil products [ 165,166]. These changes in the 
dietary pattern of fatty acid consumption have been related to the increasing and high 
prevalence of asthma observed in last twenty years, as suggested by Black and Sharp 
[1671. 
The interest in the relationship with PUFA and asthma emerges from the fact that 
leukotrienes, chemical mediators in the pathogenesis of asthma (bronchoconstriction) 
[168] can be synthesized from omega-6 PUFA. Leukotrienes are derived from AA, an 
essential omega-6 PUFA found in cellular membranes. After release from the 
membrane phospholipids by hydrolysis, two pathways can metabolize AA: through the 
enzyme cyclooxygenase (COX), which will produce prostaglandins and thromboxanes, 
or through lypooxygenase (LOX), where leukotrienes are produced (B4, LTC4, LTD4, 
and LTE4) (Figure 3.1). 
FIGURE 3.1: METABOLISM OF ESSENTIAL FATTY ACIDS 
Omega-6 PUFA Omega-3 PUFA 
LA ALA 
T *too, v 
AA A-5 desaturase EPA 
COXz LOX 
Prostaglandins Leukotrienes A4 
Thromboxanes Leukotrienes C4, D4 & E4 
Leukotrienes B4 
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Leukotrienes A4 and B4 are potent broncho-constrictors produced by mast cells and 
other inflammatory cells, including macrophages, monocytes, eosinophils and 
basophils. They attach to specific target receptors and directly induce bronchial smooth 
muscle contraction, increase vascular permeability and promote mucus secretion. They 
also stimulate infiltration of inflammatory cells into airway tissues [ 168]. 
As leukotrienes are directly derived from dietary omega 6 PUFA it has been suggested 
that the composition of dietary fatty acids may alter the capacity to synthesize these 
lipid mediators of inflammation, thus affecting inflammatory diseases like asthma 
[168]. 
Both omega-3 and omega-6 PUFA are metabolised through common pathways, using 
the same enzymes (Figure 3.1). Thus an increase in the consumption of dietary omega 
3 PUFA can inhibit the synthesis of arachidonic acid (AA) from dietary LA 
[ 169]. Omega-3 PUFA are also capable of acting as inhibitors of the enzymes COX and 
LOX. When the omega-3 PUFA eicosapentanoic (EPA) and docosahexanoic (DHA) 
are consumed they can competitively inhibit the formation of prostaglandins and 
leukotrienes derived from AA, leading to a suppression of neutrophil function and 
therefore promoting an anti-inflammatory effect [170]. 
In order to prevent an imbalance of synthesis of the metabolites derived from omega 6, 
and thus prevent the excess of thromboxanes or leukotrienes, a ratio of omega 6/ omega 
3 intake of 2: 1 to 4: 1, and a total intake of PUFA no higher than 10% of the total 
caloric intake has been recommended [171]. The typical western diet is estimated to 
have a higher ratio [172]. The intake of LA in developed countries may be as high as 
10% of total energy because of the perceived health benefits associated with 
substitution of saturated fats by PUFA in the diet [ 173]. Yunginger et aL found a steady 
increase in the incidence of asthma in American children since 1964, coinciding with a 
marked increase in the intake of LA since 1960 in that country [1741. Likewise, an 
increase in the consumption of LA in the United Kingdom was observed since the 
1970s, representing an 8% of the fatty acid intake in 1960 to a 16% in 1990 [171], 
concurrently with the period over which the prevalence of childhood asthma has 
increased in this country [70,175]. 
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3.3.2 The epidemiological evidence 
3.3.2.1 Observational studies on intake offish andfatty acids 
At present, most of the evidence from observational studies on intake of omega 3 
suggests no beneficial effects of these fatty acids or fish intake in symptoms of asthma 
or scnsitisation to allergens [106,108,114,176-178]. A possible beneficial effect by 
fish intake on lung function in adults has been reported in three large cross sectional 
studies [179-181], as well as a greater lung function in asthmatic subjects who eat fish 
[1131. In relation to scnsitisation to allergens, two cross-sectional studies have reported 
no association between fish intake and specific allergen sensitisation [ 182], or seasonal 
rhino-conjunctivitis [177]. 
There are several studies looking at intake of omega 6 fatty acids, and/or the ratio 
n6/n3 in adults, and their association with symptoms of asthma. Most of these studies 
have obtained the information from dietary questionnaires, with few studies assessing 
these fatty acids in blood. Wakai et al. reported that the highest quartile of intake of LA 
acid in adults was positively associated with rhinitis (OR 1.74; 95% CI 1.09 to 2.77, p 
per trend=0.02) [1771. Bolte et al. reported that higher intake of low-fat margarine was 
positively associated with current asthma, but intake of margarine was unrelated to hay 
fever, atopic dermatitis and sensitisation in cross-sectional study on young adults [183]. 
In the adults participating in the ECRHS survey it was found that intake of margarine 
was positively associated with hay fever in males but not in females, while intake of 
butter, margarine and oils showed no association with BHR and atopic eczema [184]. 
Evidence from case-control studies is mixed. Nagel et A reported that intake of 
margarine was positively related with physician-diagnosed asthma (OR of highest vs. 
lowest tertile 1.73; 95% CI 1.05 to 2.87; p per trend=0.05) [178]. Earlier, these authors 
also reported that intake of oleic acid (omega 9), which can be found in some vegetable 
oils, was positively associated with hay fever (OR highest vs. lowest quartile 2.86; 95% 
CI 1.22 to 6.70) [125]. Broadfield and colleagues found that intake of LA did not 
differ in cases and controls, but erythrocyte membrane's levels of LA were negatively 
associated with asthma (OR 0.45; 95% CI 0.21 to 0.95) [185]. De Luis et al. found that 
there were no differences in intake of MUFA in cases with asthma compared to healthy 
controls [ 113]. 
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With some exceptions [185], a common limitation in most of these observational 
studies on omega 6 fatty acids and respiratory symptoms of asthma, is that they do not 
include TO as a potential confounder. Estimates of the associations with those fatty 
acids have to be taken with caution, as it may be possible that other dietary sources 
may not have been measured adequately. This is particularly important in those studies 
that use margarine or other dairy products as representatives of intake of omega 6 fatty 
acids, as the proportions of omega 6 and omega 3 fatty acids may have variations. 
3.3.2.2 Clinical trials 
Some authors have reported that supplementation with PUFA had a deleterious effect 
in asthmatic adults, based on an increase in the frequency of use of a broncho-dilator 
when compared to asthmatics that did not eat any fish during the period of study (6 
weeks) [186]. Arm and colleagues found no improvement in symptoms of asthma after 
10 weeks of supplementation but reported some anti-inflammatory effects such as 
decreased LT4 production [ 187] (Table 3.19). 












Picado C Experimental VS. 
[186] 10 aspiri n-i n tolerant Experimental control diet: 
asthmatics (mean age intervention: 
52 yr) -Clinical 
Non-significant 
Enriched diet with symptoms 
increase in severity of 
6 weeks control diet 150 g sardine meal 
symptoms 
(no omega 3) and capsules of Significant decrease 
6 weeks experimental EPA, equivalent to -PEF of PEF in weeks 5 
intervention 3 g/d omega 3 and 6 compared to 
same weeks in 




13.0 vs. 7.4 puffs 
per day in week 6 
Arm jP 20 asthmatics Supplementation: -BHR to histamine Symptoms and 
[1871 -Airways response respiratory 
12 (10 atopics) EPA 3.2 g/d + to exercise (n=5) measurements 
received omega 3 DHA 2.2 g/d -Reported remained unchanged 
(mean age 27 yr) symptoms after supplementation. 
-Neutrophils 
8 received placebo Or placebo: -Leukotrienes TB4 Neutrophils, LTB4 
olive oil (LTB4) and TB5 and LT135 production 
10 weeks (LTBs) decreased 
I . significantly. 
81 
Continuation Table 3.19 
First Samplelduration of Dose Respiratory Main 
author treatment supplemented outcomes 
findings 
Arm jP 17 asthmatics Supplementation: -PEF No significant 
[1881 (mean age 26 yr) EPA 3.2 g/d + -BHR to histamine changes in almost 
DHA 2.2 g/d -BHR to inhaled none of the 
9 received omega 3 allergen outcomes studied 
8 received placebo Or placebo: -Use of after or previous to 
olive oil bronchodilator treatment with 
10 weeks -Record of either diet. 
symptoms An exception was 
a significant 
attenuation of late 
asthma response in 
those treated with 
omega 3 compared 
to placebo group. 
Wen FC 25 non-smokers 3.2g/d EPA -BHR No significant 
[1891 pollen-sensitive adults -Use of change in PEF, 
(6 months) bronchodilator cough, wheeze, 
use of medication 
Morris A 26 mild-asthmatics 8 weeks diet -FEVI No significant 
[190] enriched in omega -BHR to histamine changes in FEVI 
16 weeks 6 (n=26) -PEF or PC20 when 
-Respiratory comparing the two 
8 weeks enriched symptoms diets 
diet with SFA No changes in use 
(n=13) or MUFA of bronchodilators 
(n= 13) 
Villani F 7 atopic asthmatics 3 g/d EPA and -Airway resistance Maximum fall in 
[191] (mean age 39 yr) DHA (R.,. ) FEVI was 
-FEVI -11% after 
30 days As outcomes of treatment vs. -28% 
inhalation before treatment 
challenge with 
ultrasonically Maximum increase 
nebulised distilled in R.,, was +37% 
water after treatment vs. 
+26.5% before 
treatment 
Dry J 12 adults 3.5 g EPA -FEVI Positive effect o 
[1921 (1 year) FEVI after 9 month] 
of treatment 
Other studies found no association between respiratory symptoms and supplementation 
of PUFA at different doses and lengths of consumption [188-191]. Longer periods of 
supplementations (I year) have reported beneficial effects on lung function of 
supplementation with PUFA in adults [192] (Table 3.19). 
Overall, although there is molecular evidence to suggest that a preventive effect in 
inflammatory response and immune regulation may occur with fish and fatty acids, the 
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observational and interventional evidence available does not show a clear effect on 
omega 3 fatty acids intake and asthma and respiratory symptoms. 
Conclusion 
The biological evidence suggests that oxidative stress might be associated with the 
mechanisms involved in the asthmatic response. Evidence from experimental studies in 
laboratory settings suggests that an imbalance between the production of ROS and 
antioxidant defences leads to activation of inflammatory cells, broncho-constriction 
and a perpetuation of the inflammatory response. 
The antioxidants provided by the diet (vitamins A, C and E, jointly with flavonoids, 
and enzymatic cofactor minerals) have been shown to have specific antioxidant 
properties as scavengers, thus reducing the production of ROS and attenuating 
oxidative stress. They also seem to exert additional protective functions in relation to 
immune and inflammatory processes. Thus, they have an antioxidant and anti- 
inflammatory role in the manifestation of respiratory condition. 
The epidemiological evidence suggests that many antioxidants have a role in the 
variability of lung function. Observational studies indicate that a higher intake of 
dietary antioxidants (assessed as individually or as foods items), especially vitamin E 
and C, are positively related to lung function. These associations are less convincing 
for respiratory symptoms and asthma. There is little information on the association 
between food items rich in antioxidants and asthma, but some studies show they may 
protect against respiratory symptoms. 
Longitudinal studies are also very scarce. Most studies have been cross-sectional 
surveys, in which exposure and disease are assessed simultaneously, therefore it is not 
possible to determine whether the exposure preceded or resulted from the disease. To 
overcome this limitation, prospective investigations of incident asthma, in which both 
dietary history and some measurements of biological parameters that would support 
mechanistic links, need to be carried out. Plasma concentrations of vitamins in 
asthmatic subjects have showed no deficiencies compared to controls in several studies, 
providing some uncertainties in relation to the effectiveness of this assessment. These 
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inconsistencies may be caused by differences in the dietary intake, or alterations in the 
diet in individuals with prevalent disease, and should be interpreted with caution. 
The available evidence suggest that the consumption of higher quantities of either fruit 
or vitamin C from all dietary sources is associated with a small, but consistently higher, 
level of FEVI. Likewise, high plasma concentration of vitamin E may confer protection 
from the development of adult asthma; vitamin C in combination with other 
antioxidants confers protection against bronchoconstriction associated with ozone 
exposure, and vitamin C supplementation alone may reduce BHR. The majority of 
supplementation studies to date have involved single-dose or short-term administration 
in small numbers of adults, and have focused on asthma control rather than aetiology. 
It still remains to be answered whether dietary antioxidants protect against the 
development of asthma in adults. The assessment of other markers of antioxidant in 
plasma may offer an additional insight in the relationship between antioxidants, asthma 
and respiratory symptoms. These markers are defined in the next chapter, where the 
main markers assessed for the study of oxidative stress in asthma are described, and the 
epiderniologic evidence reviewed. 
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CHAPTER4 
Biomarkers of oxidative stress and antioxidant status in 
asthma 
It is accepted that oxidative stress is present either facilitating the manifestation of 
respiratory symptoms or as consequence of the inflammatory response in asthmatic 
subjects. There are a number of systems involved in such process, some of them 
prompting the accumulation of oxidants and thus of the inflammatory response, and 
others than act trying to counteract such damage. A group of them, dietary 
antioxidants, were reviewed in Chapter 3, and are known as inhibitors of the oxidative 
process. 
As well as dietary antioxidants, There are a number of other indices that can be 
assessed to establish the to which extent they are related to the oxidative stress present 
in asthma. Although there are different criteria to group them, the assessment of such 
indices is generally based in their composition or in their oxidative or reductive 
capacity. Chapter 4 aims to give an overview of these additional markers that are 
currently being use for the assessment of the relationship between oxidative stress and 
asthma. 
The first section of the chapter provides a definition of a biomarker as well as a brief 
epidemiological review of the most commonly used to determine oxidative stress in 
vivo in relation to asthma. The types of biomarkers are classified according to whether 
they are products of oxidation (mainly from lipids and proteins); exposure, which 
includes inhibitors and promoters of oxidative stress; and biomarkers, of 
reductive/oxidative potency of biological fluids. The review is focused in those 
biomarkers; included in the study of this thesis, and also dedicates attention to others 
that have been used in studies of adult population, but that were unfeasible to assess in 
the current study, such as malondialdehyde (MDA), nitric oxide (NO), breath 
hydrocarbons, and antioxidant enzymes. 
To analysc the extent to which dietary intake affects biornarkers of oxidative stress in 
individuals, the second section reviews the relationship that exists between dietary 
antioxidants and biornarkers of oxidative stress. The chapter concludes with 
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observations in relation to the advantages and limitations that are currently in 
discussion between biornarkers, diet and asthma. 
4.1 DEFINITION AND CLASSIFICATION OF BIOMARKERS USED FOR THE STUDY OF ASTHMA 
The oxidative damage produced during the inflammatory response of asthma generates 
a series of ROS that react with more stable molecules, affecting their structure and 
functionality. The assessment of these oxidants may provide a close idea of the level of 
oxidative stress that is affecting an individual. However, the direct measurement of 
ROS is difficult, due to their short life and their condition of highly reactive species. 
For this reason, oxidative stress has often been measured by assessing the damage that 
ROS generate on specific molecules. 
In 1993 The World Health Organization proposed that a biomarker is a substance that 
is measured in a compartment within an organism [193]. This broad definition may 
include three categories of biomarkers. These are biomarkers of effect, which can be 
recognised as associated with an established or possible health impairment or disease; 
biomarkers of exposure, defined as measurement of an exogenous substance or its 
metabolite, or the product of a reaction between an agent and some target molecule or 
cell; and biomarkers of susceptibility or reductive/oxidative capacity, as indicators of 
an inherent or acquired ability of an organism to respond to the challenge of exposure 
to a specific substance. 
The analysis of biomarkers is increasingly being incorporated in studies of asthma in 
order to have a better understanding of the magnitude and relationship between this 
disease and oxidative stress. Among the most investigated have been markers of 
nutritional exposure, such as antioxidant vitamins and minerals. Biomarkers of effect 
are related to the composition of substances produced as result of the reaction between 
ROS with biological molecules (Table 4.1). As lipids and proteins are the molecules 
more likely to be oxidised, the products derived from their oxidation are commonly 
used as biomarkers of effect or oxidative stress in asthmatic subjects, jointly with the 
products generated as consequence of the airway inflammation [194]. The 
susceptibility of asthmatic individuals to defend themselves from the damage that an 
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oxidative imbalance may cause can be measured on several endogenous chemical 
substances, such as antioxidant enzymes and uric acid. 
Table 4.1: Biornarkers used to estimate oxidative damage in asthma 
Type of biomarker Biomarkers used 
Effect: products of oxidation Isoprostanes 
Lipidperoxidation Malondialdehyde (MDA) 
Lipid hydroperoxides 
Protein oxidation Protein carbonYls 
Production of Nitric oxide (NO) 
Airway inflammation 
Exposure: inhibitors of oxidative stress Antioxidant vitamins A, C and E 
Minerals Selenium, Zinc, ? ýIagnesiurn 
GSH and enzymes GSH-Px, SOD, CAT 
Uric Acid 
Reductive/oxidative Potency Ferric reducing ability of plasma (FRAP) 
4.1.1 Biomarkers of effect of oxidative stress 
4.1.1.1 Biomarkers of lipidperoxidation 
Lipid peroxidation is a characteristic event of the damage that ROS inflict on PUFA. 
Due to their high vulnerability, they are easily targeted by ROS, initiating a chain of 
reactions where different products are synthesised. The initial products of lipid 
peroxidation of PUFA, mainly arachidonic acid, are hydroperoxides, which will follow 
further decomposition into other substances such as aldchydcs, malondialdehyde and 
eventually isoprostanes. The importance of this process in asthma is that a series of 
compounds generated as consequence of the lipid peroxidation of AA are related to the 
activation of inflammatory cells. Therefore, it has been suggested that measuring 
markers of these products also indicate that inflammation is occurring. 
a) Isoprostanes 
Peroxidation of membranlipids caused by ROS leads to the non-enzymatic production 
of a series of prostaglandin-like compounds, namely isoprostanes, which were 
discovered in 1990 by Morrow et al. [195]. The synthesis of isoprostanes can result 
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from the peroxidation of three PUFA: first, those derived from arachidonic acid (AA), 
which generates four classes of isoprostanes, of which 8-iso-PGF2,, (172-ip) has been 
investigated most extensively for its stability; second, those derived from peroxidation 
of y-linoleic acid; and third, those generated as consequence of peroxidation of 
eicosapentaenoic acid (EPA). F2-ip is commonly produced as consequence of the lipid 
peroxidation generated by ROS released from inflammatory cells in the airways or by 
most cells types present in the lungs (smooth muscle, epithelium, endothelium, 
platelets, and inflammatory cells) [196]. 
The measurement of F2-ip has generated much interest, as they provide a reliable index 
of oxidative stress in vivo [197]. The fact that isoprostanes have a stable structure has 
facilitated their measurement not only in plasma, but also in urine, broncho-alveolar 
fluids and breath condensate. The measurement in breath condensate is considered a 
non-invasive and effective method to assess oxidative stress in asthmatics that allows 
more direct conclusions on the oxidative stress that occurs in the lungs rather than 
systemic oxidative stress [195]. In addition, F2-ip is present in relatively high 
concentrations, and are detectable in healthy individuals, indicating that lipid 
peroxidation is a continuous process that takes place in physiological conditions [197]. 
It is recognised that ranges of F2-ip may vary widely in adults, as it is produced 
regularly under physiological conditions, but increased plasma and urinary levels have 
been reported in a series of pathologies in which oxidative stress is involved, such as 
hyper-cholesterolemia [198] and atherosclerosis [199]. Likewise, adults with renal 
chronic failure requiring haemodialysis have up to three times higher levels of F2-ip 
than healthy subjects [200]. There is some evidence that smoking increases oxidative 
stress in teenagers and adults as measured by biomarkers different to F2-ip [201,202] 
but the evidence coming from studies assessing F2-ip in healthy smoker adults, shows 
dissimilar results even when the medium assessed is the same. Block et al. found no 
association between smoking status in adults and their plasmatic levels of F2-ip [203]. 
Two studies have explored whether urinary levels of F2-ip are associated with smoking 
condition and if they can be reduced after a short-term supplementation with 
antioxidants: while Jacob et al. reported no associations at all, Reilly et aL reported a 
significant positive association between smoking and F2-ip, and a significant decrease 
of this biomarker after the antioxidant supplementation therapy [198,204]. Another 
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study comparing urinary excretion of F2-ip in smokers and nom-smokers found 
significant differences in the levels of F2-ip [205]. In addition, Van Hoydonck et A 
found little or none concentrations of F2-ip in exhaled breath condensate of healthy 
smokers [206]. 
The evidence of F2-ip and asthma comes from few studies, which have included a 
small number of participants. Two case-control studies in adults have reported that 
asthmatics had between 1.5 to Mold higher levels of F2-ip in exhaled breath 
condensate when compared to non-asthmatic subjects [207,208]. In line with these 
findings, a third study found higher levels of plasma F2-ip in adolescent asthmatics 
when compared to healthy matched controls [209]. Severity of asthma was also 
significantly associated with higher levels of production of F2-ip in two of these 
studies (Table 4.2) [207,209]. Evidence from studies in children also suggests that a 
higher oxidative stress as shown by higher levels F2-ip is present (Table 4.3). 
Experimental studies suggest that this may be partly explained by the capacity that F2- 
ip have to indirectly activate neutrophils, leading to enhanced adhesion to endothelial 
cells [210]. In addition, other classes of isoprostanes have been shown to be broncho- 
constrictor agents, and to contribute to non-specific airway hyper-responsiveness [211 ]. 
Evidence from RCT suggests that challenge with methacholine increases continuously 
the urinary excretion of F2-ip in adults, hours after they have had the test, which would 
imply an ongoing oxidation process [212]. On the other hand, no change has been 
found in levels of F2-ip in exhaled breath condensate of patients before and after taking 
different doses of antibiotics for several weeks [213]. 
One possible limitation on F2-ip is that the evidence accumulated so far, has been 
essentially limited only to the production of 8-iso-PGF2,,. Experimental studies have 
demonstrated that other classes of isoprostanes are equally or more specific and that 
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b) Malondialdehyde (MDA) 
Determination of MDA through the assay Thiobarbituric acid-reactive substances 
(TBARS) was one of the earliest assessments of oxidative stress in humans [221]. 
The method is based on the measurement of concentration of lipid peroxides, mainly 
MDA, after their reaction with TBARS. MDA is an end product of PUFA containing 
three or more double bonds. TBARS is commonly assessed in plasma, red cells and 
low- and very-low density lipoproteins. The method is considered an overall 
approach to systentic oxidative stress with simplicity, low cost and rapidity, which 
have prompted the use of this marker in the last 20 years as the commonest index of 
lipid peroxidation in acute and chronic diseases in which oxidative stress is involved 
[222-2281. 
TBARS has also been used in the study of oxidative stress and asthma, with mixed 
results. Elevated levels have been observed in plasma of asthmatic adults [229-23 1 ], 
but other authors have found no differences in levels of MDA in asthmatics 
compared with healthy subjects when assessed in plasma [123,232] or exhaled 
breath condensate [233]. It has also been suggested that healthy individuals with 
normal lung function have lower levels of oxidative stress as mirrored in a significant 
negative correlation between TBARS and FEVI [234]. 
The inconsistence of these results has been attributed to several limitations of the 
assay. TBARS is considered a non-specific marker of lipid peroxidation [222]. An 
example of this is given by a study that demonstrated the low specificity of the assay 
by simultaneously measuring F2-ip and MDA. It was found that the time-course of 
formation of both markers was highly correlated, indicating that lipid oxidation was 
occurring. However, values of MDA were much higher than those for F2-ip [38]. 
This is explained by the fact that TBARS captures several other compounds than 
MDA that are also reactive toward thiobarbituric acid, including sugars, amino acids, 
and bilirubin. 
Another limitation of the test is that it does not measure the free MDA content of the 
lipid oxidation but rather measures MDA generated by decomposition of lipid 
peroxides during the acid-heating stage of the test, the oxidation produced as part of 
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the laboratory technique [235]. In order to improve the specificity of the assay, the 
conventional technique of gas chromatography/mass spectrometry has been replaced 
by other methods such as high performance liquid chromatography and fluorometry. 
It is thought that through these assays it is possible to detect up to 90% of the MDA 
formed by lipids that underwent oxidative stress. In spite of this, the doubts about its 
usefulness remain under debate [235]. 
c) Breath hydrocarbons 
Pentane and ethane are volatile compounds synthesised from the oxidation of omega 
6 and omega 3 fatty acids, respectively. They are released into the breath and their 
measurement on exhaled breath condensate is a non-invasive method to assess 
oxidative stress and inflammation in the airways. The evidence published so far 
suggests that levels of hydrocarbons are significantly increased in asthmatic subjects 
[236,237]. A main limitation of this assay is the high likelihood of error of 
measurement due to the risk of contamination with ethane and pentane present in the 
air of the environment [238]. 
4.1.1.2 Biomarkers ofprotein oxidation 
a) Carbonyls of proteins 
Proteins represent the second most vulnerable target for oxidation after PUFA. ROS 
can attack the side chains of the protein, leading to formation of new products, loss 
of fun ctionality and irreparable destruction in some cases [239]. In the presence Of 02 
all amino acid residues of proteins are susceptible to oxidation by ROS, 00H being 
the commonest aggressor. Depending upon the amino acid residue that has been 
attacked different compounds will be synthesised, which can be used in some cases 
as markers of oxidative stress-mediated damage in proteins. 
Carbonyls are commonly generated by several pathways as a consequence of the 
reaction between amino acids and ROS. The presence of carbonyl groups in proteins 
has been used as a marker of ROS-mediated protein oxidation. 
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In humans it has been found that carbonyls are elevated in plasma of individuals with 
acute respiratory distress syndrome [240], in infants with chronic lung disease [241], 
and in tracheal aspirates [242]and plasma [243] from preterm babies with a birth- 
weight of <1,500g. In healthy smokers, higher levels of carbonyls in plasma have 
been found when compared to non-smokers [244]. 
The evidence of use of carbonyls as biomarkers of oxidative stress in asthmatic 
adults was found a few years ago and a small number of studies have accumulated 
(Table 4.4). Foreman et al. found that oxidation of proteins was significantly 
elevated in asthmatics after administering an allergic challenge [245]. They 
suggested that the oxidation was largely accounted for the recruitment and activation 
of eosinophils as seen in the high positive correlation between them and carbonyls. 
The other two studies in adults compared concentration of carbonyl proteins in 
asthmatics with healthy controls. Aldridge et al. found no difference in the 
production of carbonyls in sputum of stable asthmatics when compared to healthy 
controls [246]. In contrast, Nadeem et al. found that plasma carbonyls produced by 
adults with bronchial asthma were significantly higher than those found in healthy 
age-matched adults [229]. 
Two of the studies reported that carbonyls correlated positively with the production 
of eosinophils amongst the asthmatics [229,245]. One possible explanation is that 
eosinophils may be responsible for the majority of ROS generated in the airways in 
asthma. The fact that the assessment was made in broncho-alveolar lavage or sputum 
allows the observation that the production of both carbonyls and eosinophils directly 
account for the inflammatory response in lungs, and that it is not just an indicator of 
general oxidative stress as it may be considered when assessed in plasma. Also, two 
of the studies reported that there was a non significant correlation between FEVI and 
the concentration of carbonyls in sputum [246] or in plasma [229]. 
96 
Table 4.4: Epidemiological evidence of oxidative stress in asthma as measured 
by protein carbonyls 
Reference Design Diagnosis of Fluid/tissue Results 
asthma Assessed 
Junits) 
[2451 12 Patients had no Broncho- Increase of carbonyls 
asymptomatic treatment other than alveolar production 18 hr after 
atopic asthmatic rescue P2- lavage challenge when compared to 
(25.6±1.0 yr) adrenergic drugs, nmol/mg a saline challenge (0.82 
discontinued a day protein vs. 0.23; p<0.01) 






[2461 51 adults (mean Clinical history of Sputum No correlation between 
42.3yr) asthma as defined supernatant carbonyls and FEVI in 
by the American nmol/mg asthmatics 
24 healthy Thoracic Society protein 
controls (mean All subjects No significant difference in 
37.4yr) clinically stable, levels of carbonyls when the 
with no history of two groups were compared. 
asthma exacerbation 
in the last 4 weeks 
[2291 38 adults (15-40 - Recurrent Plasma Total asthmatics vs. Control: 
yr) with symptoms of nmol/mg 1.28± 0.5 vs. 0.8± 0.03 
bronchial breathlessness and protein (P<0.0001) 
asthma: wheezing, 
M: 1.2 +-0.04; Mo: 1.22± 
Mild (M) - Improvement 0.08; S 1.43± 0.09 (p>0.05) 
Moderate (Mo) ý: 12% in FEVI in 
Severe (S) response to Negative but non-significant bronchodilator correlation between 23 a-e-matched 0 carbonyls and degree of healthy controls airways obstruction 
(predicted FEV, %) (r---0.33) 
[2471 32 asthmatics Plasma No differences in levels of 
with acute nmol/mg stable vs. asthmatics with 
exacerbations protein exacerbations. 
97 stable 
asthmatics 
The assessment of carbonyls seems a reliable way to estimate oxidative stress in 
humans, although so far in asthma has been limited. It is difficult to decide whether 
these results may be extrapolated to population-based studies, in which a large 
number of healthy people are included. So far, the groups studied were very small 
and the assessment of bronchial lavage fluid is not feasible in epidemiological 
studies. 
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As the various biomarkers of lipid oxidation represent concentration of products 
generated by reactions between PUFA and ROS, there has been interest in evaluating 
to which extent these biomarkers are related to each other. There is some 
experimental evidence suggestive of a linear correlation between MDA and F2-ip 
after oxidative stress is induced [248]. To date the scarce published evidence of 
correlation between MDA and F2-ip in adults, shows that they were very weakly 
correlated to each other (r--0.13; p=0.05) [203]. 
More but conflicting evidence is available regarding the correlation between MDA 
and protein carbonyls. One study showed a good correlation between MDA and 
carbonyls of proteins as assessed in serum of healthy adults that underwent intense 
exercise (r--0.92; p=0.01) [249], while another showed borderline correlation when 
assessed in plasma of healthy adults (r--0.65; p>0.05) [250]. A third study found no 
significant correlation between these biomarkers when assessed in bronchoalveolar 
fluid in newborn babies (r--0.2; p>0.05) [25 1 ]. 
4.1.1.3 Biomarkers of airway inflammation 
a) Nitric oxide 
NO is synthesised by several types of pulmonary cells in the body, including 
inflammatory, endothelial and airway epithelial cells [252], with the highest 
production coming from macrophages and epithelial cells. As inflammatory cells can 
activate the inducible enzyme responsible for the synthesis of NO, this gas has 
gathered much attention as a biomarker of oxidative damage in asthma [253]. 
NO has physiological and pathological functions, depending if is synthesised either 
by endothelial (eNOS) and neuronal nitric oxide synthases (nNOS), or by inducible 
nitric oxide synthases (iNOS) respectively. The latter enzyme is expressed by 
epithelial and inflammatory cells, which are found in much larger amount in 
asthmatic subjects than healthy individuals [254]. The physiological effects of NO 
include its action as vasodilator tone in blood pressure regulation, neurotransmission, 
and regulatory functions of the respiratory and gastrointestinal systems. When NO is 
induced by iNOS, its production is much grater than that observed from the other 
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enzymes. Therefore, it is thought that high levels of NO are indicative of 
inflammatory response [253]. 
In addition to its condition as a marker of oxidative stress in the airways, it has been 
demonstrated that NO has the ability to react with ROS such as superoxide anions to 
form other potentially harmful reactive nitrogen species, thus acting as a pro- 
inflammatory agent [2551. 
The literature investigating the role of NO in asthma is extensive. Numerous studies 
have demonstrated that NO is elevated in exhaled breath condensate of asthmatic 
adults [213,256,257] when compared to healthy controls. It has also been suggested 
that exhaled NO offers a sensitive marker not only of oxidative stress and 
inflammation, but also a useful non-invasive way of monitoring the severity of the 
disease [253]. 
Most of the evidence regarding production of NO and asthma has been obtained 
through exhaled breath condensate. This is non-invasive and considered an accurate 
method to assess the amount of NO released from the airways. Due to its short life, 
measurement in other compartments can only be made on its sub-products, such as 
nitrites and nitrates. It has been found that they are also reliable indices of 
inflammation and oxidative stress when assessed in plasma [25 1 ]. 
There have been indications that NO decreases significantly in asthmatics on 
medication. A study reported a significant reduction in exhaled NO after 6 hours 
following a single high dose of nebulised budesonide in symptomatic moderate 
asthma, or within 2-3 days after high doses of inhaled corticosteroids [213]. A 
gradual reduction in exhaled NO has also been observed during the first week of 
regular treatment of asthma exacerbation, with maximal effect between 3 and 4 
weeks [258]. The reduction in exhaled NO has been shown to be dose-dependent 
when low doses of inhaled corticosteroids are used in patients with mild or moderate 
asthma [259]. 
The use of NO in exhaled breath condensate as marker of oxidative damage in 
asthmatic subjects is expanding. As well as being non-invasive it has high sensitivity, 
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as in asthmatics its presence is largely due to the activation of enzymes released from 
cells involved in the inflammatory response. Furthermore, it has been observed that 
the measurement of NO is related to airway reactivity and atopic status [260]. The 
findings of NO as an accurate marker of oxidative stress in asthma are promising, 
and are offering a practical, non-expensive and reliable way to obtain information on 
the oxidative damage involved in asthmatic individuals. 
4.1.1.4 Biomarkers of reductiveloxidative potency: The FRAP assay 
The body contains several antioxidants to protect against oxidative damage. These 
are usually referred as endogenous antioxidant defences. Generally, antioxidant 
nutrients are considered exogenous defences because they are provided by diet. In 
blood and cells is possible to find several antioxidant enzymes, largely responsible 
for the destruction of ROS or at least their transformation into molecules that are 
more stable and inoffensive. 
In the plasma, many of these antioxidants are circulating, so is thought that 
measurement of groups of these antioxidants may be an indirect biomarker of 
oxidative stress in the body. 
There are several assays available to assess 'antioxidant capacity of plasma', or 
'total antioxidant capacity in plasma'. They estimate the antioxidant capacity of the 
plasma of different groups of antioxidants [261]. In general, in plasma the activity of 
resistance to circulating ROS, bilirubin, uric acid, and the activity of some dietary 
antioxidants such as ascorbic acid, (x-tocopherol, and flavonoids can be assessed. 
The Ferric reducing ability of plasma (FRAP) is one of these assays, and it is usually 
referred to as 'antioxidant capacity ofplasma'. FRAP is considered as a potency test 
that asses the reductive capacity of the plasma. Its determination is based on the 
measurement of the reducing ability of specific reductants, this is, non enzymatic 
antioxidants capable of reducing an oxidant [2621. The reaction is known as redox 
reaction, in which an oxidant is reduced at the expense of the oxidation of the 
reductant. In the FRAP assay, the reductant capacity of bilirubin, vitamin C and E, 
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flavonoids and uric acid can be detected. This is explained by the fact that the 
technique uses Fe +3 as reagent, so all the antioxidants with the capacity to act as 
reductants or iron chelators will be detected [2631. 
Over the last decade there has been increasing interest in using FRAP to estimate the 
antioxidant capacity of individuals with chronic diseases, including obesity [264] and 
chronic renal failure [265]. So far, there has been only one study relating FRAP to a 
pulmonary disease, and it was carried out in neonates undergoing cardio-pulmonary 
bypass [266]. There is no current evidence regarding the antioxidant power assessed 
through FRAP in asthma in humans or in animal models of respiratory inflammation. 
In spite of the lack of epidemiological evidence regarding FRAP and asthma, several 
features make it a suitable indicator of antioxidant power in plasma. Firstly, there are 
technical advantages, as the FRAP assay gives fast, reproducible results with plasma, 
with single antioxidants in pure solution and with mixtures of antioxidants in 
aqueous solution added to plasma. The technique has a relatively low cost and is 
considered of low complexity. FRAP is also provides information of the activity of 
vitamins C and E, thus offering an approach to the reductant capacity they have. It 
has been demonstrated that FRAP correlates positively and significantly with 
plasmatic levels of ascorbic acid and tocopherol [262]. 
The assessment of FRAP also estimates the value of polyphenols as demonstrated by 
Schlezier et al. In the study of nutritional risk factors for asthma they represent one 
of the potent reductants and iron chelators available in foods [263]. The assessment 
of flavonoids individually or as a group in plasma involves technical and economic 
difficulties that are partly suppressed by the assessment of FRAP. 
4.1.3 Biomarkers of exposure: inhibitors of oxidative stress 
4.1.3.1 Antioxidant Enzymes 
The enzymatic antioxidants include the families of superoxide dismutase (SOD), 
catalase (CAT), and glutathione peroxidase (GSH-Px). 
101 
SOD is the primary extra-cellular enzyme, and it is the most highly expressed 
enzyme in lungs. It has been suggested that SOD might play a role as both an 
antioxidant and a regulator of the signalling of several inflammatory cells, such as 
eosinophils, neutrophils, and macrophages [80]. 
Antioxidant enzymes reflect current antioxidant status, which embraces some 
limitations for studying the aetiology of asthma. Levels of these enzymes as 
measured in plasma or broncho-alveolar fluid give a partial view of the effect and 
intensity that oxidative stress may be causing. Antioxidant enzymes deficiencies 
have been frequently reported in asthmatics, although there are mixed results. These 
differences may be partly explained by the fact that different analytical techniques 
and fluids are being assessed and there are no studies of correlation or comparability 
between them. 
The enzymes SOD and GSH-Px participate in the removal of some oxidants, to 
reduce them and transform them into water and other stable molecules. The activity 
of SOD has been reported as increased [267], decreased [251] or unchanged [268] in 
asthmatics compared to controls. Similarly, the activity of GSH-Px has been reported 
as decreased [25 11 and unchanged [269] in asthmatics when compared to healthy 
individuals. 
4.2. DIETARY INTAKE AND ENDOGENOUS LEVELS OF BIOMARKERS OF OXIDATION 
The possible effect that dietary intake may exert against chronic non-transmissible 
diseases has been largely explored. Biomarkers of oxidative stress in vivo have 
emerged as a tool to identify whether oxidative stress is present in those illnesses and 
as indicators of the intensity of damage. Thus there has been an increasing interest to 
clarify whether diet and its specific components are able to affect oxidative damage 
in vivo, by modifying the levels of biomarkers, and to which extent these markers 
remain unchanged by the temporal influence of diet. 
Efforts have been gathered to determine whether the effect of a dietary antioxidant 
alone or combined with others may be similar in diminishing oxidative damage, or if 
there is any synergic action when several antioxidants are administered, or if there is 
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no change at all. If the intake of a dietary antioxidant does not change the levels of a 
specific biomarker, reflect damage inflicted by compounds and products synthesised 
during oxidative stress, and which are not attenuated by dietary antioxidants. 
Alternatively, if consumption of an antioxidant does change the levels of a 
biomarker, it may indicate the capacity that the former has to constrain oxidative 
damage. 
The information obtained from FFQs does not provide certainty on the amount of 
antioxidants that will truly be available to act once is absorbed. An extensive number 
of studies have tried to address this point, by estimating through assessment of 
biomarkers how effective dietary antioxidants can be in the prevention or attenuation 
of oxidative stress (Table 4.5). 
4.2.1 Fruits and vegetables 
The investigation on the effects of fruits and vegetables on markers of oxidative 
stress has included FRAP, F2-ip, protein carbonyls and TBARS. Most of the 
evidence comes from small samples of healthy adults or 'healthy smokers'. There 
are no studies on the effect of specific dietary intake of fruits on the levels of 
biomarkers in asthmatics so far. 
It has been shown than supplementation with 200ml/d of tomato soup over a week 
increases the levels of FRAP. This increase was greater when olive oil was added to 
the soup. The authors attributed these changes to the content of lycopene and 
tocopherol of the supplementation [270]. In contrast, another group reported that 
intake of tomato juice did not affect FRAP in young males, but reduced significantly 
the levels of TBARS after two weeks of treatment when compared to basal 
conditions [271]. 
Supplementation of a daily antioxidant-rich burger plus an antioxidant-rich juice, 
equivalent to 7 daily portions of vegetables and fruits, did not exert any change on 
levels of plasma 8-EPI-PGF2.. in smokers after three weeks of treatment [272]. The 
authors reported no differences between those supplemented and the placebo, or 
within the groups when compared to baseline values. Likewise, production of 
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protein carbonyls remained almost equal in those supplemented compared to the 
placebo. 
Table 4.5: Summary of evidence regarding the effect of consumption of foods on 
markers of oxidative stress and antioxidant capacity in urine (U) or plasma (P) 







Fruits & vegetables 
Tomato soup [2701 + 
Tomato juice [27 11 Null 
Rich-antiox. Juice+ 
Rich-antiox. Burger [272] 
Null Null 
Garlic [2731 
Cream (powder) legumes and 
grains [274] 







Olive oil [2781 Null Null Null 
Beverages 
Tea [279] Null 
[280] Null 
[2811 Null 
Tea with milk [282] + 
[2831 Null 
Tea without milk [284] + 
[283J + 
Red wine [284] + 
[285] Null 
[2861 Null 
Null= No effect -= decrease in the level of biomarker assessed += increase in the level of 
biomarker assessed blank= No information available for that food and biomarker 
Garlic is considered to have antioxidant properties due to its flavonoid content [287]. 
When healthy non smokers adults received a supplement containing a concentrate of 
garlic, equivalent to the flavonoids provided by 5 apples and 50g of strawberries, 
over two weeks, it was observed that levels of plasmatic and urinary F2-ip decrease 
by 29% and 37% respectively, in relation to the basal levels [273]. 
Whole grains and legumes are rich sources of antioxidants such as phytochernicals, 
phenolic acids and flavonoids [288,2891. The supplementation with a powder 
supplement containing whole grains, beans, legumes, seeds and brown rice during 16 
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weeks, decreased by almost a third the amount of urinary 8-Epi-IPUt in men 
diagnosed with a coronary artery disease [274]. 
4.2.2 Foods rich in PUFA 
Results from in vivo studies in humans show that supplementation with PUFA 
significantly increased lipid peroxidation measured as TBARS in male smokers 
[275], menopausal women [276,2771, and young healthy women [276]. In contrast, 
supplementation with olive oil did not affect levels of TBARS and carbonyls, nor 
FRAP in moderately heavy smoker adults [278]. This allows the observation that 
adults with a higher intake of PUFA may have higher levels of lipid peroxides, 
derived from a higher oxidation rate. 
Conclusion 
There is extensive evidence that oxidative stress is a central element of the 
inflammatory response that occurs in asthmatic subject. Oxidative stress can be 
measured from the composition of body fluids or specific products of oxidation, in 
different compartments and conditions. Although biomarkers; can be grouped into 
categories according to whether they measure overall antioxidant capacity, effect of 
oxidation or susceptibility to be oxidised, the results they give can provide with 
different interpretations. This suggests that assessing only one biomarker is not 
enough to conclude that a given oxidant/antioxidant status is present in an individual, 
but contrary, may offer a partial view of the extent to which oxidative stress has 
affected. Thus, assessment in an individual may require a combination of methods 
that will represent different sides of oxidative stress. 
Alone, none of these methods can be considered as the most appropriate criterion to 
evaluate oxidative stress, but the contrary, measuring at least two of them offers a 
better understanding. Some biornarkers widely used for determining oxidative stress 
in pathological or acute conditions of oxidative stress are increasingly being used in 
combination with newer indices intended to be more specific. In relation to asthma, 
most of the evidence has been gathered around plasma levels of MDA and 
antioxidant enzymes, while other methods such as F2-ip and carbonyls of proteins 
are being recently introduced to add to the information these markers give. 
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Population based studies assessing these markers in asthmatic subjects are still rare, 
and a limitation arises, as most of the available evidence comes from studies that 
included a very small number of participants. 
Increasing evidence suggest that new biomarkers such as the measurement of F2-ip 
seem reliable to assess oxidative stress, although this may not be reflected in adults 
who have a general good health status, as proven by the contradictory evidence 
found in smokers. Thus, it may be possible that young adults with moderate or mild 
asthma symptoms may have levels of F2-ip similar to those reported in healthy 
individuals. 
The review of the relationship between dietary intake and the biomarkers included in 
the current study is inclined towards a scarce, if any, impact on the production of 
end-products of oxidative stress, as derived from oxidation of PUFA and proteins. It 
seems that F2-ip remain stable under most of the physiological conditions in which it 
has been evaluated. This may contribute to consider it as a marker of oxidative stress 
during illness, but may not indicate oxidative damage in general population with a 
healthy condition. It also suggests that different dietary habits within young adults 
with relatively good general health conditions may not be reflected in these 
biomarkers. 
A higher intake of dietary antioxidants may not influence end products of oxidation, 
but it may affect other biomarkers that reflect the general antioxidant potency of the 
organism, such as FRAP and antioxidant enzymes. This may be explained on the 
basis that these biomarkers are the first barrier to ROS thus participating in rapid 
oxidative/reductive reactions that will constrain further oxidative damage. A 
decrease in FRAP might be interpreted as a depletion of the defence, or as a higher 
activity, so either result may be favourable in terms of the antioxidant barrier that is 
taking place in plasma. Tea appears with or without milk may effectively provide 
with antioxidants that will contribute to an increase in the FRAP, depending on the 
quality and variety of the leaves. Chileans drink high amounts of this beverage, 
replacing in lower socio-economic stratum the consumption of milk during breakfast 
and teatime. Therefore, the effect that the regular consumption of tea may have 
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against oxidative stress in this population could contribute to the current knowledge 
of its relationship with biornarkers. 
Overall, the current evidence offers limited information regarding to which extent 
biomarkers are good indicators of oxidative stress in epidemiological setting with 
large number of participants. It seems clearer that in the presence of pathologies may 
confer additional insights into the intensity of oxidative damage that may takes place. 
As described in the next chapter, the participants of this study where young adults 
that live under general good conditions of health and well-being. Several biomarkers 
of oxidative damage and antioxidant status were measured in order to establish the 




5.1 CHARACTERISTICS OF LIMACHE 
Limache is an agricultural area of 50,000 inhabitants situated in the Central valley of 
Chile, 141km from the country's capital Santiago, and 31km from Valparaiso, the 
regional capital (Figure 5.1). The educational and civic activity of the population is 
concentrated in the central area of Limache. The configuration of the locality also 
comprises an outer area surrounded by hills where a considerable part of the 
population also resides (Figure 5.2). 
Access to basic services such as tap water and electricity reach a large majority of the 
area, the rural being slightly less supplied. An idea of the combined sense of rural 
and urban aspects of Limache can be appreciated in Figure 5.3. In the town of 
Limache there is a local hospital and several primary and secondary state schools 
[290,291]. Poverty in this area is similar to the national mean, with an estimated 
18% of the population classified as poor [292,293]. 
Historically, Limache has been characterised for its agriculture, which is the main 
economic activity in the area. A third of its cultivated area is used for the production 
of vegetables, a large proportion of which is sold in Santiago, or exported. Tomato, 
corn, lettuce and cabbage are the most widely cultivated products. Fruit is also an 
important product in the area, with a vast production of grapes, and 30 other species 
of fruits. To a minor extent, potatoes, lentils, beans, and some cereals are also 
cultivated, mainly for local consumption. 
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FIGURE 5.2: RURAL SURROUNDINGS OF LIMACHE 
FIGURE 5.3: A VIEW OF A STREET IN LIMACHE 
5.2 SELECTION OF SUBJECTS 
This thesis was part of a non-concurrent prospective study aimed to assess risk 
factors in early childhood and in adult life of asthma and cardiovascular disease in 
Chilean young adults. The fieldwork was carried out between January 2001 and 
April 2003. 
A sampling frame of 3,096 individuals, corresponding to all the births that took place 
in the Hospital of Limache and in Olmue between 1974 and 1978, was used to 
randomly select 1,232 adults that were involved in the main study. There were a 
number of individuals that were prevented from taking part in the study and thus 
randomly replaced until reaching the required sample number. Main excluding 
reasons consisted of emigration from the area (11.3%), unwillingness to participate 
(7%), death (3.2%), and custodial sentence, disability, or lactation (3.3%). 
This locality and its rural surroundings were chosen because of the existence of 
obstetric and paediatric records for all births since 1966. The rate of emigration to 
other parts of the country is below 30% per decade. Health assessments were carried 
out in one location and most of the major socio-economic groups of the country were 
represented. Even in cases when a participant may have left Limache it was 
envisaged that their parents or other close relatives would be available and through 
them it would be possible to contact the subject selected in the sample. 
In those years, births were recorded manually in books kept in the hospital. An 
example of this is provided in Figure 5.4, with a page of the book corresponding to 
the registry of births of October 1977. The left hand side page indicates from left to 
right, the date of birth, time, full name of the baby, length, weight, and whether a 
female or a male. The right hand side page provides additional information on the 
type of delivery the mother had, and the signature of the person who filled in the 
pages (normally a midwife or midwife assistant) 
The study was approved by the Ethics Committee of the Faculty of Medicine, 
University of Chile. 
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FIGURE 5.4: A BOOK OF BIRTH REGISTRIES IN THE HOSPITAL OF LIMACHE 
5.3 COLLECTION OF DATA FOR OUTCOMES STUDIED 
All the assessments in this study were carried out by university nurses specially 
trained for this survey. Participants were invited to attend a morning session in a 
room of the Hospital of Limache, specially adapted for the study. Contact with 
selected participants was mainly made through telephone when possible, or they 
were approached personally. An example of the visits carried out by the fieldworkers 
at the house of one participant is shown in Figure 5.5. 
The assessments included respiratory questionnaires, spirometric measurements, 
methacholine challenge, and dietary food ftequency questionnaires. 
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FIGURE 5.5: AN EXAMPLE OF A HOUSE VISITED BY FIELDWORKERS 
5.3.1 Respiratory Questionnaire 
In order to ascertain information on asthma symptoms and related risk factors, a 
Spanish translation of the Main Questionnaire of the European Respiratory Health 
Survey (ECRHS) was used [294]. This questionnaire was designed and adapted from 
that of the International Union Against Lung Tuberculosis Diseases (IUALTD) as 
part of a study aimed to obtain a standardized assessment of asthma prevalence and 
some of its risk factors in adults from Europe. It includes questions on respiratory 
symptoms and medical history; occupation; information on damp, mould, soft 
furnishing and exposure to domestic gas appliances; air pollution; use of inhaled and 
oral drugs for the treatment of breathing problems; and use of services. The validity 
of the ECRHS questionnaire has been assessed [295]. 
Most of the information requested in the ECRHS Main Questionnaire was used in the 
Chilean study, with a few modifications to make it appropriate for the population 
studied (Table 5.1). The questions to ascertain respiratory symptoms in the Chilean 
study were the same than those of the ECRHS (Appendix I A). Although the 
question of whether asthma was diagnosed by a doctor was asked to the participants, 
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this was not considered as a main outcome. The rationale for this was that very few 
people in Limache would actually have their asthma diagnosed by a physician, found 
to be 38 in the sample. 
Table 5.1: Differences in type of questions included in questionnaires of the 
Chilean study and that of the ECRHS 
Item ECRHS Chile 
On cough and No further question on the cause of attack of Did this attack of cough have 
phlegm cough coincided with having a cold? 
Has a doctor given you 
On asthma Are you currently taking any medicines written instructions on how to 
including inhalers, aerosols or tablets for asthma? manage your asthma, or what to 
do in case of an asthma attack? 
On asthma Have you ever noticed that your asthma got worse Not included 
(women with your monthly cycle? 
only) Have you been pregnant since your asthma 
started? 
What happened to your asthma during your 
pregnancies? 
On allergies Have you ever had an itchy rash that was coming Have you ever had an itchy rash 
and that was coming and going for 
going for at least 6 months? the last 12 months? 
On Several questions regarding medical attention An item was included about any 
management required as consequence of asthma, including GP, of 10 types of medicines used to 
Of nurses, and physiotherapist. Likewise it is asked if alleviate respiratory symptoms 
asthma the patient has had any lab tests to check his/her and if yes, the form of use 
condition of asthmatic. A number of questions are (inhaled, tablets or syrup), the 
asked regarding the type of inhaler an asthmatic daily frequency and the last 
patient is using, including specific oral drugs (i. e. month he/she used them. 
beta-2-agonists, methylxanthines, steroids, anti- 
leukotrienes, ketotifen) 
5.3.2 Spirometric measurements 
All the respiratory manoeuvres were carried out by nurses, who explained in detail 
what the test consisted of to the participants. The nurses stated that the aim of the test 
was to find out how much air could be blown out of the lungs and how forcefully it 
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can be blown out. In Appendix I B, the Lung Function Questionnaire (Part 1) and 
Protocol of Data Collection Sheet (Part 2) are included. FEV, and FVC were 
measured using a Vitalograph device model 2120 Spirotrac IV. These measurements 
were performed according to the recommendations from the American Thoracic 
Association (1987) because in Chile reference values have been published using 
these recommendations [296]. FEV, as percentage of predicted value was based on 
Knudson and colleagues' recommendations [297], which were used to calculate the 
estimations in the Vitalograph. 
With the participant in standing position and with a nose clip, he/she was asked to 
follow these steps: take in as much breath as possible; place the mouthpiece in 
his/her mouth; close his/her lips tightly around the mouthpiece; and finally, blow 
through the mouthpiece into the spirometer, blowing the air out as hard, fast and 
fully as possible. The participant was asked to continue pushing air out for as long as 
possible to obtain the FVC value, or to stop when the nurse said so, to obtain the 
FEVI value. Throughout this procedure, the nurse was providing positive 
encouragement and confidence to the participant so that he/she could push out as 
much air as possible. 
If he/she failed to produce at least two technically satisfactory manoeuvres after five 
attempts, the nurse carefully explained again how to conduct the manoeuvre and 
allowed four more attempts. Any participant who was unable to produce two 
technically satisfactory manoeuvres after nine attempts was not further required to do 
the procedure and no FEVI or FVC data were collected for that individual. The 
number of attempts rejected was recorded in the Lung Function Data Collection 
Sheet (Appendix IB, Part 2). 
An unsatisfactory manoeuvre was considered as such if there was (a) a start of 
expiration with excessive hesitation or false start, (b) coughing during the first 
second of the manoeuvre, thereby affecting the measured FEVI value, or any cough 
that interfered with the accurate measurement of FVC; (c) a leak in the system or 
around the mouthpiece; (d) an obstructed mouthpiece. The highest value for FEVI, 
(best FEVI) produced in up to five satisfactory measures was used in the analysis. 
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5.3.3 Methacholine challenge 
The tidal breathing method with varying concentrations of methacholine was used to 
assess bronchial responsiveness to methacholine challenge [2981. This modality of 
challenge was chosen because the challenge with concentration is the most 
commonly used method in Chilean hospitals. The nurses that worked in this study 
were trained in a hospital in the capital, specialized in the technique of challenge 
with concentration of methacholine. 
The participants were advised to avoid smoking for I hour, using a 02-agonist or 
anticholinergic inhaler for 4 hours or oral medication (P2-agonist, theophylline or 
antimuscarinic) for 8 hours before the test. Those reporting a heart condition, 
epilepsy, current pregnancy or breastfeeding were excluded. 
After the baseline spirometry was carried out, the nurses recorded the best initial 
FEV, as a percentage of the total predicted (Appendix 113, Part 2). The two minutes 
tidal volume breathing protocol was used for those whose FEV, was at least 70% of 
predicted value. A Hudson nebuliser was used, which delivered a flow of 0.13 
ml/min of saline diluent while the subject was breathing at tidal volume. A 
Vitalograph 2121 and software Spirotrac IV following the ATS norms [299] was 
used for FEV, measurements. 
FEVI was measured about one minute after the nebulisation and best control FEV, as 
a percentage of the best initial FEV, calculated. If this value was less than 90% of the 
best initial FEVI, the methacholine challenge was not carried out and administering 
40gg salbutamol was used to reverse bronchoconstriction. Increasing concentrations 
of 0.5,1.00,4.00,8.00 and 16 mg/ml were subsequently administered and FEV, was 
measured after each tidal breathing period. The test ended when a 2: 20% fall of FEV, 
occurred or a concentration of 16 mg/ml was reached. 
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5.4 ASSESSMENT OF INDEPENDENT VARIABLES 
5.4.1 Assessment of dietary intake 
5.4.1.1 Characteristics of the Food frequency questionnaire (FFQ) and its 
administration to theparticipants 
The consumption of 65 food items was assessed through the use of a semi- 
quantitative FFQ assessing dietary intake over the last month. The FFQ included a 
range of staple foods, antioxidant-rich foods and fatty foods (rich in saturated and 
hydrogenated fatty acids). The foods included in the FFQ represented approximately 
90% of common daily intake of food in the Chilean population [301]. The selection 
criteria also considered whether these foods were part of the most usual diet of the 
population. 
Appendix IC shows the FFQ used for this study. The questionnaire included 9 major 
groups of foods: (1) fruits with high levels of vitamin C and flavonoids; (2) 
vegetables rich in vitamin A and E; (3) legumes; (4) animal meat (chicken, beef, 
poultry, pork); fish with high levels of fat (salmon, tuna) and shellfish. Eggs were 
also included in this group for their high content of animal proteins; (5) cereals 
(bread, pasta, rice, sweet biscuits and cakes); (6) fatty foods (offal, margarine, butter, 
bacon, sausage and frankfurter); (7) dairy foods (whole or skimmed milk, cheese, 
yoghurt, milky desserts); (8) sugar, jam, honey, sweets; (9) others: red wine; non- 
alcoholic drinks such as juices, tea, and coffee. An additional question was added on 
consumption of nutritional supplements. 
The participants were asked the amount and frequency of consumption of each food. 
Subjects were asked as follow: "How often do you eat, e. g., oranges in a week? " If 
the person replied that they ate that food item less frequently, they were asked "how 
often? " The second column of the FFQ registered the response of the participant, as 
to how many times per week/month they ate each item. In the case of bread, tea, 
coffee, sugar, and salt, the person was asked "How often do you eat, e. g., bread in a 
day? " The rationale for this was that these foods are part of the daily diet of the 
Chileans, and their consumption is very frequent. 
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Secondly, the participants were asked "When you eat this item, how much do you 
normally eat? " The fieldworkers showed them samples of home-size portions to 
facilitate the identification of the size of the portion consumed by the person. The 
information was registered in the third column. 
Afterwards, the fieldworker had to fill in column 4 of the questionnaire, transforming 
the home-size portions into grams multiplying by the frequency of consumption. The 
equivalent standards in grams corresponding to the home-portions were taken from 
the guidelines of the Chilean Ministry of Health [302]. These guidelines are intended 
to be a reference of what should be eaten on a daily basis to keep health and to avoid 
chronic diseases related to an excessive intake of fats and sugars. They give a list of 
the foods according to the recommended intake, specifying those amounts in portions 
that are easily understood by the general population (tea spoon, cup, units, etc). 
The last step was to obtain an estimated daily consumption of each food item in 
grams. For this, the fieldworker divided the grams obtained in column 4 by 7 or 30, 
depending on whether the subject reported consuming that item weekly or monthly, 
respectively. An example of this calculation is provided in the FFQ included in 
Appendix I C. 
Nearly all the food items included in this FFQ were available for consumption 
throughout the year. An exception was the intake of strawberries, which are only 
harvested in summer and in this area it is very uncommon for them to be available 
other times of the year. The fieldwork was carried out over two years and therefore 
some people were interviewed in summer, but for those who were not, they were 
specifically asked "When you eat strawberries in summer time, how often and how 
much do you normally eat? " The procedure to fill in the rest of the FFQ was the 
same as that followed with the other food items. 
5.4.1.2 Validation of FFQ 
In order to evaluate the validity of the questionnaire used in this study, the FFQ was 
compared against a 24 hours-recall questionnaire used as the standard. A sample of 
40 participants responded to the FFQ followed by three non-consecutive 24 hours 
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recalls, administered so as to obtain information on dietary intake during weekdays 
only. Participants were asked to describe all those foods and meals that they had had 
the previous day. Food intake was recorded as 'standard portion-sizes' and then 
translated into grams. Only those foods common to both questionnaires were 
analysed (21 items). Although fish was of interest for its content of omega 3 fatty 
acids, it was omitted from the comparison due to the lack of consumption reported in 
the 24-hours recall. 
Mean intake of each food estimated by the FFQ was compared with that obtained 
from the 24-hours recall. Limits of agreement and mean difference between methods 
were calculated as recommended by Bland and Altman [3031. The differences 
between the measures of each food item by participant were plotted against the 
average of the two to provide a visual assessment of the variation of differences. The 
intra-class correlation coefficient (ICC) was also calculated as a relative 
measurement of agreement. 
Compared with 24-hour recall questionnaire, the FFQ overestimated energy intake 
(347.3 kcal/day), as well as consumption of citric fruits, beef, bread, potatoes and 
avocado, but underestimated consumption for four vegetables. With few exceptions, 
the ICC for fruits, vegetables, dairy products and beverages was 0.9 or above, 
denoting high level of agreement confirmed by reasonably narrow limits of 
agreement. The limits of agreement for orange and avocado were wide with an ICC 
of 0.47 and 0.58, respectively. The ICCs for cereals were mediocre (between 0.23 
and 0.48) and poor for pulses and meats, consistent with the wide limits of agreement 
for these food items. 
Two examples are presented in Figure 5.6. In Figure 5.6 (A) the graph shows that 
consumption of apple had a relatively good agreement. Both in the FFQ and the 24- 
hours recall its intake was reported with a similar frequency. This is observed by the 
narrow limits of agreement and the mean difference close to zero. The case of bread 
(Figure 5.6 (B)) shows that its consumption was overestimated in the FFQ compared 
to the 24-hours recall with a large difference of means and wide limits of agreement. 
Overall, it was concluded that the PFQ appeared to be a good instrument to assess 
usual intake of foods rich in antioxidants. 
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FIGURE 5.6 ExAmPLES OF BLAND AND ALTMAN PLOTS FOR AGREEMENT IN 
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5.4.2 Nutrient estimates 
The American Table of Food Composition is the reference used in Chile for 
estimates of nutrient intake and therefore was used in our study for the determination 
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The program for nutritional analysis was based on the Nutrient Database of the 
United States Department of Agriculture (USDA), which provides information on 
energy and 28 nutritional components in more than 5,000 foods [305]. The surveys 
that contributed to this database were the Nationwide Food Consumption Survey and 
the Continuing Survey of Food Intakes by Individuals conducted by USDA, and the 
National Health and Nutrition Examination Survey conducted by the Department of 
Health and Human Services. This nutrient database has been widely used in dietary 
surveys in Chile [306-308]. Nutritional information provided by the Chilean 
Chemical Food Composition Table (which gives a description of macro and micro- 
minerals for a wide range of staple food produced or harvested in the country) was 
also used to obtain chemical composition of staple foods produced locally (e. g. 
kneaded yeast bread) [309]. 
In order to assess the levels of agreement and comparability of estimates obtained 
from these sources of food composition, in collaboration with my supervisors I 
carried out a comparison against the British Table of Food Composition [310]. The 
nutrient estimates of the British Table of Food Composition were obtained using the 
program IDA (Integrated Dietary Analysis) [311], based on the Royal Society of 
Chemistry Database 1988-1995, plus all available supplements and appendices, 
obtained from a series of analytical studies commissioned by the Ministry of 
Agriculture, Fisheries and Food [312,313]. 
Estimates of nutrients using each of the two sets of tables of food composition were 
independently obtained, in Chile for the USA (Chilean) Table of Food Composition 
and in the UK for the British Table of Food Composition. Although the British 
Tables are not adapted to the peculiarities of the Chilean diet this did not constitute a 
major problem, as only one item of food, 'longaniza', was unavailable and finally 
entered as 'sausage'. Agreement between estimates was expressed by limits of 
agreement, as recommended by Bland and Altman [303]. 
The mean differences between the two tables of food composition showed higher 
estimates when using the American (Chilean) Table for macronutrients (that ranged 
from 5.3% to 8.9%). For micronutrients, a bias towards a higher mean was observed 
for vitamin E, iron and magnesium when the American (Chilean) Table was used, 
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but the opposite was observed for vitamin A and selenium. The ICC ranged from 
0.86 (95% CI 0.81-0.91) for iron to 0.998 (95% CI 0.995-1.00) for vitamin A, 
indicating high to excellent agreement. Limits of agreement for macronutrients and 
vitamins A and C were satisfactory. 
5.4.3 Flavonoid data 
As in Chile there are no local data available on the flavonoid content of foods, this 
intake was established using Dutch food composition data compiled between 1992 
and 2000 [314-317], which were based on analyses by high performance liquid 
chromatography, of a comprehensive set of commonly consumed foods, taking on 
board seasonal and year-to-year variability. 
Three major classes of flavonoids were obtained: flavonols (quercetin, kaempferol, 
myricetin), flavones (apigenin, luteolin) and catechins [(+)-catechin, 
(+)-gallocatechin, (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, and 
(-)-epigallocatechin gallate]. The symbols (+) and (-) refer to the molecular structure 
of the different catechins. These flavonoids are chemically known as enantiomers. 
This means that each of the catechins has a unique spatial configuration that makes 
them different in molecular structure to the other catechins [318]. 
5.4.4 Biomarkers 
Four biomarkers; were assessed in plasma: antioxidant capacity of plasma, uric acid 
(both biomarkers of antioxidant status), 172-isoprostanes and protein carbonyls 
(biomarkers of oxidative stress). The techniques for assessment of these biomarkers 
were developed in the Laboratory of Pathophysiology, part of the Faculty of 
Medicine, University of Chile. Blood samples were collected in the morning (30 mQ 
and stored at -68 degrees Celsius until they were analysed. Data were collected for 
600 participants because the sample collection for this purpose started later than the 
rest of the data collection. 
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5.4.4.1 Antioxidant capacity ofplasma (FRAP assay) 
FRAP was calculated according to the method of Benzie and Strain. The technique 
uses a feffic-tripyridyltriazine complex that is reduced to the ferrous (Fe 2) form. The 
reagents were obtained from Hoffman-LaRoche Ltd. Switzerland. The technique is a 
good miffor of the effect that vitamin C, E and flavonoids have in plasma, as it 
captures their scavenging properties [262]. 
5.4.4.2 Uric acid in plasma 
Uric acid was assessed through an enzymatic method [319] Human GMbH provided 
the reagents. Plasma uric acid is a potent antioxidant capable of reducing some free 
radicals through the donation of electrons under physiological or pathological 
conditions. Jointly with vitamin C it is considered one of the most powerful 
scavengers in plasma. 
5.4.4.3 Isoprostanes (F2-ip) 
Levels of F2-ip were assessed in plasma by immunoassay test ELISA [320]. The KIT 
of 8-isoprostane EIA was provided by XXYMAN Chemical Company. The 
technique used measures the free amount of 8-epi-prostaglandin F2,, that it is 
produced as consequence of the oxidation and release of arachidonic acid to the 
extra-cellular environment. 
5.4.4.4 Protein carbonyls 
Carbonyls of proteins were assessed by the method of Reznik and Packer, using a 
spectro-photometric method [3211. The method measured the reaction of di-nitro- 
phenyl-hydrazine with protein carbonyls to form protein hydrazones, and results 
were expressed as nmol carbonyl/mg protein. This occurs as consequence of the 
attack of oxygen radicals to specific bonds of amino acids of the protein, shifting its 
structure, initiating carbonyl formation and leading to the degradation of the protein. 
The formation of these carbonyls indicates that oxidative stress took place. 
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5.5 STAIISTICAL ISSUES 
5.5.1 Dependent variables 
Symptoms of asthma and BHR to methacholine (as slope) were the primary outcome 
measures in the study. Asthma symptoms were ascertained as follow: (1) wheezing 
in the last 12 months, (2) woken with shortness of breath, and (3) having at least one 
respiratory symptom (wheezing in the last 12 months, woken with shortness of 
breath in the last 12 months, and breathlessness at rest). 
As the simple percentage Of PC20 <16mg/ml wastes the information in the size of 
PC20 in those with an estimate, a least squares concentration-response slope was 
used, analogous to dose-response slope [322]. The slope was calculated with a 
regression of the percentage fall of FEVI on concentration for each participant. 
For the statistical analyses, lung function was analysed as the highest (best) value of 
FEVI reached out of five attempts, and the FEVI/FVC. 
5.5.2 Independent variables 
Five groups of explanatory variables were included as independent variables and 
analysed as quintile groups. These were: (1) fruits, (2) vegetables, (3) nutrients, (4) 
flavonoids, and (5) biomarkers of antioxidant status and oxidative stress. Fruits and 
vegetables rich in antioxidants and vitamins were grouped and their total intake 
analysed. Total daily intakes of orange, kiwi, strawberry, and mandarin were 
summed and defined as "total fruit intake". For "total vegetable intake", daily total 
intake of the following food items was considered: beetroot, chard, sweet pepper, 
garlic, onion, tomato, potato, pumpkin, carrot, and avocado. Secondary analyses 
were also carried out individually with these and other food items of potential 
interest for their relation with the main antioxidant hypothesis being tested or for 
their association with asthma. A number of food items rich in saturated and mono 
unsaturated fatty acids were also included (Appendices 2 and 3). 
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Antioxidant nutrients with described antioxidant capacity in relation to asthma and 
lung function were included in the main analyses: vitamins C, E and total vitamin A; 
minerals selenium and zinc. Additionally, intake of omega 3 fatty acids and ratio 
WO was also analysed for their role in the antioxidant/oxidant balance in the 
respiratory system. 
Three major subclasses of flavonoids were analysed: flavonols, flavones, and 
catechins. As quercetin (the main flavonol) was very highly correlated with total 
flavonol intake, flavonols were analysed as a group only. Similarly, as intake of 
epicatechin was highly correlated with catechins and total catechins, the three main 
contributors to the intake of total catechins in this study, the analyses are presented as 
total catechins. 
Levels of biomarkers in plasma were also included as explanatory variables: FRAP, 
uric acid, F2-ip and carbonyls of proteins. Correlations between biornarkers with 
each other and with food items were calculated. 
5.5.3 Potential confounders 
Adjustments were made for sex, age, height (for FEVI only), current smoking, 
overcrowding, number of years of education, socio-economic status, weight at birth, 
BMI (weight (kg)/height (M)2) , and 
TEL 
For the current study, the associations between BHR slope and explanatory variables 
were analysed considering the additional potential confounders FEV, percentage 
predicted, FEVI%FVC, and atopy as it has been demonstrated in general population 
that these variables are independently related to BHR [323]. 
Skin test reactivity to eight allergens (supplied by Allergy Therapeutics) was 
performed: D pteronyssinus, cat fur, dog hair, Alteniaria altenzata, cockroach, a 
mixture of grass pollens considered the main contributors to pollen in the air in 
Santiago [300] (oats grass, crested dogstail, cocksfoot, rye grass, meadow grass, 
vernal bent, brome, meadow foxtail, Timothy, meadow fescue, Yorkshire fog), a 
mixture of weeds and shrubs (mugwort, fat hen, orache, nettle, plantain), and a 
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mixture of trees (birch, beech, oak-common, alder, ash, hazel, poplar, plane, elm, 
willow). Histamine was used as the positive control and an uncoated Phazet as the 
negative control. 
The tests were performed on the volar surface of the forearm using a standard 
template and the wheal size was recorded at 15 minutes as the biggest diameter and 
the diameter at 900 to its midpoint, each to the nearest whole millimetre. The mean 
wheal of the diameters was then calculated. A skin prick reaction was regarded as 
positive if the wheal mean diameter was 3mm or greater. Subjects were considered 
atopic if they have a positive reaction to any of the allergens tested. 
The criterion for defining socio-economic status in this population was based on 
previous analyses on the association between multiple socio-economic indicators 
with asthma in the adults taking part in the main study of Limache [324]. These 
indicators were investigated taking into account that this population was comprised 
of young adults aged 22 to 28 years, and in Chile it is common that they are not fully 
independent from their parents at this stage. The measures asked in the questionnaire 
included years of primary, secondary or higher education in the participants and their 
parent, breadwinner occupation, an index of type and ownership of house as some 
people may have owned a poor quality house, while others rented/owned a solid one; 
household overcrowding; number of belongings reflecting socio-economic status 
such as gas-fuelled water heater device, personal computer, fridge, washing machine, 
and microwave oven; car ownership; completion of a welfare form and total number 
of siblings. 
Previous analyses showed a statistically significant association between having fewer 
'number of belongings' (0 to 2 compared to 3 to 5) and each of the asthma symptoms 
under consideration: wheezing in the last 12 months (OR 1.39,95% CI 1.01 to 1.80; 
p--0.01), wheezing and another asthma symptom such as waking up with 
breathlessness or breathlessness at rest (OR 1.65,95% CI 1.20 to 2.40; p=0.007), and 
frequent wheeze or another asthma symptom (OR 2.07,95 % CI 1.10 to 4.04; p=0.04) 
[324]. 
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5.5.4 Sample size calculation of the main study and detectable difference for 
90% power in this thesis 
The sample size for the main study was calculated based on the regression coefficient 
of FEVI on birth weight in a previous study [325] and converted into a correlation. It 
considered birth weight because of the programming and early life risk factors 
hypothesis being tested. As stated in the application to the Wellcome Trust Fund: 
"With a sample of 1,100 subjects, it was possible to detect at the 5% level with 80% 
power, a correlation of 0.085 (corresponding to a regression coefficient of 0.624 
SDs/Ratio birthweigth/gestational age) between FEVI and birth weight'. A sampling 
frame of 3,096 individuals, corresponding to all the births that took place in the 
Hospital of Limache between 1974 and 1978 was used to randomly select 1,300 to 
allow for losses. A total of 1,232 were involved in the main study. A number of 
individuals were prevented from taking part in the study and thus randomly replaced. 
The determination of detectable difference in the current study was carried out post- 
hoe. The SDs used were for intake of vitamins C and E, and selenium reported by 
asthmatics and non-asthmatics in the study of Picado and colleagues [ 112] that 
included 118 asthmatic subjects aged 41.6 (SD 1.4) and 121 controls aged 38.8 (SD 
1.3). The aim of that study was to assess the possible relation between dietary intake 
of macro and micronutrients and asthma. Three criteria were used to define asthma: 
having wheeze in the last 12 months; having two or more of the following respiratory 
symptoms: wheezing, waking up with shortness of breath, and day time shortness of 
breath at rest; and answering 'yes' to the question of having asthma (Table 5.2). 
Taking as example vitamin E and the 327 cases who reported having wheeze in this 
population, this study has 90% power to detect a difference between the means of 
intake of vitamin E between 6.25 and 6.7 assuming that the SID in the asthmatic 
subjects is 2 and the SID in the non-asthmatics is 2.4 [112] (Table 5.2). 
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Table 5.2: Determination of detectable difference in nutrient intake with 90% 
power at the 5% level of significance in asthmatic (A) and non- 
asthmatic (NA) adults 
Detectable difference in milligrams (SD used in calculation) 
Criterion Vitamin E Vitamin C Selenium 
NA A NA A NA A 
According to those who 6.7(2.4) 6.25(2.0) 165.0 147.5 78.0 72.5 
had wheezing in the last (98.0) (75.0) (35.0) (20.0) 
12 months (n=327) 
According to those 6.7(2.4) 6.15(2.0) 165.0 144.5 78.0 72.0 
participants with two or (98.0) (75.0) (35.0) (20.0) 
more of the following 
respiratory symptoms: 
wheezing, waking up with 
shortness of breath, and 
day time shortness of 
breath at rest (n= 186) 
According to those who 6.7(2.4) 5.75(2.0) 165.0 130.5 78.0 68.5 
answered 'yes' to whether (98.0) (75.0) (35.0) (20.0) 
they were asthmatics 
(n=54). 
5.5.5 Analyses 
All independent variables were tested for linearity in relation to each of the outcomes 
included in this thesis. As there was no evidence for non-linearity, the explanatory 
variables are presented as quintile groups with P-values for linear trend. 
Multiple linear regressions and multiple logistic regressions were used to assess the 
association between the outcomes and risk factors. Multiple linear regression 
analyses were used to assess the association between measurement of FEVI, 
FEVI/FVC and BHR, with fruit, vegetable, nutrient and flavonoid intake. The 
adjusted model included as potential confounders sex, age, height (in the case of 
FEVI), socio-economic variables (grouped as explained above), weight at birth, 
BMI, and TEI. For BHR slope the potential confounders FEVI%, FEVI%FVC and 
atopy were also added [323]. The association between respiratory symptoms of 
asthma and the independent variables was examined with multiple logistic 
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regression, including the following potential confounders: sex, age, socio-economic 
variables, weight at birth, BMI, and TEL 
To examine the association between each of the outcomes studied and biomarkers; as 
independent variables, TEI was not included in the multiple regressions. The 
rationale for this is that TEI is unlikely to affect levels of biomarkers; of oxidative 
stress or antioxidant status included in the current study. 
As a large number of comparisons were carried out, adjusted p values were modified 
according to the Bonferroni method [326]. P-values were multiplied by the number 
of tests carried out for each outcome i. e. in each table. This approach was chosen due 
to the outcomes being correlated. Corrected P-values are shown only when the 
nominal P-value was less than 0.05. 
The Bonferroni correction was also applied in the results shown in appendices 2 and 
3, for the analyses that shown a nominal P-value less than 0.05. In those cases where 
the Bonferroni P-value was higher than 1.0 is stated to be 1.0 [326]. 
The statistical analyses were performed with STATA 8.2 [327]. 
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CHAPTER6 
RESULTS 1: Characteristics of the population and their 
dietary intake 
6.1 GENERAL CHARACTERISTICS OF THE POPULATION 
1192 out of 1232 adults in the study sample completed the FFQ. The exclusion of 40 
cases occurred because this study started shortly after the main one and it was not 
possible to contact again these 40 individuals to obtain dietary information. The 
sample included a slightly greater proportion of women (54.4%). Women were more 
likely to stay at home and look after the family while the men were more likely to be 
working in the fields or in town, being more difficult for them to enter the study, 
which took place during weekdays. 
The median BMI was near to the overweight cut-off in men, and just over 25 in 
women, indicating that around 50% of the participants were overweight (Table 6.1). 
The mean heightof men and women was considerably lower than the mean of height 
in western developed countries. 





Mean (SD)* Mean (SD)* 
Age (yr) 24.9(l. 6) 24.7(l. 6) 
Adult weight (kg) Median (IQR) 70.1 (63.0 to 77.9) 61.5 (54.9 to 70.0) 
Adult height (cm) 168.1(6.1) 156.3(5.5) 
BMI (kg/rn') Median (IQR) 24.7 (22.6 to 27.2) 25.1 (22.6 to 28.6) 
Weight at birth (g) 3184 (488.2) 3192 (508.0) 
Length at birth (cm) 49.4 (2.2) (n=542) 49.4 (2.1) (n=647) 
* Except as stated 
Information on lung function was obtained in 1,187 cases. Men had a mean FEV, IL 
higher than women. Wheeze in the last 12 months was reported by over a quarter of 
the participants. Women reported higher prevalence of waking with shortness of 
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breath and breathlessness at rest and 45% had at least one respiratory symptom 
(Table 6.2). 
Table 6.2: Characteristics of dependent variables and some confounders 
included in the study 
I Variable Males Females 
Measurements of lung function 
N Alean (SID) N Mean (SID) 
Lung Function FEVI (1) A 542 4.12 (0.53) 645 3.09 (0.38) 
FEVI as % of predicted value 
for age and sex # 
541 105.2 (10.91) 645 105.3 (10.69) 
FEVI/FVC 542 0.86 (0.047) 645 0.88 (0.048) 
Prevalence of respiratory outcomes N % N % 
Wheeze in the last 12 months 143 26.3 184 28.4 
Respiratory 
symptoms 
Having at least one 
respiratory symptom (wheeze, 
woken with shortness of 
breath or breathlessness at 
rest) 
202 37.1 291 44.8 
Woken with shortness of 
breath 
58 10.7 107 16.5 
Breathlessness at rest 89 16.4 148 22.8 
Atopy 
Sensitised to at least one 
allergen 
145 26.7 171 26.4 
Atopy and wheeze in the last 
12 months 
51 9.4 60 9.2 
Atopy and at least one 
respiratory symptom 
71 13.1 78 12.0 
BHR 
16mg/mL 
Positive response to 
methacholine 
38 7.5 98 16.3 
BHR as slope: N, mean (SD) 504 -0.05 (1.48) 602 0.002 (1.65) 
Confounders N % N % 
Smoking Current smoker 367 67.5 319 49.2 
Education 12 years of full time 
education 
272 50.0 324 50.0 
Estimation of 
No of household belongings 
0 or 1 75 13.8 93 14.3 
socio- 2 164 30.2 223 34.4 
economic level 3 173 31.9 211 32.5 
4or5 131 24.1 122 18.8 
A Highest of five measurements 
# FEVI as percentage of predicted value was calculated from Knudson's recommendations [297] 
Having a washing machine, microwave, gas-fuelled water-heating device, refrigerator or a computer 
at home 
A quarter of the participants were sensitised to at least one allergen. The combination 
of atopy and at least one respiratory symptom was present in just over 10% of the 
participants. BHR prevalence, defined as a 20% fall in FEVI to a concentration of 
methacholine of up to 16 mg/mL, was twice as common in women as in men. 
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A high percentage of the sample population were current smokers. Full high school 
education was accomplished by 50% of the participants. 
In the current study, there were no participants reporting use of any type of asthma 
medication 
Plasma levels of FRAP, uric acid, and protein carbonyls were calculated for 585 
cases. 16 samples were not included in the analyses as the blood samples arrived 
defrosted to the laboratory in Santiago. In the case of F2-ip, 564 samples were 
included in the analyses. As before, some samples arrived unfrozen to Santiago 
(n=27), and in 9 cases the laboratory technique failed and it was not possible to carry 
out the determination of the biomarker again due to insufficient blood. Levels of 
FRAP and uric acid were 20% average higher in men than in women, while levels of 
F2-ip were 12% greater in males. Levels of protein carbonyls were very similar in 
the two groups (Table 6.3). 




Median [IQRI N 
Females 
Median [IQRI 
FRAP (pM) 284 340.3 [291.8 - 407.81 301 285.5 [243.5 - 333.71 
Uric Acid (mg/dL) 284 4.7 [4.0 -5.6] 301 3.9 [3.3 -4.7] 
Protein carbonyls 
(nmol/mg protein) 01 
284 0.9 [0.6 - 1.11 301 
1 
0.8 [0.6 - 1.11 
F2-ip (pg/mL) 1 277 28.0 [22.5 - 36.1] 
1 287 24.9 [19.1 - 33.71 
The two biornarkers of antioxidant status FRAP and uric acid showed the highest 
coffelation among all the biomarkers. FRAP was also positively and statistically 
significantly correlated with carbonyls and F2-ip, although more weakly than that 
observed with uric acid. A positive correlation was observed between carbonyls and 
F2-ip, which reached statistical significance (Table 6.4). 
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Table 6.4: Pearson's correlation between biomarkers 
Correlation [95% confidence interval] (p value) 
Biomarker FRAP Uric acid Carbonyls 
Uric Acid 0.29 [0.22 to 0.37] (<0.001) 
Carbonyls 0.14 [0.06toO. 22] (0.001) 0.04 [-0.04toO. 12] (0.36) 
F2-ip 0.13 [0.04toO. 21] (0.03) 0.14 [0.05 to 0.221 (0.00 1) 0.13 [0.05 to 0.21 ] (0.00 1) 
6.2 FoOD AND NUTRIENT INTAKE 
Mean consumption of fruits and fresh vegetables was slightly above the 
recommendations given by the Chilean Ministry of Health with its Guidelines on the 
Pyramid of Foods [301]. In Britain, this is comparable to the Department of Health 
Recommendations '5 a day', where 5 portions of fruits or vegetables are being 
recommended to the public as an optimum intake to prevent obesity and chronic 
diseases [328]. The Chilean population studied had a consumption of almost 6 units 
of fruits and vegetables, which may be equivalent to 7 to 8 portions of the British 
food guidelines (Table 6.5). 
Table 6.5: Daily intake of fruits and vegetables and level of adequacy according 
to the Chilean Pyramid of food 






Fruits Orange 119.8 [106.9 to 132.71 
Lemon 22.8 [20.9 to 24.61 
Kiwi 34.0 [25.2 to 42.81 
Apple 82.5 [74.6 to 90.4] 
Strawberry 15.8 [12.8 to 18.9] 
Mandarin 73.4 [64.3 to 82.5] i i /d Total 348.3 [325.6 to 371.11 
3.5 un ts 3 un ts ay 
Vegetables Beetroot 22.0 [19.5 to 24.51 
Chard 15.2 [13.4 to 17.01 
Sweet pepper 8.5 17.2 to 9.71 
Garlic 4.8 [4.4 to 5.2] 
Onion 50.3 [46.6 to 54.11 
Tomato 183.2 (168.1 to 198.1 
Pumpkin 21.7 (20.6_to 22.81 
Carrot 40.0 [37.1 to 43.01 
Avocado 97.0 [87.3 to 106.7] 
Total 442.7 [420.0 to 465.3] 
2 1/4 regular 2 regular 
plates/day 
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The predominant fruits consumed were orange, mandarin and apple. Tomato and 
avocado were the main vegetables consumed by the population, with almost two and 
one unit per day, respectively (Table 6.5). Estimated mean daily intake of legumes 
was sufficient to reach the recommended intake per week (Table 6.6). 
Bread is a staple food in Chile, and thus widely consumed by the participants, with 
more than 3 units per day on average (371g/d), kneaded yeast bread being the 
commonest type of bread consumed. Intake of the rest of the cereals, rice, pasta, and 
potato (included in this category for its content of complex carbohydrates) were 
within the recommended intake (Table 6.6). Consumption of chicken and beef was 
roughly equivalent to a portion of each per week, which exceeds slightly the 
recommended intake of one portion a week. Similarly, foods with high content of 
sugar were commonly consumed. This was specially reflected by the consumption 
of soft drinks while the intake of dairy products, in particular milk, was well below 
the recommended amounts per day. 
Intake of tea reached an average of a cup per day in this population (Table 6.6). 
Intake of energy and macronutrients is presented in Table 6.7. The estimated average 
requirement (EAR) established by the UK Department of Health was used to 
estimate the adequacy of the intake [313]. As in Chile, these recommendations are 
based in the guidelines of FAO/WHO/UN. It could be argued that the only difference 
between the British and Chilean nutritional recommendations is related to the 
proportions of macronutrients. In Britain, the advisable percentage of fats derived 
from energy intake is 35%, and that of total carbohydrates is 50%. In Chile, these 
values are :5 30 and 60% for fat and carbohydrates, respectively, which has to do 
with the fact that cereals, and in particular bread, are main components of the staple 
diet in Chileans. Therefore, the British standard is used to estimate adequacy of 
intake in the studied population. 
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Table 6.6: Daily intake of other major food items and equivalent estimated 
home-size portions consumed based on the recommendations of the 
Chilean Pyramid of Food 




the Pyramid A 
Legumes Beans 21.6 [20.4 to 22.9] 2 portions, or 2 
Lentils 15.3 [14.3 to 16.31 small plates a week 
Chickpeas 4.2 [3.6 to 4.8] 1 portion twice a 
week 
Cereals Total Bread 371.3 [358.8 to 383.91 3-4 units 2-3 units/day 
Rice 42.2 [39.9 to 44.61 1 1/4 CUP 
Pasta 25.0 [23.3 to 26.7] Up to 2 cups of rice 
Potato 172.2 [165.2 to 180.2] or 3 regular-size 
Total 240.0 [231.2 to 248.81 potatoes or I small 
p ate of pasta/day 
Aninial Beef 53.4 152.2 to 56.31 1 regular portion 
proteins Chicken 16.2 [15.1 to 17.21 
Ribs 12.3 [11.2 to 13.81 
Fish 10.5 [9.6 to 11.41 1 regular portion 
once a week 
Egg 31.2 [29.1 to 33.3] 1/2 unit I unit twice a week 
Fattyfoods Oil 14.4 [13.8 to 15.01 3 tea-spoons Consume in small 
amounts 
Bacon 0.5 [0.2 to 0.81 1/4 unit 
Sausage 5.6 [4.9 to 6.3) Consume in small 
Frankfurter 11.7 110.8 to 12.61 amounts 
Ham 17.9 [16.3 to 19.51 1/4 portion or 
1/2 Consume in small 
Offal 2.9 [1.9 to 3.81 small slice amounts 
Margarinelbutter 10.6 [9.7 to 11.5] 3teaspoons Consume in small 
Mayonnaise 6.0 [5.4 to 6.61 amounts 
Dairy Milk 105.2 [93.4 to 117.01 1/2 cup or 2 slices 3-4 cups of milk or 4 
Cheese 12.9 [11.5 to 14.3] of cheese slices of cheese/ day 
Sweets Sugar 27.7 [26.3 to 29.01 
Jam 2.9 [2.0 to 3.8] 3 table spoons Consume in small 
amounts 
Cake 15.2 [13.4 to 17.0] 1 unit per week Consume in s all 
amounts 
Honey 1.110.8 to 1.51 Trace Consume with 
moderation 
Soft drink (Coke) 324.6 [299.1 to350.2] 2 regular glasses 
Juice 55.8 [42.6 to 68.9] Consume in small 
amounts 
Beverages Tea 205 [184.1 to 225.91 1 cup No specific 
Coffee 12.0 [8.0 to 16.01 recommendation 
Red wine 48.5 [36.4 to 60.6] 1/3 glass No specific 
recommendation 
Other Salt 5.1 [4.8 to 5.5] 1 tea spoon 6g or I tea- 
spoon/day 
Avoid adding to 
prepared meals 
* Total bread and cereals shown separately 
A Recommendations for some food items are given as portions per day or per week 
135 
Table 6.7: Estimated daily intake of energy and macronutrients in the studied 
population and percentage of the British recommended values 
Males Females 
Energy & Median [IQRI EAR* % of Median [IQRI EAR* % of 
Macronutrients EAR EAR 
Energy (kcal) 3439.5 2550 kcal 134.9 2279.0 [1170.7-2844.7] 1940 kcal 117.5 
12665.3- 4415.51 
Proteins (g) 129.6 44.4 g 292 92.1 [71.0-118.11 36.0 g 256 
198.4- 163.31 
Carbohydrates (g) 502.6[385.1-625.2] 50% TEI 136.0 328.8 [254.4-427.8] 50% TEI 138.0 
% TEI 58.5 57.7 
Total lipids (g) 97.9 [71.1-137.6] 35% TEI 73.1 66.1 [48.2-91.9] 35% TEI 74.6 
% TEI 25.6 26.1 
PUFA (g) 26.2 [18.3-36.1] 6.5% TEI 106.2 18.7 [13.3-25.51 6.5% TEI 113.8 
% TEI 6.9 7.4 
MUFA (g) 36.6 [25.5-55.11 13% TEI 73.8 23.3 [16.7-35.51 13% TEI 70.8 
% TET 9.6 9.2 
SFA (g) 26.1 [18.9-38.11 ll%TEl 61.8 17.1 [11.7-25.11 ll%TEI 61.8 
% TEI 6.8 6.8 
Omega 3 (g) 0.2410.1-0.51 0.2% 1.2 0.2 [0.1-0.41 0.2% TEIA 4.0 
% TEI 0.06 TEIA 0.08 
Omega 6 (g) 11.9 [7.7 -17.0] 1.0% 310 8.515.8-13.11 1.0% TEIA 340 
% TEI 3.1 TEIA 3.4 
Ratio n6/n3 48.4 [23.7 - 107.41 2-5: 1 46.4123.3-108.91 2-5: 1 
Cholesterol (mg) 323.1 200 mg 161.5 192.7 [132.6-276.41 130 mg 148.2 
[217.5-458.0] 1 1 1 1 
* EAR= Estimated average requirements for adults aged 19-50 years 
* The British Panel of Dietary Reference values stresses that these recommendations are the 
individual's minimum intake. 
The participants had a TO above the EAR per day, particularly men. Carbohydrates 
were the main source of energy, with nearly 60% of TEI in both groups. Total lipid 
intake reached 75% of the British recommended values, with MUFA and SFA intake 
also below the recommendations. Intake of PUFA reached the recommended values, 
mainly due to intake of omega 6, as intake of omega 3 was extremely low. This was 
also mirrored in a ratio WO of 47: 1, exceeding by far the recommended range of 2- 
5: 1 [329]. 
With regard to intake of micronutrients (Table 6.8), consumption of nearly all 
vitamins was above the Recommended Nutritional Intake (RNI). Vitamins C and E 
were those consumed in more quantity in relation to the RNI. For folic acid the RNI 
was unmet both for men and women, the latter having a consumption of just over a 
third of the RNI. Women also had an insufficient intake of niacin, as it only reached 
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nearly 65% of RNI. Intake of all minerals met the RNI in men and women, with the 
exception of calcium, whose consumption was nearly 50% of the RNI in women. 
Intake of iron, magnesium and selenium duplicated the RNI in men, while women 
had an intake of iron within the recommended range of RNI, and a sufficient intake 
of minerals. 
Table 6.9 shows the distribution by quintile groups of total vegetable and fruit intake, 
and nutrients included in the analyses. Intake of omega 3 fatty acids was below the 
requirements for most participants and the WO was well above the recommended 
ratio. For all other nutrients and grouped foods, only participants in the first quintile 
had a lower intake than that recommended. 
Table 6.8: Estimated daily intake of micronutrients in the studied population 
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ND= Not defined 
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Table 6.9: Distribution of food and nutrient intake by quintiles 
Food/ nutrient Quintile 
groups 
Limits of intake Recommended intake 
(As referenced in Tables 6.5, 
6.7 and 6.8) 
Total tfui( intake (g 1 1 0.0-964 1111it" pel khý / ý100 g 
2 97.1 - 190.7 
3 191.0 - 300.7 
4 ; 03.4 - 491.7 
5 49-1.4 - 4419.6 
Total ýcgeuiblc intake 1 82.8 - 118.5 2 regular plates 4M 9 
2 3 18.7 - 440.1 
3 440.4 - 590.1 
4 . 582.0 - 796.0 
5 799.9 - 4867.0 
vitainin C (111g) 1 14.7 - 73.3 40 my, I'Or jimIcs and feniales 
2 73.4- 113.4 
3 113.6 - 171.3 
4 17 1.4 - 264.6 
5 264.6- 1933.3 
Vitamin F, 1 3.0- 11.3 Males 4 nw 
2 11.3 - 15.1 Feinales ; nig, 
-3 
15.1 - 18.9 
4 Is. 9- 21 5.0 
5 25.1 121.9 
Total \ilalllin A (! 10 1 7.3.1 778.9 Males 700 It g 
2 779.7- 1 165.3 Females 600 It& 
3 1165.3 - 1645.2 
4 1646.6 - 2527.6 
5 2541.2 - 18960.9 
Oinega .1 faitý acids (2) 1 0.0-0.07 
0.21/; TH 
2 0.08-0.16 Fqtliýalcnt ill gralnsý 
-1 
0.16-0.26 Males: 5.7, " 
4 0.27-0.50 Females: 4.3L, 
5 0.50-4.1 
Ratio onicra 6/omc,! -,: i 
3 1 0.2: 1 19: 1 
2 20: 1 37: 1 
37: 1 62: 1 
4 62: 1 129: 1 
5 130: 1 5336: 1 
Sclenilln) 1 15.3 -83.1 Males 75 lig, 
2 83.1 108.9 Fcnlalcý 00 it&, 
3 109.1 - 138.8 
4 139.1 - 184.9 
.5 184.9 - 602.4 
Zi tic (Ing) 1 1.8-6.6 MaIcs 7 mu 
2 6.6-8.7 l. elliales 5 Ing 
3 8.7- 10.6 
4 10.6- 13.6 
5 13.6-43.9 
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Table 6.10 provides information on population-based surveys in Britain and Chile, 
with estimates of dietary intake in adults and percentage of adequacy of EAR in the 
case of energy and macronutrients, or of RNI for vitamins and minerals. Dietary 
information in Britain was obtained from the latest British National Diet and 
Nutrition Survey carried out between 2000 and 2001, which examined the dietary 
intake of a representative sample of adults aged 19 to 64 years. A 7-day weighed- 
intake dietary record was used for the quantification of food and nutrient intake in 
1,724 respondents [330]. The values for micronutrients included in Table 6.10 
correspond to those adults aged 25 to 34 years, as it was the closest to the group 
studied in Limache. 
Table 6.10: Mean daily macro and micronutrient, intakes as percentages of 
recommended values in adults from Britain and Chile 
Chile *[% of EAR] UK A[% of EAR] 
Males Females Males Females 
Energy (Kcal) 2,324 [91.1] 1,668 [86.0] 2,313 [90.11 1,640 [85.01 
% Contribution of macronutrients to energy intake in surveyed adults [% EAR] 
Proteins 14.5 [96.71 13.9 [92.31 16.5 [110.01 16.6 [110.71 
Carbohydrates 57 [114.0] 58 [116.01 47.7 [95.41 48.5 [97.01 
Total Fat 28.0 [80.01 28.0180.01 35.8 [102.31 34.9 [100.0] 
PUFA N/A N/A N/A N/A 
SFA 7.0 [63.41 8.0 [72.71 13.4 [121.81 13.2 [120.01 
001-1 MUFA N/A N/A 12.1 [93.11 11.5 [104.51 
Omega 3 N/A N/A 1.0 [500.0] 1.0 [500.0] 
Omega 6 N/A N/A 5.4 [540.0] 5.3 [540.01 
Mean intakes as percentage of RNI i n surveyed adults 
Vitamin A 87 102 80 78 
Vitamin C 165 160 162 170 
ca Vitamin E 400 300 N/A N/A 
Folic acid 127 111 151 170 
Calcium 80 48.9 123 99 
Iron 150 100 131 60 
.4 0 Phosphorus N/A N/A 243 190 
Magnesium N/A N/A 86 76 
e p ý 
Zinc 118.6" 194" 95 98 
Selenium N/A N/A 86 
* Vata from Uhile obtained from ret. [3U-1 A Data from Britain obtained from ref. 1330] 
#Data on zinc obtained from ref. [3311 
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British recommendations of protein are given in the form of EAR or RNI for men 
and women but not as percentage. However, the report of the British Survey 
informed protein intake only as -% contribution to energy intake. As their 
recommendation for fat is 35% TO and carbohydrates 50% it was assumed that a 
100% met recommended value for proteins would be a 15% of TEL 
In Chile, information on dietary intake in the general population is much more 
limited and it comes mainly from small studies, which may not always be 
representative and are usually designed to test hypotheses related to specific illnesses 
rather than just evaluate dietary intake on its own. The Chilean mean energy and 
nutrient intakes presented in Table 6.10 correspond to a survey carried out in 
Santiago, aimed to explore the dietary pattern of 859 adults aged 35.8± 6.9 years old 
attending any of 120 health care units of the Chilean public health system [307]. 
Data on zinc were not available in this study, and therefore were taken from an 
earlier study assessing zinc intake in a sample of 37 adults aged 20 to 35 years old 
from low socio-economic stratum living in Santiago [331]. These nutritional values 
are presented as percentage of the British RNI. 
The two countries report a fairly similar dietary intake in terms of its nutritional 
adequacy, the Chilean population having a lower fraction intake of fats and higher in 
carbohydrates. The available comparable data on micronutrients suggests that both 
populations have an adequate intake of antioxidant vitamins and minerals, but that 
consumption of calcium is below the recommended values in Chilean females (Table 
6.10). The participants of Limache had an intake that confirms these similarities and 
differences, although the intake of vitamin A was adequate and sufficient in the 
current study (Table 6.8). 
Correlations between intake of macronutrients and those micronutrients included in 
the main analyses and TO are presented in Table 6.11. All macro and micronutrients 
were statistically significantly correlated with TEL Amongst macronutrients, the 
carbohydrates had the highest correlation with TEI. PUFA, MUFA and SFA also 
showed high correlations with TEI, but these were much weaker with omega 3 and 
omega 6. Vitamin E and the minerals selenium and zinc were highly correlated with 
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TEI. In contrast, vitamins A and C, carotene, retinol, and flavonoids were only 
weakly correlated with TEI. 
Table 6.11: Correlation between macro and micronutrients and energy intake 
Type of 
nutrient 
Nutrient Pearson's correlation with TO 
195% confidence interval]* 
Macro- Proteins 0.78 [0.76 to 0.80] 
nutrients Carbohydrates 0.94 [0.936 to 0.95] 
Lipids 0.87 [0.85 to 0.88] 
PUFA 0.75 [0.73 to 0.78] 
MUFA 0.83 [0.81 to 0.84] 
SFA 0.83 [0.81 to 0.84] 
Omega 6 0.41 [0.36 to 0.45] 
Omega 3 0.24 [0.19 to 0.30] 
Ratio omega 6/omega 3 -0.09 [-0.15 to -0.031 
Vitamins Carotene 0.24 [0.18 to 0.29] 
Retinol 0.24[0.19 to 0.29] 
Total vitamin A 0.31 [0.26 to 0.36] 
Vitamin C 0.38 [0.33 to 0.42] 
Vitamin E 0.70 [0.67 to 0.73] 
Minerals Selenium 0.87 [0.85 to 0.881 
Zinc 0.80 [0.78 to 0.82] 
Flavonoids Total catechins 0.27 [0.22 to 0.32] 
Flavonols 0.31 [0.26 to 0.361 
Flavones 0.09 [0.03 to 0.14] 
* All correlations showed ap value <0.001 
Correlations between main antioxidant foods and nutrients and biomarkers of 
antioxidant status are surnmarised in Table 6.12. The measurement of FRAP captures 
the reductant capacity of vitamin C and E in the plasma, but in this study there were 
no correlations with either of these nutrients. A negative and statistically significant 
correlation was found between carrot and P-carotene (a major nutrient of carrot) 
with FRAP. In the case of uric acid, positive and statistically significant coffelations 
were found with PUFA, omega 6, vitamin E, selenium, and zinc. 
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Table 6.12: Correlation between selected antioxidant food items and nutrients, 
and biornarkers of antioxidant status 
Type of 
food/nutrient 
Food item (g) Pearson's correlation with biomarkers of antioxidant 
status [95% confidence interval] 
FRAP Uric Acid 
Fruits Orange C, -0.06 [-0.14 to 0.021 -0.0 1 [-0.09 to 0.07] 
Lemon 0.02 [-0.07 to 0.10] 0.05 [-0.03 to 0.131 
Kiwi -0.08 [-0.16 to 0.0 1] -0.02 [-0.10 to 0.06] 
Apple -0.00 1 [-0.08 to 0.08] -0.05 [-0.13 to 0.041 
Vegetables Garlic -0.01 [-0.09 to 0.07] 0.02 [-0.06 to 0.101 
Onion -0.0 1 [-0.10 to 0.07] 0.04 [-0.04 to 0.12] 
Pumpkin -0.07 [-0.15 to 0.0 1] -0.05 [-0.13 to 0.03] 
Carrot -0.11 [-0.19 to -0.031 -0.08 [-0.16 to 0.0 1] 
Avocado -0.03 [-0.11 to 0.061 0.07 [-0.02 to 0.15] 
Tea -0.06 [-0.14 to 0.02] -0.03 [-0.11 to 0.061 
Fatty acids PUFA -0.02 [-0.10 to 0.06] 0.11 [0.03 to 0.19]* 
MUFA 0.04 [-0.04 to 0.121 0.07 [-0.01 to 0.15] 
SFA 0.07 [-0.02 to 0.15] 0.06 [-0.03 to 0.14] 
Omega 6 -0.04 [-0.13 to 0.041 0.14 [0.06 to 0.221A 
Omega 3 -0.0 1 [-0.09 to 0.08] -0.0 1 [-0.09 to 0.071 
Ratio omega 
6/omega 3 
-0.04 [-0.12 to 0.04] 0.02 [-0.06 to 0.101 
Antioxidant. micro- P-Carotene -0.10 [-0.18 to -0.02] * -0.06 [-0.14 to 0.031 
nutrients ' Retinol 0.05 [-0.04 to 0.13] -0.03 [-0.12 to 0.051 
Total vitamin A -0.06 [-0.14 to 0.03] -0.07 [-0.15 to 0.021 
Vitamin C -0.06 [-0.14 to 0.02] 0.02 [-0.06 to 0.101 
Vitamin E -0.03 [-0.11 to 0.05] 0.12 [0.04 to 0.201^ 
Selenium 0.07 [-0.01 to 0.151 0.12 [0.04 to 0.201A 
Zinc 0.05 [-0.04 to 0.13] 0.13[0.05toO. 211^ 
*p=0.01 A p: 5 0.0049 
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CHAPTER7 
RESULTS ll: Associations between respiratory symptoms, 
and BHR with dietary antioxidants, fatty acids and 
biomarkers 
7.1 RESPIRATORY SYMPTOMS AND THEIR ASSOCIATION WITH FRUFFSAND VFGE, rABL. ES, 
NUTRIENTS, FLAVONOIDS AND BIOMARKERS 
7.1.1 Having wheeze in the last 12 months 
Consumption of frults and vegetables was unrelated to having whecze in the last 12 tn tl 
months in the adults of Limache (Table 7.1 ). In relation to nutrient intake, the same 
lack of association was shown both univariately and after adjusting for potential Cý 
confounders with most antioxidants, except t'()r vitamin E, for which the ORs were 
consistently above 1.00 but the association was weakly statistically sionificant (Table 
7.2). There was also no evidence for an association with any of the SUbclasses of 
flavonoids StUdied (Table 7.3). For blornarkers, a pcr quintile increase in the plasnia 
levels of FRAP was negatively associated with the prevalence ot'wheeze in the last 
12 months, being this association of borderline statistical significance (Table 7.4). L- I-- 















Fruit's (LO I I. 00 0.13 1.00 0.24 
1.10 (0.75 to 1.63) 1.17 (0.79 to 1.75) 
3 0.89 (0.60 to 1.32) 0.97 (0.64 to 1.47) 
4 0.72 (0.48 to 1.09) 0.75 (0.49 to 1.15)_ 
5 0.87 (0.58 to 1.30) 0.93 (0.61 to 1.42) 
Vc,, ctah1cs 1 1.00 0.95 I. M 0.87 
( 1, ) 2 0.98 (0.65 to 1.47) 1.00 (0.06 to 1.53) 
3 1.28 (0.87 to 1.90) 1.33 (0.88 to 2.02) 
4 0.90 (0.59 to 1.35) 0.94 (0.61 to 1.45) 
5 1.03 (0.69 to 1.54) 1.08 (0.68 to 1.7 1 )d 
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Vitamin C (im-0 1 1.00 0.28 1.00 0.35 
1 0.94 (0.63 to 1.40) 0.99 (0.66 to 1.50) 
3 1.13 (0.77 to 1.68) 1.20 (0.80 to 1.80) 
4 0.75 (0.50 to 1.14) 0.77 (0.50 to 1.19) 
5 0.85 (0.57 to 1.27) 0.90 (0.57 to 1.40) 
Vitamin F, (II)L) 1 1.00 0.42 1.00 0.08 
2 1.09 (0.73 to 1.04) 1.22 (0.80 to 1.87) 
3 1,07 (0.71 to 1.61) 1,22 (0.79 to 1.90) 
4 1.11 (0.74 to 1.67) 1,30 (0.91 to 2.06) 
5 1.24 (0.93 to 1.85) 1.68 (10) to 2.83) 
Total vilainin A 1 1.00 0.83 1.00 0.61 
QI L') 2 0.79 (0.53 to 1.19) 0.89 (0.59 to 1.35) 
3 0.85 (0.57 to 1.27) 0,94 (0.62 to 1.42) 
4 0.96 (0.65 to 1.43) 1.00 (0.66 to 1.52) 
5 0.97 (0.65 to 1.43) 1.07 (0.69 to 1.05) 
Omega 3 fattý 1 1.00 0.93 Hx) 0.41 
acids (1110 2 1.18 (0.79 to 1.76) 1.21 (0.80 to 1.83) 
3 1.12 (0.75 to 1.68) 1.1 -1 (0,9 1 to 1.98) 
4 1.16 (0.77 to 1.74) 1.30 (0.95 to 1.99) 
5 1.06 (0.70 to 1.59) 1.18 (0.77 to 1.82) 
Ratio n6/n I 1 1.00 0.20 1.00 0.51 
2 1.43 (0.95 to 2.17) 1.46 (0.95 to 2.22) 
3 1.422 (0.94 to 2.15) 1.42 (0.93 to 2.17) 
4 1.55 (1.03 to 2.34) 1.51 (0.99 to 230) 
5 1.26 (0.83 to 1.92) 1.16 (0.75 to 1.78) 
Sclenium 01ý,, ) 1 1.00 0.42 1.00 0.89 
2 0.76 (0.51 to 1.14) 0.80 (0.53 to 1.23) 
3 0.97 (0.65 to 1.43) 0.99 (0.64 to 1.54) 
4 0.92 (0.62 to 1.37) 0.98 (0.59 to 1.63) 
5 0.75 (0.62 to 1.37) 0.82 (0.42 to 1.59) 
Zinc (1110 1 1.00 0.08 1.00 0.44 
0.77 (0.52 to 1.14) 0.93 (0.55 to 1.26) 
3 0.77 (0.52 to 1.15) 0.99 (0.57 to 1.3 
4 0.69 (0.46 to 1.03) 0.74 (0.45 to 1.21) 
5 0.76 (0.51 to 1.12) 0.85 (0.47 to 1.54) 
J 
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Unadjusted model Adjusted model 
Odd,, ratio (95.1, CI) P-value 
(for Ircii(l) 
Odds ratio (95/( Ch P-valuc 
(tor trend) 
Flaý oncs I I. M 0.12 1.00 0.16 
(1110d) 2 0.96 (0.63 to 1.45) 0.95 (0.62 to 1.45) 
3 1.19 (0.80 to 1.78) 1.2 1 (0.80 to 1.83) 
4 1.02 (0.68 to 1.54) 0.98 (0.64 to 1.50) 
5 1.37 (0.921 to 2.04) 1.37 (0.90 to 2.07) 
Flavonols 1 1.00 0.84 1.00 0.49 
Ont, M) 2 0.85 (0.57 to 1.26) 0.79 (0.52 to 1.19) 
3 0.93 (0.62 to 1.38) 0.88 (0,59 to 1.33) 
4 0.83 (0.55 to 1.24) 0.75 (0.50 to 1.14) 
5 0.97 (0.65 to 1.43) 0.87 (0.57 to 1.34) 
T01,11 I HO 0.19 1.00 0.19 
calechins 0.94 (0.62 to 1.41) 1.06 (0.69 to 1.61) 
(nig/d) 3 0.86 (0.57 to 1.30) 0.95 (0.61 to 1.46) 
4 0.98 (0.65 to 1.47) 0.99 (0.65 to 1.51) 
15 1.31 (0.88 to 1.93) 1.40 (0.92 to 2.15 ý ---, 
I 
Table 7.4: Association between having -wheeze in the last 12 months and plasma 
biomarkers 
Plasma bioniarker Quintile 
groups 
Unadjusted model Adjusted model 
Odds ratio OY; Ch 11 \aitle 
(t . or [tell(]) 
Othk iatio (95'; Ch %allre 
Oor liend) 
FRAP (It NI) I. M 0.11 1W 0.05 
2 1.09 (0.02 to 1.92) 1.08 (0,59 to 1. ()_S) 
3 1.1-3 (0.70 to 2.10) 1.17 (0.65 to 2,1111 
4 0.80 (0,44 to 1.44) 0.73 (0.39 to 1.37) 
5 0.69 (0.37 to 1.26) 0.57 (0.29 to 1.11 
III ic Acid 1 1.00 0,40 1.00 0,53 
2 1.22 (0.68 to 2.19) 1.13 (0.62 to 2,07) 
1 0.93 ý 0.50 to 1.71 0.93 (0.49 to 1.75) 
4 1.23 (0.69 to 2.21 1 ý21 (0,65 to 
2,25) 
5 1.32 (0.74 to 2.36) 1.21 10.65 to 2.27) 
PI k4C Ill ("llholIN 1, 1 1.00 (Q4 1.00 02 
(nnr/IIIL 11101CIII) 
- 0.91 (0.51 to 
1.62) 0.95 (0.52 to 1.72) 
1 1.29 (0,74 to 2.27) 1.35 (0.75 to 2.41) 
4 1.00 (0.56 to 1.78) 0.99 (0.55 to 1.78) 
0.6 (0.33 to 1.14) 0.62 (0,33 to 1,17) 
1`24soploslanc, 1.00 005 I. W MIS 
(pghllt, ) 2 0.74 (0.41 to 1.33) 0.65 (0.35 to 1.20) 
i I lfý 1, ) (0.85 to 2.60) 1.52 (0.85 to 2.72) 
4 Oý8 1 (0.46 it) 1.49) 0.83 (0.45 to I. S. S) 
5 0.43 (0.23 to 0.84) (). 43 (0.22 to 0.8S) 
The associations between wheeze in the last 12 montlis (commonest reported 
symptom) with total fruit and vegetable intake, as well as with vitamins, the best 



























7.1.2 Waking at night with shortness of breath 
Consumption of fruits or vegetables showed no association with waking at night 
with shortness of breath (Table 7.5). Similarly, intake of' nutrients (Table 7.6), and 
flavonoids (Table 7.7), as well as plasma levels of biornarkers (Table 7.8), did not 
show an association with waking at night with shortness of breath in any of the C* L- 
analyses. 





Unad. justed model AdJusted model 
Odds raiio (951/( Cl) P-ýaluc 
(for tiend) 
Odds ratio (9514 Cl) P-\alue 
([Or trend) 
1 00 56 1.00 0.48 
2 0.97 (0.59 to 1.59) 0.97 (0.58 to 1.62) 
3 0.73 (0.43 to 1.23) 0.73 (0.42 to 1.25) 
4 0.72 (0.43 to 1.23) 0.7-1 (0.42 to 1.23) 
5 0.97 (0.59 to 1.60) 0.94 (0.46 to 1.58) 
vc"Clabics 1 1.00 0.67 1.00 0.87 
2 0.74 (0.43 to 1 . 
27) 0.73 (0.42 to 1.28) 
3 1.2 1 (0.74 to 2.00) 1.26 (0.75 to 2.1 1 
4 0.83 (0.49 to 1.42) 0.80 (0.46 to 1.4 1 
5 1.07 (0.65 to 1.78) 1 1 1.02 (0.57 to 1.8 1 
149 




Unadjusted model Adjusted model 
OddS ratio (95"/( Cl) p- % al tic 
(for trcii(l) 
Odd.,, ratio (95(,, ' CD P-% altic 
(1*0r trend) 
Vitamin C 1 1.00 0.87 1.00 0.52 
Ing) 0.97 (0.59 to 1.62) 0.94 (0,55 to 1.59) 
3 0.97 (0.58 to 1.63) 0.92 (0.54 to 1.56) 
4 0.90 (0.53 to 1.52) 0.79 (0.46 to 1.36) 
5 J. W (0.60 to 1.08) 0.89 (0.50 to 1.57) 
Vitamin F 1 1.00 0.82 1.00 0.96 
- 1.61 (0.96 to 2.69) 
1.67 (0.98 to 2.93) 
3 1.21 (0.71 to 2.08) 1.23 (0.70 to 2.17) 
4 HH) (0.57 to 1.75) 1.01 (0.54 to 1.97) 
5 1.26(0.73 to 2.15) 1.3 3 (0.67 to 2.6 1) I 
, rotai 1 1.00 0.94 1.00 0.65 
ýitamin A 1.3 1 (0.79 to 2.18) 1.32 (0.79 to 2.23) 
(! tg) 3 1.00 (0.59 to 1.71 ) 1,00 (0.58 to 1.72) 
4 0.89 (0.5-1 to 1.54) 0.86 (0.49 to 1.5 1) 
5 1.20 (0.71 to 2.0 1) 1.09 (0.62 io 1.91 
Omci-, a 3 1 1.00 0.55 1.00 0.42 
fatty acids 2 1.34 (0.78 to 2.29) 1.35 (0.79 to 2.33) 
(1110 
.1 
1.40 (0.82 to 2.39) 1.48 (0.85 to 2.56) 
4 1.44 (0,84 to 2.45) 1.56 (0.90 to 2.72) 
5 1.14 (0.05 to 1.98) 1.22 (0.69 to 2.18) 
Ratio 0/0 1 1.00 0.41 1.00 0.14 
2 1.00 (0.60 to 1.69) 0.98 (0.59 to 1.66) 
3 1.18 (0.71 to 1.96) 1.16 (0.70 to 1.93) 
4 1.09 (0.64 to 1.80) 1.05 (0.63 to 1.77) 
5 0.73 10.42 to 1.227) 0.69 (0.39 to 1.22) 
Selciliurn 1 1.00 0.29 1.00 0.51 
(! 1 2 1.19 (0.71 to 2.00) 1.11 (0.65 to 1.89) 
3 1.48 (0.90 to 2.44) 1.39 (0.80 to 2-19) 
4 1.04 (0.90 to -? . 44) 
0.93 (0,49 to 1.79) 
5 - . 0.72 (0.41 to 1.27) 0.58 (0.24 to 1.37) 
Zinc (Ing') 1 1.00 0.18 1.00 0.64 
0.81 (0.49 to 1.36) 0.92 (0.48 to 1.40) 
-1 
0.97 (0.59 to 1.60) 1.02 (0.59 to 1.75) 
4 0.94 (0.57 to 1.55) 1.00 (0.55 to 1.82) 
55 0.67 (0.39 to 1.15) 0.66 (0.31 to 1.44) 
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Unadjusted model AdJusted model 




Od(k ratio (954 CI) P-ý ýIILIC 
(for trend) 
Fla% ones 1 1.00 0.80 1.00 0.88 
Ong/d) 2 0.78 (0.46 to 1.32) 0.79 (0.46 to 1.34)_ 
3 0.91 (0.54 to 1.51) 0.87 (0.52 to 1.47) 
4 0.78 (0.46 to 1.32) 0.73 (0.43 to 1.25) 
5 1.07 (0.65 to 1.76) 0.98 (0.43 to 1.1-5) 
Flavonols 1 1.00 0.28 1.00 0.37 
Ono/d) 2 0.96 (0.57 to 1.64) 0.99 (0.44 to 1.36) 
3 0.76 (0.43 to 1.33) 0.77 (0.78 to 2.2 1) 
4 1.34 (0.81 to -1.21 ) 1.31 (0.78 to-2.2 1) 
5 1.15 (0.69 to 1.93) 1.13 (0.65 to 1.96) 
Total 1 1.00 0.28 1.00 0.18 
catechins 0.85 (0.49 to 1.48) 0.93 (0.77 to 2.3 1 
g() 3 1.16 (0.69 to 1.95) L L34 (0.77 to 
4 1.2 3 (0.7 3to2.06) _ 1.37 (0.80 to-2.35) 
5 1.16 (0.69 to 1.951)- 1.28 (0.74 to 2.23) 






Unadjusted model Adjusted model 
Odds ratio (95ý1' CI) 
O'Or trcnd) 
CI) Odds ratio (951ý, 11-N", Iluc 
O'Or trend) 
FRAP (! (M) 1 1.00 0.33 1.00 0.56 
2 0.93 (0.44 to 1.98) 0.92 (0.42 to 1.98) 
3 0.86 (0.40 to 1.85) 0.93 (0.43 to 1.99) 
4 1.00 (0.47 to 2.11) 1.00 (0.48 to 2.13) 
5 0.59 (0.216 to 1.36) 0.66 (0.27 to 1.63) 
- LJric Acid _ 1 _ 1.00 0.22 1.00 0.41 
Ont, hil') 2 0.66 (0.32 to 1.35) 0.67 (0.32 to 1.38) 
3 0.39 (0.17 to 0.89) 0.41 (0.18 to 0.97) 
4 0.38 (0.16 to 0.86) 0.41 (0.18 to 0.98 ý 
5 0.78 (0.39 to 1.59) 0.88 (0.42 to 1.87) 
Protein 1 1.00 0.65 1.00 0.65 
Carhonyls 2 1.93 (0.85 to 4.37) 1.92 (0.94 to 4.42) 
3 1.59 (0.69 to 3.70) 1.53 (0.65 to 3.60) 
protein) 4 1.34 (0.56 to 3.18) 1.34 (0.56 to 3.23) 
5 1.57 (0.68 to 3.66) 1.56 (0.66 to 3.66) 
F2- 1 1.00 0.41 1.00 0.65 
isoprostancs 2 1.65 (0.76 to 3.59) 1,74 (0.78 to 3.87) 
(po n) 3 1.29 (0.57 to 2.89) 1.42 (0.62 to 3.24) 
4 1.13 (0.49 to 2.59) 1.17 (0.50 to 2.78) 
5 0.83 (0.34 to 2.00) 0.97 (0.40 to 1.40) 
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7.1.3 Having at least one respiratory symptom 
There was no association between total intake of fruit or vegetables and having at 
least one respiratory symptom (Table 7.9). Analyses for intake of nutrient 
antioxidants and ornega 3 fatty acid also showed no evidence for an association with 
this OLIICOIIIe (Table 7.10). 
Amongst flavonoids, intake of total catechins showed a positive association with 
respiratory symptoms, which was of borduline nominal statistical significance in the C- 
univariate and adjusted model, but the Bon ferron 1 -corrected P-value was above 0.1 
(Table 7.11). No associations were observed for the other two groups of flavonoids 
studied. 
The logistic regressions vvith plasina levels of bioniarkcrs showed F-21soprostanes 
had a nominally statistically significant negative association with having at least one L- Z- I- 
respiratory symptom, but again the Bonferroni-con-cctcd P-value was above 0.1 
(Table 7.12). 















Frints ho 1 1.00 0.17 HX) 0.14 
2 0.93 (0.65 to 1.34) 0.97 (0.67 to 1.4 1 
3 0.99 (0.02 to 1.28) 0.92 (0.63 to 1.34) 
4 0.66 (0.45 to 0.95) 0.66 (0.45 to 0.96) 
5 0.89 (0.62 to 1.29) 0.89 (0.60 to 1.30) 
ve"Clables 1 1.00 0.79 1.00 0.96 
C, 2 0.85 (0.59 to 1.23) 0.94 (0.58 to 1.23) 
-1 
1.14 (0.79 to 1.63) 1.14 (0.78 to 1.66) 
4 0.89 (0.61 to 1.28) 0.89 (0.59 to 1.29) 
L1 
5 1.04 (0.72 to 1.50) 1 1.00 (0.65 to 1.5 1) 1 
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Unaqjusted model Adjusted model 
Odds ralio (95/( Cl) P-VýIILIC 
(for Ircrid) 
Odds ralio (95/( Ch P-\ al lie 
for trc nd) 
Vitamin C 1 1 . 00 
0.47 1 . 
00 0.11 
Ono) 2 - 0.76 (0.53 to 1.09) 0.75 (0.52 to 1.10) 
3 0.99 (0.69 to 1.42) 0.90 (0.66 to 1.40) 
4 0.69 (0.48 to 1.00) 0.63 (0.43 to 0.93) 
5 0.86 (0.60 to 1.24) 0.78 (0.52 to 1.17) 
Vitamin F 1 1.00 0.53 1.00 0.29 
OntO 2 1.04 (0.72 to 1.49) 1.11 (0.76 to 1.62) 
-1 
0,99 (0.69 to 1.43) 1,05 (0.71 to 1.56) 
4 1.11 (0.77 to 1.60) 1.18 (0.79 to 1.78) 
5 1.1-2 (0.78 to 1.61) 1.31 (0.82 to III) 
- 
Total vitainin 1 10) 0.99 1.00 
0.73 
A (it 0 2 0.79 (0.55 to 1.13) 0.93 (0.57 to 1.22) 
3 0.98 (0.61 to L-16) 0.90 (0.62 to 1.32) 
4 0.79 (0.55 to 1.13) 0.76 (0.52 to 1.12) 
5 0.99 (0.69 to 1.42) 0.97 (0.65 to 1.44) 
Omega 3 flitly 1 10) 0.45 1.00 
acids. (lntvý) 2 1.07 (0.74 to 1.54) 1.09 (0.75 to 1.58) 
3 1.35 (0.94 to 1.94) 1.49 (1.02 to 116) 
4 1.13 (0.78 to 1.63) L-17 (0.86 to 1.86) 
5 1.11 (0.77 to 1.60) 1.23 (0.83 to 1.81) 
Rafio nO/n3 I I. 00 0.71 1.00 
0.98 
2 1.16 (0.80 to 1.67) 1.14 (0.78 to 1.66) 
-1 
1.32 (0.92 to 1.90) 1.31 (0.90 to 1.90) 
4 1.38 (0.95 to 1.99) 1.33 (0.92 to 1.94) 
5 1.0 1 (0.70 to 1.46) 0.92 (0.63 to 1.35) 
Selenium (jig) 1 1.00 0.44 1.00 0.997 
2 0.95 (0.66 to 1.37) 0.99 (0.67 to 1.41) 
3 1.07 (0.74 to 1.52) 1.1 1 (0.74 to 1.66) 
4 1.03 (0.72 to 1.45) 1.11 (0.70 to 1.76) 
5 0.79 (0.54 to 1.14) 0.94 (0.46 to 1.52) 
Zinc (Inc, I Hx) 0.18 1.00 0.53 
2 0.80 (0.56 to 1.15) 0.86 (0.59 to 1.25) 
1 0.79 (0.55 to 1.14) 0.87 (0.58 to 1.30) 
4 0.93 (0.65 to 1.34) 0.99 (0.64 to 1.54) 
5 0.70 (0.49 to 1.01) 0.72 (0.42 to 1.25) 1 
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F] m ones I 1. (X) 0.14 1.00 1 
ong/d) 0.81 (0.56 to 1.17 0.8 1 (0.55 to 1.17) 
3 1.02 (0.71 tol. 47) 1.0 1 (0.70 to 1.47) 
4 0.92 (0.64 to 1. ; 2) 0.86 (0.59 to 1.26) 
5 1.28 (0.89 to 1.84) 1.20 (0.82 to 1.76) 
Flavonols I Hx) 0.59 10) 0.98 
Onghl) 0.83 (0.57 to 1.19) 0.79 (0.54 to 1.15) 
3 0.99 (0.62 to 1.28) 0.86 (0.59 to 1.26) 
4 1,02 (0.71 to 1.46) 0.94 (0.65 to 1.38) 
5 1,01 (0.70 to 1.45) 0.92 (0.62 to 1.36) 
Total II Hx) 0.05 Hx) 0.04 0.12 
catechins 2 1.05 (0.73 to 1.52) 1.17 (0.80 to 1.71 ) 
3 0.92 (0.64 to 1.33) 1.01 (0.68 to 1.49) 
E 
4 1.21 (0.84 to 1.74) 1.26 (0.86 to 1.85) 
5 1.40 (0.97 to 2.01 )1 1 1.510.02 to 2.24) 1 
Table 7.12: Association between having at least one respiratory symptom and 

















FRAP (pNI) I Hx) 006 I. M 0.08 
2 1.19 (0.71 to 2.01 ) 1.15 (0.67 to 1.98) 
3 1.37 (0.81 to 2.30) 1,40 (0.82 to 2.39) 
4 0.83 (0.49 to 1.42) 0.83 (0.47 to 1.45) 
5 0.66 (0.38 to 1.13) 0.64 (0.35 to 1.15) 
I Iric Acid I LW 0.14 1. (X) 0.19 
(mi., Ydl-) 2 OJA (0.39 io 1.08) 0.60 (0.35 to 1.02) 
3 0.45 (0.26 lo 0.76) 0.44 (0.25 to 0.76) 
4 0.56 (0.33 to 0.95) 0.56 (0.32 to 0.98) 
1 5 0.09 (0.41 to 1.16) 0.09 (0.39 to 1.18) 
Prolcin 1 10) 0.61 1.00 0.60 
Cmbonyk 1 0.86 (0.51 to 1.44) 0.99 (0.52 to 1.52) 
(1111ving 
l i ) -3 
0.85 (0.50 to 1.43) 0.94 (0.49 to 1.44) 
pro c n 
4 0.90 (0.53 to 1.52) 0.87 (0.51 to 1.49) 
5 0.84 (0.50 to 1.4 1) 0.90 (0.50 to 1.47) 
F2- Hx) (). (X)8 I. M 0.03 0.12 
isoprostancs 2 0.92 (0.55 to 1.56) 0.94 (0.49 to 1.46) 
3 LI 1 (0.66 to 1.88) 1.17 (0.68 to 2.01 ) 
4 0.78 (0.45 to 1.33) 0.79 (0.45 to 1.39) 
5 0.46 (0.26 to 0.80) 0.49 (0.28 to O. SX) 
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7.2 BHR SLOPE AND ITS ASSOCIATION WITH FRUrrS AND VEGETABLES, NUTRIENTS, 
FLAVONOIDS AND BIOMARKERS. 
Analyses with BHR slope were carried out in 1,106 Subjects. Univariate analyses 
showed a non-statistically significant trend for a negative association between both 
total fruit and vegetable intakes with BHR slope. Adjusted mUltiple linear regression 
did not change the direction or statistical significance of the relations (Table 7.13). 















Falik (LI) 1 0 0.42 0 0.17 
2 -0.19 (-0.48 to 0.10) -0.19 (-0.49 to 0.10) 
3 -0.25 (-0.54 to 0.04) -0.27 (-0.5 1 to 0.08) 
4 -0.17 (-0.46 to 0.12) -0.2 1 (-0.53 to 0.08) 
1 5 -(). 18 (-0.47 to 0.11 ) -0.22 (-0.53 to 0.08) 
VeLmables 1 0 0.41 0 
00 2 -0.18 (-0.47 to 0.11 ) -0.24 (-0.54 to 0.05) 
3 -0.04 (-0.33 to 0.25) -0.09 (-0.38 to 0.2 1) 
1 41 -0.15 (-0.43 to 0.14) 
1 
-0.21 -0.52 to 0.09) 
L- 
1 51 -0.15 (-0.44 to 0.14) 
1 
-0.25 (458 to 0.07) 
Per-quintile increase in vitamin C intake was negatively related to BHR in the zn 
adjusted model (Table 7.14) and selenium was positively associated with BHR. After 
Bonferrom correction, the association wall vitamin C was no longer statistically 
significant, while there was still evidence for an increase in BHR with selenium Z: ý 
intake. 
Intake of flavonoids was unrelated to BFIR slope in this population. MUltivanable 
analyses showed negative associations with flavonols and total catechins, but they 
were not statistically significant (Table 7.15). In relation to plasma bloniarkers, a 
similar negative association was observed with F2-ip but (lid not reach statistical Z:, 
significance (Table 7.16). 
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Table 7.14: Association between BHR (mg- I) and nutrient intake 
Nutrient Quintile 
groups 
Unadjusted niodel Adjusted model 




1)ifl'cicil(-e ol nIcall', 
(9517, Cl) 
1)-% allic 
(1 or trcild) (lioilletroili 
corrected) 
Vitamin C 1 0 0.16 0 0.0.4 0.28 
(1110 
-0.16 (-0.45 to 0.12) -0.18 (-0.37 to 0.05) 
3 -0.22 (-0.51 to 0.07) -0.27 (-0.57 to 0.02) 
4 -0.17 (-0.46 to 0.11 ) -0.23 (-0.52 to 0.07) 
5 -0.22 (-0.51 to 0.06) -0.35 (-0.67 10 -0.0-4) 
Vitamin E 1 0 ()ý88 0 0.56 
MIO 0-08 (-0.21 to 0.37) 0.06 (-0.23 to 0.36) 
3 0.12 (-0.17 to 0.41 ) 0.08 (-0.22 to 0.38) 
4 0.10 (-0.19 to 0.39) 0.04 (-0.28 to 0.37) 
5 -0.04 (-0.33 to 0.25) -0.14 (-o. 51 to 0.23) 
Total 1 0 0. (11 0 0.68 
itamin A 2 -0.06 (-O. 3i to 0.22) -0.04 (-o. 33 to 0.26) (p ) 3 0.16 (-0.12 to 0.45) 0.17 (-0,12 to 0.47) 
4 -0.07 (-0.36 to 0.22) -0.10 (-0. -10 to 0.20) 
5 0.09 (-0.20 to 0.38) 0.10 (-0.21 to 0.4 1) 
( -3 
1 0 0.43 0 0.42 
kaly 2 -0.09 (-O. 3ýS to 0.20) -0.08 (-0-37 to o . 
21) 
t Inlo) 3 0.05 (-0.24 to 0.34) 0.03 (-0.26 to 0.33) 
4 0. ()8 (- D. 2 1to0.3 7) 0.08 (-0.22 to 0.3X) 
51 0.05 (-0.24 to 0.34) 0.06 (-0.24 to 0.36) 
Ratio 110/113 1 0 0.29 0 0.3 ý 
2 0.21 (-D. 08 to 0.49) 0.20 (-0.09 to 0.49) 
3 0.21 (-0.08 to 0.50) 0.17 (-0.12 to 0.46) 
4 -0.08 (-0.37 to 0.21 ) -0.07 (-0.36 to 0.22) 
5 -0.03 (-0.32 to 0.26) -0.03 (-0.32 to 0.26) 
sck-Ilium 1 0 0.0 0.00 (H) 1 
(pg') 2 0.32 (0.03 to 0.61 0.38 (0.08 to 0.67) 
0.23 (-0.06 to 0.51 0.41 (0.09 to 0.72) 
4 0.13 (-0.16 to 0.42) 0., 41 (0.05 to 0.77) 
5 0.41 (0.13 to 0.70) 0.89 (0.43 to 1.34) 
zilic 11 0 0. -17 0 0. -40 
2 0.0 1 (-0.28 to 0.30) 0.05 (-0.25 to 0.3-4) 
.3 
0.1 S (-0.11 to 0. -47) 0.21 (-0.11 to 0.53) 
-1 0.13 (-0.16 to 0.42) 0.16 (-0.19 to 0.50) 
.5 
0.06 (-0.23 to 0.35) 0.13 (-o. 30 to 0.55) 
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Table 7.15: Association between BIIR (mg'l) and flavonoid intake 
Flavonoids Quintile 
groups 







(951/( Cl) Oor trcnd) 
Flavoncs 1 0.29 0.39 
Oni-, /d) 2 -0.02 (-0.31 to 0.27) -0.02 (-0.31 to 0.27) 
3 0.08 (-0.21 to 0.37) 0.09 (-0.21 to 0.37) 
4 0.0 1 (-0.28 to 0.30) -0.0 1 (-0.31 to 0.29) 
5 0.16 (-0.13 to 0.45) 0.14 (-0.16 to 0.44) 
Flavonols 1 0.97 0.94 
(11ILY(l) 2 -0.11 (-0.40 to 0.18) -0.10 (-0.39 to 0.19) 
3 -0.20 (-0.49 to 0.09) -0.19 (-0.47 to 0.12) 
4 -0.0 1 (-0.30 to 0.28) -0.002 (430 to 0.30) 
5 -0.04 (-0.33 to 0.25) -0.04 (-0.35 to 0.27) 
Total 1 0.57 0.44 
calechins 2 -0.12 (-0.41 to 0.17) -0.15 (-0.44 to 0.15) 
(111L, () 3 0.02 (-0.27 to 0.31 -0.01 (-0.31 to 0.29) 
4 -0.00 (435 to 0.23) -0.10 (-0.40 io 0.20) 
5 -0.13 (-0.16 to 0.25) -0.16 (-0.46 to 0. 













(1 . or tren(1) 
FRAP (p NI) 1 0 0.70 0 0.79 
2 0.2 1 (-0.23 to 0.65) 0.17 (-0.28 to 0.62) 
3 -0.12 (-0.56 to 0.32) -0.15 (-0.60 to 0.30) 
-4 0.0 1 (-0.43 to 0.46) 0.03 (-0.43 to 0.49) 
5 -0.001 (-0.44 10 0. -44) 0.00 1 (-0.48 to 0.48) 
Uric Acid 1 0 0.99 0 0.65 
c 2 0.12 (-0.32 to 0.50) 0.15 (-0.29 ýo 0.59) 
3 0.15 (-0.29 to 0.60) 0.20 (-0.26 to 0.65) 
4 -0.05 (-o. -49 to 0.40) -0.0 1 (-0.47 to 0.45) 
5 0.12 (-0.33 to 0.56) 0.20 (0.27 to 0.67) 
Proicin 1 0 0.82 0 0.64 
CarbonyIs 1 0.23(-0.21 to0.67) 0.29 (-0.15 to 0.7-4) 
(iiiii/iI1Lý 3 0.23(-0.21 to 0.67) 0.2 1 (-0.24 to 0.66) 
prolein) 
-4 0.19 (-0-25 to 0.63) 0.17 (-0.27 to 0.61 ) 
5 -0.05 (-0.49 to 0.40) -0.06 (-0.51 to 0.38) 
F2- 1 0 0 0.41 
2 -0.02 (-0.47 to 0. -13) 0.30 -0.15 (-0.62 to 0.3 1) 
3 -0. -15 (-0.70 to 
0.21 ) -0.31 (-0.78 to 0.15) 
4 -0.51 (-0.97 to -0.04) -0.57 (-1.04 to - 1.00) 
5 -0.03 (-0.49 10 0.43) -0.02(-O. -48to0.45)_l 
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CHAPTER 8 
RESULTS III: Associations between lung function with 
dietary antioxidants, fatty acids and biomarkers 
8.1 FEVI AND FEVI/FVC AND THEIR ASSOCIATION WITH FRUITS AND VEGETABLES, 
NUTRIENTS AND PLASMA BIOMARKERS 
Table 8.1 shows the association between FEV, and frult and vegetable intake. The 
Unadjusted analysis showed that total intake of vegetables was positively related to a 
greater FEVI, which disappeared after adjustment for potential confounders. 
Analyses with individual food items (Appctidix 3) showed that intake of garlic and Zý 
onion was positively associated with a greater FEV, Nit this association lost 
statistical significance after Boil ferron i -correct ion. In relation to nutrient intake 
(Table 8.2), Linivariate analyses showed a statistically significant association between 
FEV, and intake of vitainin E, oniega 3 fatty acids, selenium, and zinc. Aftcr L- 
controlling for confoundcrs, only intake of omega 3 fatty acids rcmaincd statlý, tlcally C- L- 
sionificantly associated with a greater FEVI. However, Bonferroni correction raised C, L- 
the P-value above 0.1. 





Unadýjusted niodcl Adjusted model 








Fruits (L, ) l 0 0.07 0 0.09 
? 0.05 (-0.07 to 0.17) -0.02 (-0.09 to 0.05) 
3 0.04 (-0.09 to 0- 16) 0.03 (-0.04 to 0.10) 
4 0.02 (-0.10 to 0.14) 0.02 (-0.05 to 0.09) 
5 0.14 (0.02 1o0.27) 0.05 (-0.02 10 0.12) 
veg, clahles 1 0 <0.00 1 0 0.74 
2 0.16 (0.04 to 0.28) 0.03 (-0.04 to 0.10) 
3 0.25 (0.12 to 0.37) 0.0 1 (-0.06 to 0.08) 
4 0.26 (0.13 to 0.38) 0.0 1 (-0.06 to 0.08) 
5 0.31 (0.18 to 0.43) 0.03 0.05 to 0.10) 1 11 
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Table 8.2: Association between best FEV, (L) and nutrient intake 
Nutrient Quintile 
groups 
Unadjusted model Adjusted model 











Vilainin C 1 0 0.17 0 0.75 
Ong) 2 0.05 (-0.07 to 0.17) -0.05 (-0. ] 2 to 0.01 ) 
-1 
0.07 (-0.05 to 0,19) -0. W2 (407 to 0.07) 
4 0.05 (-0.07 to 0.18) 0.004 (406 to 0.07) 
5 0.09 (-0.03 to 0-22) -0.02 (-0.09 to 0.06) 
vitaillin E 0 <0.00 1 0 0.61 
Oliv) 0.05 (-0.07 to 0.17) -0.06 (-0.13 to 0.01 ) 
-1 
0.16 (0.04 to 0.28) -0. W4 (-0.08 to 0.07) 
4 0.29 (0.17 to 0.41 ) -0.02 (409 to 0.00) 
5 0.46 (0.34 to 0.59) 0.01 (-0.08 to 0.09) 
Totid 1 0 0.94 0 0.7S 
ýitaniin A 0.09 (-0.03 to 0.2 1) 0.06 (-O. (X)4 to 0.13) 
qlgý 
-3 
0.07 (-0.05 to 0.19) 0.04 (-0.03 to 0.11) 
4 0.05 (-0.07 to 0.18 1 0.0 1 (-0.06 to 0.08) 
5 0.02(-O. ]OtoO. 15) 0.02 (-0.06 to 0.09) 
0111ci-'a " 1 0 <0.001 0 0.02 0.14 
0.05 (-0.07 to 0.17) 0.04 (-0.03 to 0.11 
(Mi! ) 
.1 0.12 (00) 
1 to 0.25) 0.05 (-0.02 to 0.11 1 
4 0.24 (0.12 to 0.16) 0.08 (0.01 to 0.14) 
-5 
0.25 (0.13 to 0.37) 0.08 (0. W5 to 0.15) 
Rýilio n6hil 1 0 0.20 0 OJ I 
2 -0.02 (-0.14 to 0.11) -0.0 1 (-0.07 to 0.06) 
1 0. W4 (-0.12 to 
0.13) 
-0.03 (-0.10 to 0.04) 
4 -0.04 (-0.16 to 0.08 1 ). 0 1 (-0.06 to 0.08) 
5 -0.07 0.19 to 0.06) -0.07 (-0.14 to -0. W5) 
SCIC1141111 1 0 <0.001 0 0.0 
i_9 2 0.08 (0.02 to 0.25) -0.0 1 (408 to 0.06) 
3 0.26 (0.15 to 0.37) -0.04 (-O. l I to 0.03) 
4 0.48 (0.37 to 0.00) -0.06 (-0.14 to 0.03) 
5 0.75 (0.63 to 0.86) -0.02 0.13 to 0.09) 
Zinc (11w) 1 0 0.02 0 0.82 
2 0.14 (0.02 to 0.25) 0.02 (-0.05 to 0.09) 
3 0.30 (0.11) to 0.42) -0.05 (-0.12 to 0.03) 
4 0.54 (0.42 to 0.65) 1 -0.0 1 (-0.09 to 0.07) 
5 0.68 (0.57 to 0.80) 0.0 1 (-0.09 lo 0.1 h 
Intake of the three im 'or classes of flavonoids studied wits statistically significantly 1i I- 
associated with a (, reatcr FEV, in the unad'ustcd analyses. After controlling for L- 'I 
potential confounders, the assoclation with flavones disappeared but it remained of 
borderline statistical significance for I'lavonols and total catechins (Table 8.3). 1ý 
Among plasnia lcvels of biomarkers, a quintile increase in the levcls of FRAP wits 
related to a reduction of FEVI, association that remained statistically significant aficr 
Bonfcrroni correction (Tabic 8.4). 
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Table 8.3: Association between best FEV, (L) and flavonoid intake 
Flavonoids Quintile 
, groups 
Unaýjusted inodel Aýjusted model 








Flavones 1 0 0.00 1 0 0.96 
2 -0.00 1 (-0.12 to 0.13) 0.0 1 (-0.05 to 0.08) 
3 -0.12 (-0.24 to 0.002) 0.02 (-0.05 to 0.09) 
4 -0.12 (-0.25 to -0.002) -0.002 (-0.07 to 0.07) 
5 -0.17 (-0.27 to -0.002) 0.0 1 (-0.06 to 0.07) 
Flavollols 1 0 <0.001 0 0.08 
(nig/d) 2 0.10 (-0.02 to 0.23) 0.07 (0.003 to 0.14) 
3 0.11 (_O. () 1 to 0.23) 0.05 (-0.02 to 0.12) 
-4 0.10 (-0.03 to 0.22) 0.05 (-0.02 to O. 
'l 2) 
5 0.25 (0.13 to 0.37) 0.08 (0.0 1 to 0.16) 
Total 1 0 <0.001 0 0.06 
catechills 0.14 (0.0-1 to 0.26) -0.0-4 (-o. 1 1 to 0.03) 
(Int, (1) c 3 0.35 (0.23 to 0.47) 0.03 (-0.03 to 0.11) 
41 0.33 (0.220 to 0.45) 0.0-4 (-0.03 to 0.11 ) 
1 51 0.35 (0.23 to 0. -47) , 0. O4(-o. 03i00.11) , 
In relation to the ratio FEVI/FVC, there was no evidence of association with fruit 
intake. Consumption oftotal vegetables was negatively associated with FEVI/FVC in I 
the Linivariate model as the quintile conSLInIptIOII increased. Stich association became 
weaker after adjusting for all potential confounders crable 8.5). - ? -I 
C01114imption of vitamin E, sclenium and zinc was negatively associated with this 
outcome as shown by the difference of means in the crude model. After controllill(I r-I 
for confounders, the association found with vitamin E intake was no lon(ycr observed, 
whereas that with selenium and zinc still showed a neLlative trend but the 
associations were not statistically significant (Table 8.6). The analyscs with 
flavonoids showed that only total intake of catecluns were associated with 
FEVI/FVC. In the univariate model this association was highly statistically 
si-nificant, but after controllino for confounders remained negative but it became :7 1- 
Much Weaker (Table 8.7). Plasma biomarkers were unrelated to FEVI/FVC (Table 
8.8). 
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Unadjusted model Adjusted model 
Difference of ineans 
(95ý, '( Cl) 
P-\altic 
(for li, cii(1) 
1)i 1'1'ei-CI)CC 01- nicafv, 
(95', ý Cl) 
11-\ýlitie 




1 `R AP (p NI) 1 0 <0.001 0 0.0 1 0.04 
0.20(0.02 [o0.37) 0.06 (-0.04 to 0.15) 
0.28 (0.11 to 0.45) 0.02 ( -0.08 to 0.11 ) 
4 0.4-4 (0.26 to 0.61) -0.01 (-o. 09 10 0.11) 
5 0.40 (0.23 to 0.57) -0.13 (-0.23 to -0.03) 
Uric Acid 1 0 <0.001 0 0.66 
2 0.08 (-0.09 to 0.25) 0.0 1 (-0.08 to 0.11 ) 
3 0.28 (0.11 to 0. -45) 0.08 (-0.02 to 0.18) 
4 0.41 (0.2-4 to 0.58) 0.03 (-0.06 10 0.1-3) 
5 0.38 (0.21 to 0.55) -0.04 (-0.1 -4 to 0.07) 
protein 1 0 0 0.9-4 
Carhom Is 0.05 (-0.12 to 0.23) 0.03 (-0.06 to 0.13) 
(IIIII/Ing. 3 0.06 (-0.12 to 0.24) 0.0 1 (-0.09 to 0.11 ) 
protein) 
-4 0.11 (-0.00 to 0.29) -0.0 1 (-0.11 to 0.09) 
5 0.1-4 (-0.04 to 0.31) 0.02 (-0.08 to 0.12) 
F2- 0 0.0 1 0 0.67 
- 0.18 (0.01 to 
0.30) 0.09 (-O. (X)5 to 0.19) 
3 0.28 (0.10 to 0.46ý 0.07 (-0.03 to 0.16) 
4 0.11 (-0.07 to 0.29) -0.0 1 (-0.11 to 0.09) 1 5 0.29 (0.11 to 0.46) . 
0.07(-O. 02to0.17) 





Una(tiusted model AdJusted model 




Diffelence if) Ific"Ins 
(95'/( (1) 
P-valkic 
(1, ()[- Ircnd) 
1'ruits (. g) 1 0 0.25 0 0.21 
-0.002 (-0.01 to 0.0 1) -0.004 (-0.01 to 0.0 1) 
3 (). ()()1 (-()1() 1 to 0.0 1) -0.002 (-0.01 to 0.004) 
4 -0.003 (-0.01 to 0.0 1) -0.005 (-0.01 to 0.004) 
5 -0.0 1 (-0.0 1 to 0.003) -0.005 (-0.01 to 0.003) 
vc! 
-, Ct, tl)ics 
1 0 0.003 0 0.10 
0.002 (-0.01 to 0.0 1) 0.004 (-0.01 too. 01) 
3 -0.0 1 (-0.02 to -0.00 1 -0.0 1 (-0.02 to 0.002) 
41 -0.0 1 (-0.02 to -0.003) 1 -0.0 1 (-0.02 to 0.0002) 
5 -0.0 1 (-0.02 to 0.00 1) -0.002 (-0.01 to 0.007) 
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Table 8.6: Association between ratio FEVIIFVC and nutrient intake 
Nutrient Quintile 
groups 
Unadjusted model Adjusted model 








Vitamin C (III-) 1 0 0.26 0 0.44 
2 -0.002 (-0.01 to 0.0 1) -0.0002 (-0.01 to 0.0 h 
3 -0.0 1 (-0.02 to -0.002) -0.01 (-0.02 to -0.0005) 
4 -0.003 (-0.01 to 0.004) to 0.0 1) 
5 -0.005 (-0.01 to 0.004) -0.003 (-0.01 to 0.0 1) 
Vitamin F, ono 1 0 0.02 0 0 
2 (). om 100.01) 0.002 (-0.01 to 0.0 1) 
3 -0.01 (-0.01 toO. 003) -0.004 (-0.01 to 0.0 h 
4 -0.005 (-0.01 to 0.004) -0-. -000-1 
(-0.0 1 to 0.0 1 
5 -0.0 1 (-0.02 to -0.004) -0.0 1 (-0.02 to 0.0 1 
Total vitamin A 1 0 0.15 0 0.19 
0 2 0.0 1 (-0.003 to 0.0 1) (). ()1 to 0.0 1 
3 -0.005 (-0.01 to 0.004) -0.004 (-0.01 to 0.004) 
4 -0.005 (-0.01 to 0.004) -0.004 (-0.01 to 0.005) 
5 -0.002 (-0.01 to 0.0 h -0.00 1 (-0.0 1 to 0.0 1 
Onic! -, a 3 flittv 1 
0 0.83 0 0.52 
acids ong) -0.003 (-0.01 to 0.01 -0.003 (-0.01 to 0.01 
3 (). om to 0.0 1 0.002 (-0.01 100.01) 
4 -0.001 (-0.01 to 0.01 0.002 (-0.0 1 100-01) 
5 -0.002 (-0.01 100.01) (-(). () 1 100.01) 
Ratio n6/n 1 0 0.54 0 0.69 
2 -0.002 (-0.01 to 0.0 0 (-(). () I to 0.0 1 
3 -0.0 1 (A02 to 0.0 1) -0.0 1 (-0.0 1 to 0.002) 
4 to 0.0 1) 0.002 (-0.01 to 0.0 1) 
5 -0.0 1 (-0.0 1 to 0.004) -0.003 (-0.01 to 0.0 0 
Sclenium Q10 1 0 <0,00 1 0.09 
2 -0.002 (-0.01 to 0.0 1) -0.003 (-0.01 to 0.0 h 
1 -0.004 (-0.01 to 0.005) -0.00 1 (-0.0 1 to 0.0 1) 
4 -0.0 1 (-0.02 to -0.003) -0.0 1 (-0.02 to 0.003) 
5 -0.02 (-0.03 to -0.0 1) -0.0 1 (-0.03 to 0.000 1 
Zinc 011Y) 1 0 <0.00 1 0 0.14 
2 0.005 (-0.004 to 0.01) 0.0 1 (-0.003 to 0.0 1) 
3 -0.005 (-0.01 to 0.003) -0.002 (-0.01 to 0.01) 
4 -0.02 (-0.03 to -0.0 1) -0.0 1 (-0.02 to 0.000 1) 
5 -0.0 1 (-0.02 to -0.002) 1 (-(). () I to 0.0 1) 
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Table 8.7: Association between ratio FEVI/FVC and flavonoid intake 
Flavonoids Quintile 
groups 
Unadjusted model Adjusted model 
Diff, clence of' 111caw", 







Flavones Ono/d) 1 0.88 0.77 
-0.00 1 (-0.0 1 to 0.0 1) -0. (X) 1 (-0.0 1 to 0.0 1) 
3 0.005 (-0.004 to 0.0 1) 0.0021 (-0.0 1 to 0.0 1) 
4 to 0.0 1) -0.002 (-0.01 to 0.0 1) 
5 0.00 1 (-(). () I to 0.0 1) I (-(). () I to 0.0 1) 
I`Ln, oflols ww/d) I O. Is 0.99 
2 -0.00 11 to 0.0 1 0.001 (-0.01 to 0.01 
3 -0.003 (-0.01 to 0.0 1) -(). O()l to 0.0 1) 
4 -0.01 (-0.01 toO. 004) -0.002 (-0.01 too. 01) 
5 -0. (H)4 (-0.01 to 0.0(9) 0. (X)2 (-0.01 (00.01) 
Total catechins 1 0.00 1 0.09 
2 -0.002 (-0.01 to 0.0 1) 0.0003 (-0.01 100.01) 
3 -0.0 1 (-0.02 to -0.002) -0.0 1 (-0.02 to 0.003) 
4 -0.01 (-0.02 to -0.004) -0.0 1 (-0.02 to 0.002) 
5 -0.01 (-0.02 to -0.003) -0.0 1 (40 1 to 0.004) 






Unadjusted model Adjusted model 








FRAP (! tNI) 1 0 0.16 0 0.95 
2 0.003 (-0.01 to 0.02) 0.01 (-(). 0 1 to 0.02) 
3 -0.02 (-0.03 to -0.003) -0.0 1 (-0.02 to 0.0002) 
4 0.00 1 (-0.0 1 to 0.0 1) 0.0 1 (-0.0 1 to 0.02) 
5 -0.0 1 (-0.02 to 0.004) -0.0002 (-0.01 to 0.0 1) 
Uric Acid 1 0 0.27 0 0.77 
Olli-, ML) 2 0.0 1 (-0.005 to 0.02) 0.0 1 (-O. (H)3 to 0.022) 
3 0.003 (-0.01 to 0.02) 0.0 1 (-O. (X)5 to 0.02) 
-4 -0.005 (-0.02 to 0.0 h 0.002 (-0.01 to 0.0 h 
5 -0.00 1 (-0.0 1 to 0.0 1 0.0 1 (-0.0 1 to 0.02) 
1 0 0.12 0 0.26 
CarbonvIs I -0. M4 (-0.02 to 0.0 1) -0.0 1 (-0.02 to 0.0 1) 
3 -0.0 1 (-0.02 to 0.004) -0.0 1 (-0.02 to 0.003) 
prolcill) 4 -0.0 1 (-0.02 to 0.0 1) -0.0 1 (-0.02 to 0.0 1) 
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9.1 MAIN FINDINGS, STRENGTHS AND LIMITATIONS OF THE THESIS 
9.1.1 Main findings 
Overall, there were a large number of tests carried out that showed none or little 
evidence for an association between dietary intake of antioxidants and fatty acids, and 
biomarkers of oxidative stress with respiratory outcomes. An exception was the 
negative association found between BHR slope and intake of vitamin C, which was 
observed univariately and in the multivariable models. As Bonferroni correction gave a 
.-V P-value above 0.05 this may be a type I error due to the number of tests carried out. 
Contrary to that expected, BHR slope was positively associated with intake of 
selenium, with a P-value below 0.05 after Bonferroni correction. In addition, a greater 
FEVI was positively associated total intake of catechins and plasma levels of FRAP 
were positively associated with FEVI. 
9.1.2 Strengths of the study 
This thesis is the first population-based study carried out in a Latin American country 
assessing the association between dietary intake and several biomarkers of oxidative 
stress with lung function, respiratory symptoms, atopy and BHR, in a sample 
comprising nearly 1,200 young adults. This is also the first study assessing the 
association between the biomarkers F2-ip, protein carbonyls, uric acid and FRAP with 
respiratory outcomes related to asthma in a community-based study. The limited 
evidence on F2-ip and protein carbonyls as biomarkers of oxidative stress in asthma 
comes largely from clinical studies that have included a small number of participants 
with specific conditions of asthma and may not reflect the situation in the general 
population. 
The prevalence of respiratory symptoms and the assessment of lung function, and 
atopy were determined using a standardised methodology based on the protocol of the 
ECRHS, which was aimed to estimate the prevalence of asthma and its risk factors 
across Europe. The use of such a protocol has the advantage that it allows comparison 
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between the prevalence of asthma in Chile and that in Europe and to explore the 
aetiology of the disease using the same instruments. 
Another strength of this study was that trained professionals administered the 
questionnaires to collect information on diet, asthma and risk factors. This reduced the 
possibility of having incomplete questionnaires. 
The FFQ used in this study was specifically designed to assess consumption of dietary 
antioxidants and fatty acids, and those food items considered part of the usual dietary 
intake of the people in Chile, thus including a selection of 62 food items. The 
professionals who administered the questionnaire were unaware of the antioxidant 
hypothesis being tested, thus diminishing the risk of infori-nation bias. 
Most of the results published so far on asthma and diet have the limitation of focusing 
on particular nutrients or food items in isolation. This thesis examined a wide range of 
foods and nutrients. The study of Woods and colleagues is the only one so far looking 
at the associations of food and nutrient intake with asthma [106], which included self- 
reported symptoms of asthma, and measurements such as BHR and atopy. In spite of 
analysing a wide range of individual nutrients, only a few grouped food items were 
presented in the study of Woods et al. Information in relation to fruits and vegetables 
was limited, with three categories for fruits (1-2 pieces a day, apples and pears 
together, and berries), and vegetables (2-4 servings, green leafy, and tomatoes) so it 
provided limited range of sources of antioxidants studied. In addition, they adjusted for 
very few potential confounders, which for example did not include socio-economic 
level, an important determinant of dietary intake and asthma. 
In the current study the association between dietary intake and asthma was explored 
not only in relation to self-reported symptoms of asthma but also to BHR, a more 
objective measurement, in contrast to most of the current epidemiological evidence 
limited to self-reported symptoms [332]. This may have been an advantage, as it 
reduced possible cultural bias in people that may for example, misunderstand the 
concept of wheeze or interpret it as something different. 
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The choice of using the tidal breathing method to assess BHR facilitated the test in the 
participants as it requires breathing normally during two minutes instead of matching 
the exhalation with the exact time at which the methacholine is released. In Chile, the 
tidal breathing method has been commonly used in the specialised services, and the 
nurses received training in a hospital dedicated to respiratory diseases in order to be 
able to perform the manoeuvre correctly. 
9.1.3 Limitations of the study 
The design of this study was cross-sectional, and so it is not possible to establish the 
temporality of the association between nutrient or food exposure and respiratory 
outcomes. The endpoints of interest were present at the time when data were collected, 
and thus an assessment of disease status and exposure were at a single point in time, 
making it unfeasible to determine whether the exposure preceded or resulted from the 
disease. 
Another limitation of this thesis is related to the use of an FFQ to estimate dietary 
intake. It is well known that assessing nutrient intake through questionnaires may 
introduce measurement and recall bias. In this study it is unlikely that dietary reporting 
bias had occurred, as all the participants were interviewed about many other aspects of 
health than dietary intake, and were unaware of any of the hypotheses being tested, in 
particular about the link between antioxidant nutrients and asthma. The FFQ in this 
study was standardised, based on a pilot study first, and compared to a 24 hour-recall 
questionnaire. The validation study showed that the level of agreement was good to 
excellent for most of the food items, with the exception of fish, whose consumption 
was very low by either questionnaire but reported higher in the FFQ than in the 24- 
hours recall. 
A third limitation of the study was that the assessment of biomarkers of oxidative stress 
and of antioxidant status was only possible in approximately 50% of the participants. 
This occurred because the study had already started when funding for determination of 
these biomarkers was obtained and it was unfeasible to take again blood samples to 
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estimate these biomarkers in a proportion of the participants. Nevertheless, this is the 
largest epidemiological study assessing F2-ip in general population. 
In addition it was not possible to assess biomarkers, of nutritional exposure because of 
the lack of facilities to assess them in Chile, which prevented this study from 
contributing to the current debate on the effect of plasma levels of vitamins and 
minerals, for example, in relation to symptoms of asthma. The measurement of FRAP 
contributed to overcoming this limitation, as it provides an indirect estimation for 
activity of vitamin C and flavonoids in plasma. 
The assessment of biomarkers of nutritional exposure such as vitamin C and others in 
different tissues and fluids can be considered a more reliable or at least less subjective 
estimation of nutrient exposure, although is not free from limitations related to 
reproducibility, validation and interpretation of causality [333]. This may partly 
explain the inconclusive epidemiological evidence obtained from dietary intake in 
relation to asthma symptoms as reviewed in Chapter 3. 
All the biomarkers of this study were assessed in plasma, and may not reflect oxidative 
stress as direct consequence of asthma as would other biomarkers assessed in more 
specific sites. FRAP and uric acid are indicators of the general antioxidant capacity 
observed in plasma, while carbonyls of proteins reflect general oxidative damage. 172- 
ip is a marker and a mediator of oxidative damage, and its production is related to the 
oxidation of specific fatty acids involved in the inflammatory response implicated in 
the asthmatic response, which adds more precision to the possible oxidative imbalance 
derived from asthma. It may be suggested that assessment of these biomarkers in more 
specific sites such as exhaled breath or condensate air may ascertain better the 
oxidative stress related to asthma, but the current evidence is still very limited to draw 
such conclusions. 
9.2 JUSTIFICATION IN THE USE OF SELECTIED CONFOUNDERS 
In this study very few antioxidants showed an association with any of the outcomes 
studied before and after controlling for confounders. One of the factors affecting the 
estimation of dietary intake from an FFQ is the heterogeneity of the population studied 
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in terms of age and sex, but these considerations did not affect the lack of associations 
in the majority of the analyses. With BHR and respiratory symptoms, for example, 
little change was observed when adjustments for potential confounders were carried 
out. 
As many comparisons were carried out in this study, the issue of whether further 
adjustments to P-values were necessary was considered. An adjustment for multiple 
comparisons in epidemiological studies has been considered unnecessary by some 
[334,335], essential by others [336], or subject to the investigator's decision [337]. In 
this study, the Bonferroni correction was carried out in those tests when a nominal 
statistically significant association was found. Thus, a conservative approach was 
taken. 
9.2.1 Adjustment for TO 
The effect of TO was assessed in a separate model with all the other potential 
confounders (Appendices 2 and 3) in order to assess the effect of measurement error. 
The FFQ designed for this study, ascertained intake of individual food items and 
nutrients in order to be more specific of which food items may or may not account for 
associations, but the inclusion of many food items tends to overestimate TEI [338]. In 
the design of this FFQ, every attempt was made to cover the most traditional food 
items consumed by Chileans and also those that were important for their content of 
antioxidants or fatty acids. Taking into account this criterion, the FFQ was limited to 
just 62 food items. In spite of these precautions, overestimation of macronutrients was 
confirmed in the validation carried out against a 24 hours questionnaire administered 
on three occasions to a sample of the participants, which justifies further the 
adjustment for energy intake. 
As suggested by Willet, measurement errors for specific nutrients tend to be highly 
correlated with errors for total energy intake, because they are calculated from the 
same food items. Thus, adjustment for TO will control for the effect of correlation 
between nutrients and TEI [339]. Macronutrients are usually highly correlated with 
TEI, and lack of adjustment by energy intake when associations with nutrients are 
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sought can obscure true associations -or the lack of them- or provide spurious 
associations between nutrient intakes and disease [339]. 
A constraint in several observational studies is that TEI is not adjusted for when 
assessing relations between diet and respiratory outcomes, and it is possible that these 
findings or the lack of them may be obscured by the effect of TEI. For example, some 
authors have reported a beneficial inverse association between intake of vitamin C and 
morning cough [ 107], BHR [III], atopy [ 122], and allergic asthma [ 113], but none of 
these were adjusted for TEI. 
A number of other studies that have controlled for a limited number of potential 
confounders but excluded TEI, have reported a beneficial inverse association between 
consumption of vegetables and bronchial asthma [340], between intake of green leafy 
vegetables and current asthma [106], or tomatoes and atopy [1061. These findings 
could be obscured by the effect of TEI. The same limitation arises from studies that 
have found positive associations between fruit intake and a greater FEVI [158], 
incidence of asthma [154], current asthma, BHR and atopy [1061. 
In the case of asthma and BMI, there has been much debate on whether body size and 
obesity play a role in the incidence of the disease or if they are concurrent diseases 
[3411. This hypothesis was tested in the population of Limache, finding that BMI was 
positively associated with symptoms of asthma but it was. negatively associated with 
BHR. Waist circumference was unrelated to asthma symptoms and BHR, thus 
suggesting that a causal relationship between body size and asthma is unlikely [3421. 
9.2.2 Adjustment for socio-economic and demographic variables 
As reviewed by Tohill et aL, epiderniologic studies indicate that several socio- 
economic and demographic factors that could be related to a disease are also strongly 
related to consumption of fruits and vegetables [343]. In this thesis, the analyses of 
fruits and vegetables included adjustments for sex, age, and height (in the case of 
FEVI), and a number of socio-economic and demographic variables. There is sound 
evidence that a higher consumption of fruits and vegetables has been associated with 
being older, higher educational level, being less sedentary, not smoking, as well as a 
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general healthier diet characterised by lower consumption of fats and of red meat [344- 
348]. 
A methodological limitation in several observational studies is the lack of adjustment 
for socio-economic variables or educational level, when assessing the relation between 
consumption of fruits and vegetables and respiratory symptoms or lung function. The 
large cross-sectional study by Tabak et al. in adults from Finland, Italy and The 
Netherlands reported a positive association between FEVI and fruit in those with an 
intake above the median, but adjustments for socio-economic factors or educational 
level were not made [97]. Similarly, in the MORGEN study a beneficial association 
was reported on intake of fruit juice and vegetables with FEVI, but the authors did not 
adjust for socio-economic level [155]. Knekt and colleagues reported a beneficial 
association between apple and orange intake with incidence of asthma in a 
retrospective longitudinal study, but with a limited adjustment for confounders [154]. 
9.3 MAIN ASSOCIATIONS BETWEEN ANTIOXIDANTS AND RESPMATORY OUTCOMES 
9.3.1 Associations between antioxidant vitamins and measurements of asthma 
Vitamins C, E and A are the nutrients most extensively investigated in epiderniologic 
studies for their antioxidant and in the case of vitamins C and E, anti-inflammatory and 
anti-allergic effects on asthma. In this study, the daily consumption of all these 
vitamins was well above the EAR and also higher than the recommendations given by 
the Chilean Ministry of Health. Intake of vitamin E was almost 5 times higher than 
recommended values, while those of vitamin C and A were triple and double the 
recommendation, respectively. 
A negative association was found between intake of vitamin C and BHR slope. The 
multivariable analyses with BHR slope controlled for FEVI%/FVC, FEVI% and atopy 
as potential confounders, so this finding was not explained by lung function or skin 
allergen sensitisation variation. The fact that the intake observed in this population was 
well above the RNI may lend further support to this possible protective effect, on the 
grounds that vitamin C is a powerful antioxidant and its modulator effect on the 
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respiratory tract can be observed with higher intakes of the antioxidant. when provided 
with the diet. 
It could be argued that this is a chance finding, as although it remained statistically 
significantly associated with BHR slope after controlling for all potential confounders, 
the P-value was no longer significant after Bonferroni correction. It is expected that the 
tests could produce some type I errors due to the multiple comparisons carried out. 
The evidence from other observational studies is very limited in relation to vitamin C 
and BHR to draw conclusions on the possible effects of this antioxidant. A cross- 
sectional study carried out in a sample of 1,601 Australian adults found no association 
between a per mg increase in intake of vitamin C and BFIR (OR 0.96, CI: 0.71 to 1.3 1) 
[106], while in a small case-control study, Soutar and colleagues showed that those 
with a positive response to methacholine had significantly lower intake of vitamin C 
than those who did not have a positive reaction [I I I]. 
In the current study, there was no association between respiratory symptoms, or BHR 
and increasing intake of vitamin E. This is in agreement with the large majority of 
evidence currently available from observational studies that have assessed intake of 
vitamin E in relation to wheeze [94,109], asthma [1101, seasonal symptoms (allergy, 
atopy, eczema) [I I I], cough [94], phlegm [94], shortness of breath [94], current asthma 
[ 106], asthma ever [ 106], and BHR [III]. 
There is some evidence from a longitudinal study that high vitamin E intake is 
associated with a lower incidence of asthma over a ten-year period in women [ 114], 
and that plasma levels of vitamin E are lower in adults with moderate allergic asthma 
(as defined by GINA) when compared to healthy individuals [123]. In contrast, one 
study reported that those with a higher intake of vitamin E had a higher prevalence of 
productive cough [94]. The lack of consistent findings indicates that a high degree of 
uncertainty over the effect of vitamin E on asthma remains. 
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9.3.2 Association between antioxidant. vitamins and lung function 
Dietary intake of vitamins or vegetables was unrelated to measurements of lung 
function in the adults from Limache. The epidemiological evidence on diet and 
respiratory health is suggestive of some beneficial effect of vitamin C on lung function 
as reviewed in detail in Chapter 3. This thesis does not provide evidence to support 
these findings. 
Similarly, vitamin E in adults from Limache was not associated with lung function. In 
this regard, the epidemiological evidence is far less conclusive than that for vitamin C 
and it will require further studies to clarify its role if any. Britton and colleagues 
reported an increase of 20.1 ml and of 5.3 ml for FEVI and FVC in adults from 
Nottingham as the intake of vitamin E increased by I SD [921. Butland et al. also 
showed that aI SD increase of vitamin E was associated with a 39.1 ml increase of 
FEVI after, but not before adjusting for energy intake, and a weaker but still significant 
increase remained after controlling for vitamin C and apple intake [ 100]. 
Hu and colleagues found a significant increase in FEVI in their study when vitamin E 
was the only nutrient in the multivariable model, but this beneficial association was no 
longer observed when vitamin C and P-carotene were included simultaneously with 
vitamin E [96]. Two other large cross-sectionals studies found no association between 
intake of vitamin E and FEVI [94,97] or FVC [94]. 
9.3.3 Association between vegetable or fruit intake and respiratory symptoms, 
BHR or lung function 
The main analyses of this thesis showed no association between intake of fruits and 
vegetables with any of the outcomes studied. It has to be pointed out that the additional 
statistical analyses carried out with individual food items showed statistically 
significant associations, although the P-values were raised above 0.1 after Bonferroni 
correction (Appendices 2 and 3). 
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A positive association was observed between intake of garlic and onion and a greater 
FEVI, (Appendix 3, Table E (1)) as well as a negative association with BHR slope 
(Appendix 2, Table A (1)). After Bonferroni correction these associations lost 
statistical significance. It is known that garlic and onions are rich in organosulfur 
compounds [349]. Additionally, onions are characterised by their high content of 
flavonoids, particularly anthocyanins and flavonols (such as quercetin and its 
derivatives). 
The organosulfur compounds, specifically the alk(en)yl cysteine sulphoxides found in 
these two foods, act as antioxidants with free radical-scavenging properties to inhibit 
lipid peroxidation [350]. The flavonoids found in onions can function as chain- 
breaking antioxidants by scavenging some radical species [351]. They may suppress 
lipid peroxidation by recycling other antioxidants, such as (X-tocopherol, by donating a 
hydrogen atom to the (x-tocopherol molecule. In addition, they can chelate pro-oxidant 
metal ions, such as iron and copper, thus preventing free radical formation from these 
pro-oxidants while simultaneously retaining their own free-radical scavenging 
capability [35 1 ]. 
These facts may contribute to prevent or diminish the damage induced by oxidative by 
irritants such as the methacholine, and facilitate a general better maintenance of the 
oxidant balance in the lungs. Although a possible chance finding cannot be ruled out, 
the potential public health significance of these findings should be explored further. 
Regarding legumes, it was observed that consumption of lentils was related to a lower 
risk of prevalence of having at least one respiratory symptom, which was statistically 
significant before but not after Bonferroni correction (Appendix 2, Table D (1)). Most 
of the evidence in relation to intake of legumes and asthma is about the glycoproteins 
that they contain, which have been recognised as food allergens [352,353]. However, 
it has been recognised that legumes, and in particular lentils, are rich in 
proanthocyanidins, the major group of polyphenols, and also have some content of 
catechins, such as (+) catechin-3-glucose, (+)-catechin and (-)-epicatechin [354]. The 
findings of the negative association observed in the current study between lentils and 
respiratory symptoms could be explained by the antioxidant properties displayed by 
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these antioxidants, and lend further support to the hypothesis that polyphenols and 
flavonoids could have a beneficial role against respiratory symptoms. 
9.4 INTAKE OF FLAVONOIDS 
In the current study the relation between symptoms of asthma and BHR, as well as 
lung function measurements, with intake of three major subclasses of flavonoids was 
assessed. There was a predominant lack of associations found in these analyses with 
the exception of an association between total catechins intake and best FEV]. These 
findings are in line with Tabak et A who found that total intake of catechins were 
positively associated with a greater FEVI in a sample of 17,453 adults from The 
Netherlands [155]. 
There is limited epidemiological evidence of an association between different classes 
of flavonoids and respiratory symptoms. Very recently we have found no association 
between any of the three classes of flavonoids and asthma or chronic sputum in adults 
from London [156]. Another study reported that quercetin (the main flavonol), and 
herperitin and naringenin (flavonones), but not catechins, were negatively associated 
with incident asthma [154]. In the current study, no associations were found for 
flavonols and flavones and symptoms of asthma, and although flavonones were not 
measured, none of their dietary sources (orange, lemon and kiwi) were related to any 
respiratory symptom or BHR. 
The median (IQR) intake of total flavonoids in the Chilean population was 48.7mg 
(24.2 to 113.5). A mean intake of 58 mg/d (SD 46) was reported for a study of adults in 
The Netherlands, which assessed the same classes of flavonoids as the current study 
[155]. A cohort study of 10,040 Finnish adults reported lower values of total flavonoid 
intake. As in this study, they assessed flavones (quercitin, kaempferol and myricetin) 
and a subclass of flavonones (naringenin and hesperitin) that were not calculated in the 
Chilean population, but excluded measurements of catechins, which may explain the 
differences in the observed intakes [154]. 
The median (IQR) intake of catechins in Chileans was 19.1 mg/day (8.8 to 66.4), 
similar to that reported in postmenopausal American women [355], and considerably 
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lower than that reported by us in adults from London (median (IQR) 81.2 (32.5 to 
135.7) mg/day) [156] and by others in Dutch elderly men [356]. The intake of total 
catechins in the studied adults agrees with the average one cup of tea a day reported. 
The FFQ administered in Chile was specifically designed to ascertain consumption of 
flavonoid-rich food items, taking into account their availability in the area where the 
study was conducted and their being part of the usual dietary intake of this population. 
These included apple, strawberry, garlic, onion, tea and red wine. The list of foods 
included in the questionnaire was revised and agreed by the Dutch creators of the 
database that collaborated with the study (Arts, personal communication). 
Additional individual analyses with tea, apples and red wine (main dietary sources of 
catechins), demonstrated no associations with the primary outcomes of interest or with 
measurements of lung function in this study, which could indicate that the beneficial 
effect of catechins may not be causal. It has to be noted that the two main catechins 
found in tea, namely epigallocatechin gallate (ECGg) and epicatechine gallate, are less 
biologically active in vivo than are other catechins [357]. 
Flavonoids have the capacity to reduce asthma inflammation through antioxidant, anti- 
allergic and anti-inflammatory properties by different mechanisms, which include their 
ability to act as scavengers of nitric oxide, inhibiting histamine release, arachidonic 
acid metabolism, and cytokine production [35 1 ]. 
A positive association between a higher intake of catechins and having at least one 
respiratory symptom was also found. One possibility is that despite their well-known 
antioxidant activity, the pro-oxidant effect previously mentioned for EGCg may have 
explained these results. 
9.5 INTAKE OF FATrY ACIDS 
9.5.1 Omega 6 and omega 3 fatty acids 
The estimated 47: 1 ratio n6/n3 found in this population was much higher than the 
range recommended as healthy. According to Simopolous, the healthy range varies 
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from 1: 1 to 5: 1 depending on the disease under consideration [358], with a general 
recommendation of 2: 1 [329]. Such a high ratio in this population is explained by the 
low consumption of fish, which only reached I Og per day in average, in linewith other 
studies on dietary habits in the country [359] and with the per capita intake of 
5. lkg/year described for the Chilean population [166]. This ratio also corresponds to 
the increased consumption of omega 6 found in hydrogenated oils. This is 
representative of the current tendency observed in Chile [166,359], characterised by a 
steady rise in the consumption of products manufactured with hydrogenated oils, and a 
decrease in the consumption of solid fats of animal origin, including butter. 
In the analyses, there was no indication of an association between intake of fatty acids 
omega 3 and respiratory symptoms of asthma, BHR or lung function. There is evidence 
that dietary supplementation with omega 3 reduces AA concentration in neutrophils, 
generation of LT [360] and airway late response to allergen exposure [188], which is 
consistent with the proposed mechanisms by which omega 3 modulates asthma and 
inflammation in the respiratory tract [167]. The findings in this Chilean population are 
not suggestive of such a beneficial effect, at least for asthma. 
9.6 BIOMARKERS OF OXIDATIVE STRESS AND ANTIOXIDANT STATUS 
9.6.1 F2-ip 
Levels of oxidative stress as assessed from plasma F2-ip did not show any association 
with the measurements of asthma, with one exception. A nominal statistically 
significant negative association was observed between plasma F2-ip and having at least 
one respiratory symptom in the adjusted model, but the Bonferroni correction raised 
the P-value above 0.1. 
The measurement of plasma levels of F2-ip in this population was undertaken for 
several reasons. Firstly, since its discovery, increasing clinical and experimental 
evidence has demonstrated that the level of F2-ip is a good indicator of oxidation in 
vivo [38]. Secondly, the production of F2-ip has relevance in relation to asthma, as its 
production is derived from AA, and this PUFA is directly associated with the 
inflammatory events that take place during the manifestation of asthma symptoms. 
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Therefore it would be expected that higher levels of F2-ip would be found with higher 
prevalence of manifestations of inflammation. 
In addition, F2-ip is relevant for the study of asthma as it is not only a biological 
marker but also a mediator of oxidative stress, and thus may play an active causative 
role in the development of the disease. A number of experimental studies have 
demonstrated that F2-ip is a mediator of inflammation, jointly with other isoprostanes, 
directly involved in the pathology of asthma, and that it affects airway smooth muscle 
contraction, and it is a potent bronchoconstrictor [361-362]. 
The results of the current study do not support any of the findings of experimental 
evidence. One reason to be taken into consideration is that most of the existing data 
were obtained in rodents. There is evidence of different response to F2-ip according to 
the type of animal where the biomarker is assessed. For example, airways in rabbits 
[363] and dogs [364] do not constrict in response to either 8-iso-PGE2 or F2-ip, and a 
relaxant response to F2-ip has been observed in the pulmonary arteries of rat [365]. 
Therefore, the strength of the evidence has to be viewed with caution. There are 
relatively few studies done in human tissues suggesting that is a constrictor agent [364, 
366,367] and from human pulmonary vessels demonstrating that F2-ip is released 
under conditions of oxidative stress when exposed to NO or COX [3691, but these 
findings may not reflect what occurs in population-based studies. 
F2-ip is produced in variable amounts both in conditions of health and illness, so it is 
normal to detect F2-ip, at least in plasma, in healthy subjects. In this study, the mean 
value of plasma F2-ip was 30pg/ml (range 5.6 to 95.4), which may be a reference for 
the range within which values of F2-ip may be found in the community. 
This study assessed F2-ip in plasma, a less specific measure of oxidative stress than 
that of other sites. Plasma is much more likely to indicate normal synthesis that occurs 
in the cell membranes during processes of reactions of oxidation-reduction in different 
organs and systems and is not as specific as those of airways. A large proportion of 
F2-ip obtained from exhaled breath condensate comes from that produced and released 
from the respiratory airways, suggestive of production of lipid peroxidation occurring 
in the airways rather than mirroring any systematic process of oxidative stress. 
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However, this may not always be possible to assess in large community studies due to 
the high cost involved. In this study, the methodology to determine exhaled F2-ip or 
NO was not feasible due to its high cost at the time the study was carried out. 
The methodology used for the estimation of F2-ip in this population was based in an 
immunoassay, which is one of the several techniques utilised for determination of PG- 
like compounds. As indicated by Roberts et al. [38], the main limitation of this 
technique is that interfering substances in biological fluids (i. e. plasma, serum) can be 
encountered and interfere with the immunoassay. As immunoassays can produce an 
accurate measure in buffer systems that do not contain large amounts of biological 
substances [38], more recent kits, such as the one used for the current study, include 
buffer solutions and purification to eliminate interfering substances, thus increasing the 
reliability of the test. In a recent review, Morrow highlighted that immunoassays are 
becoming increasingly used in quantification of F2-ip due to their low cost and relative 
ease of use [368]. 
The lack of association between F2-ip and most of the respiratory outcomes may also 
correspond to the fact that those who reported respiratory symptoms may have had a 
mild form of asthma rather than a more severe manifestation of symptoms. It may be 
possible that differences in F2-ip can be detected when more severe manifestations of 
symptoms are present, and thus, a much greater production of the biomarker will be 
produced in comparison to those with no symptoms at all. 
Inclusion of BMI and sex as confounders was considered based on previous evidence 
suggesting that women are more likely to have higher values of F2-ip [203] and of lipid 
peroxides [369], possibly linked to a higher deposit of body fat, and thus of substrate 
for lipid peroxidation. However, in this study controlling by sex and BMI did not affect 
the relationship between F2-ip and lung function, BHR, or respiratory symptoms in the 
presence of atopy. 
The finding of increased levels of F2-ip both in the circulation and in the urine of 
smokers [198,370] is consistent with the fact that cigarette smoke contains a large 
number of oxidants and free radicals that could directly initiate and propagate the 
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process of lipid peroxidation [37 1 ]. In the present study, we controlled for smoking but 
even without adjustments did not find an association. 
9.6.2 Protein carbonyls 
Little has been reported regarding protein carbonyls and their association with asthma. 
As mentioned in Chapter 4, determination of protein carbonyls has been considered a 
useful tool to determine oxidative stress in several diseases, with very limited evidence 
of its use in asthma. For this study, the assessment of carbonyls of proteins was chosen 
because, after PUFA, proteins are the most vulnerable molecules for oxidation. It 
would therefore be expected that, if oxidative stress is present, a higher production of 
carbonyls would exist, mainly as consequence of the oxidation that amino acids 
residues undergo in the presence Of 02- In this study no associations were found 
between plasma carbonyls and self-reported symptoms of asthma or BHR, suggesting a 
lack of association with the disease. 
A lack of association between plasma carbonyls and respiratory symptoms of asthma 
was also found in a case-control study carried out in 38 subjects with mild, moderate 
and severe bronchial asthma and 23 age-matched healthy controls [229]. It may be 
possible that because carbonyls were assessed in plasma in that study as well as in the 
current study, circulating carbonyls in plasma corresponded to physiological amounts 
and not necessarily related to oxidative stress but to normal oxidation in the plasma. 
Possibly, carbonyls of proteins assessed in broncho-alveolar lavage [245] are specific 
of oxidation related to respiratory oxidation, although this has not been confirmed in 
carbonyls measured in sputum supernatant [246]. The evidence for this is limited to 
studies based on a small number of people with a severe asthma, and this methodology 
cannot be used in epidemiological studies. 
Overall, it was not possible to confirm other findings of higher F2-ip or carbonyls of 
proteins in subjects with respiratory symptoms. The available evidence from clinical 
experiments should be regarded with caution, as they may not be applicable to 
population-based studies. 
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9.6.3 FRAP and uric acid 
In this population, there were no associations between measurements of asthma and 
these biomarkers. The assessment of FRAP was chosen for two reasons. Firstly, it 
provides some insights on the potential action that antioxidants contained in the diet 
could exert, and this was particularly important due to inability to estimate plasma 
levels of vitamins in this study. FRAP is an assay that mirrors the antioxidant action of 
several compounds that contribute to the total antioxidant power of the plasma. These 
are ascorbic acid (15%), alpha-tocopherol (5%), bilirubin (5%), uric acid being the 
largest fraction of FRAP with an estimated contribution of 60% [262]. Secondly, it has 
been suggested the possible participation of polyphenols can also be estimated [263] 
due to their capacity to act as iron chelators, which can be detected with the 
measurement of FRAP. 
The lack of associations found between biomarkers of oxidative stress and respiratory 
symptoms of asthma and BHR slope might suggest that F2-ip and protein carbonyls are 
not sufficiently specific in plasma or that their utility is reduced if assessed in general 
population, where more severe respiratory illnesses are scarce. 
9.7 CONCLUSIONS AND FURTHER DIRECTIONS 
In this cross-sectional study, we found little supportive evidence of a relationship 
between dietary antioxidant intake and asthma, as assessed with subjective 
measurements of self-reported respiratory symptoms, or a more objective measure. 
There was a consistent pattern of lack of associations between antioxidant vitamins, 
minerals and food items with these primary outcomes. 
The lack of associations found between different plasma biomarkers and respiratory 
outcomes of asthma is an important contribution to the current knowledge in this area. 
In spite of the relatively good experimental and clinical evidence for showing a 
positive association between F2-ip and asthma, this relation may not be found in 
community-based studies. This study provides a reference on the physiological range 
that can be expected in young adults. 
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A future study would benefit from the inclusion of oxidative stress assessed in more 
specific sites. The fact that FRAP was mostly unaltered in this population, confirms 
that there is a good balance between substances being oxidised and those reduced in 
plasma. The ranges found here were within the values reported as normal in the 
literature, and applied to a much higher number of people. The levels of markers of 
oxidative stress in plasma may not be related to asthma if the disease is not present 
with more severe symptoms or exacerbations. Therefore, new methodologies such as 
assessment in exhaled breath, or condensate air concentration of F2-ip or other more 
specific markers of oxidative stress like NO and MDA could provide a better insight on 
the relationship between general antioxidant status and susceptibility to oxidative stress 
in those that have asthma in the community. 
The fact that some food items may reduce the risk of having BHR, as found with garlic 
and onion, raises the question of whether such effect is persistent. On the other hand, 
the issue of whether fruits and vegetables rich in antioxidants and the individual 
antioxidants have a real effect on the prevalence of asthma in adults requires further 
investigation. 
This thesis provides limited evidence for associations between dietary intake of 
antioxidants and symptoms of asthma or lung function. The use of biomarkers of 
oxidative stress and antioxidant status in plasma in the general population may not be 
useful in reflecting oxidative damage related to asthma. It could be possible that a 
beneficial effect could be observed in populations exposed to lower levels of 
antioxidants than those in this study. 
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APPENDIX I 
Questionnaires used in the thesis 
This appendix includes two parts: (A) A translated version of the ECRHS 
questionnaire administered to the participants of the study; (B) the Lung Function 
Questionnaire (Part 1) and Data Collection Sheet (Part 2); and (C) a translated version 
of the FFQ. 
The translated ECRHS is slightly different to that used for the European study, where 
several questions were aimed to assess the use of medication in these adults. For the 
purposes of the study in Chile, it was assumed that very few individuals would have 
received medication. This information was obtained in a shorter way. 
There were a number of other items added in order to adapt the questionnaire to the 
local situation of Limache, especially those related to socio-economic background. 
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I AM GOING TO ASK YOU SOME QUESTIONS. AT FIRST THESE WILL BE MOSTLY ABOUT 
YOUR BREATHING. WHEREVER POSSIBLE, I WOULD LIKE YOU TO ANSWER'YES'OR'NO'. 
Wheeze and tightness in the chest 
1. Have you had wheezing or whistling in your chest at any time in the last NO YES 
12 months? I F-1 
IF'NO'GO TO QUESTION 2, IF'YES': 
NO YES 
1.1 Have you been at all breathless when the wheezing noise was presentf-I F-1 
1.2. Have you had this wheezing or whistling when you did not have NO YES 
a cold? Iý II 
2. Have you woken up with a feeling of tightness in your chest at any time in NO YES 
the last 12 inonths? F 11-1 
Shortness of breath 
3. Have you had an attack of shortness of breath that came on during the day NO YES 
when you were at rest at any time in the last. 12 months? rý Fý 
4. Have you had an attack of shortness of breath that came onfollowing NO YES 
strenuous activity at any time in the last 12 months? II F1 
5. Have you been woken by an attack of shortness of breath at any time in the NO YES 
last 12 months? Fý F] 
Cough and phlegm from the chest 
6. Have you been woken by an attack of coughing at any time in the last 12 NO YES 
months? IIF1 
6.1 Was this cough related to a cold at that time? F-1 F-I 
NO YES 
7. Do you usually cough first thing in the morning in the winter? Fý [71 
[IF DOUBTFUL, USE QUESTION 8.1 TO CONFIRM] 
NO YES 
8. Do you usually cough during the day, or at night, in the winter? F1FI 
IF'NO'GO TO QUESTION 9, IF'YES': 
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8.1 Do you cough like this on most days for as much as three months NO YES 
each year? MM 
9. Do you usually bring up any phlegm from your chest first thing in the NO YES 
morning in the winter? [IF DOUBTFUL, USE QUESTION 10.1 TO CONFIRM] rýrI 
10. Do you usually bring up any phlegm from your chest during the day, or NO YES 
at night, in the winter? IýFI 
IF INO'GO TO QUESTION 11, IF'YES': 
10.1 Do you bring up phlegm like this on most days for as much as three NO YES 
months each year? FI F-1 
Brea "hin 
NO YES 
11. Do you ever have trouble with your breathing? FI F1 
IPNO'GO TO QUESTION 12, IF'YES': 
11.1 Do you have this trouble TICK ONE 
BOX ONLY 
a) continuously so that your breathing is never quite right? 
b) repeatedly, but it always gets completely better? 
c) only rarely? 
12. Are you disabled from walking by a condition other than heart or lung NO YES 
disease? 171 F1 
12.1 If yes, state condition: 
12.2 Are you troubled by shortness of breath when hurrying on level NO YES 
ground or walking up a slight hill? FIFI 
IF INO'GO TO QUESTION 13, IF'YES': 
12.2.1 Do you get short of breath walking with other people of NO YES 
your own age on level ground? I IF] 
12.2.2 Do you have to stop for breath when walking at NO YES 
your own pace on level ground? F1 [71 
13. Only for women and only if you have problems with your breathing. 
Do your breathing problems (wheezing, chest tightness, difficulty to breath) happen in 
a particular moment of your menstrual period? 
b) repeatedly, but it always gets completely better? 
c) only rarely? 
IICK ONE 
BOX ONLY 
13.1 Yes, during the week previous to the start of my period 
13.2 Yes, during my period 
B 
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13.3 Yes, in the week after my period 
13.4 Yes, in another moment of the month 
13.5 No, because I do not have periods 
13.6 No, because I am a male 
13.6 No, it has nothing to do with my periods 
Asthma 
NO YES 
14. Have you ever had asthma? FIII 
IF'NO'GO TO QUESTION 15, IF'YES': 
NO YES 
14.1 Was this confirmed by a doctor? FI Fý 
YEARS 
14.2 How old were you when you had your first attack of asthma? 
YEARS 
14.3 How old were you when you had your most recent attack of asthma? 
14.4.1-6 Which months of the year do you usually have attacks of asthma? 
NO YES 
14.4.1 January / February 
14.4.2 March / April 
14.4.3 May June 
14.4.4 July August 
14.4.5 September / October 
14.4.6 November / December 
YES 
14.5 Have you had an attack of asthma in the last 12 months? F-I Fý 
IF'NO'GO TO QUESTION 15, IF'YES': 
14.6 How many attacks of asthma have you had in the last 12 NUMBER 
months? 
14.7 How many attacks of asthma have you had in the last 3 NUMBER 
months? 
14.8 How many times have you woken up because of asthma 
in the last 3 months? NUMBER 
14.8.1 Nearly every night 
14.8.2 More than once a week 
14.8.3 More than once a month but less than once a week 
14.8.4 Less than twice a month 
14.8.5 None 
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14.8.6 1 have not had this problem because I take medicines to avoid it 
14.9 How often has asthma caused you problems in the last 3 months? 
14.9.1 Frequently 
14.9.2 Once a day 
14.9.3 More than once a week but less than once a day 
14.9.4 Less than once a week 
14.9.5 None 
14.9.6 1 have not had this problem because I take medicines to avoid it 
III 
NUMBER 
14.10 Has a doctor given you written instruction on how to manage your asthma, 
or what to do if you have an asthma attack? NO YES F] F1 
AlleEgies 
NO YES 
15. Do you have any nasal allergies, including hay fever? IIFI 
AGE 
15.1 How old were you the first time you had this allergy? 
16. Have you ever had a nasal secretion, or your nose blocked due to a 
congestion without having a cold? NO YES 1-1 F-I 
IF'NO'GO TO QUESTION 17, IF'YES': 
16.1 
- 
Have you ever had a nasal secretion, or your nose blocked due to a 
congestion without having a cold in the last 12 months? 
NO YES 
F-1 
IF 'NO' GO TO QUESTION 17, IF'YES': 
NO YES 
16.1.1 When this happens, do you also have red eyes and itchiness? IIF1 






f) November/ December 
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NO YES 
17. Have you ever had eczema or any other type of allergy in your skin? IýM 
18. Have you had redness or rash in your skin, appearing and disappearing in the last 12 
months? 
18. Which part of your body is affected by this rash and itchiness? 
NO YES 
Fý F-I 
19. Are you allergic to insect bites? 
19.1. To what type of insects? 
NO YES 
F-I F-1 
20. Have you ever had problems with your breathing after taking a medicine? NO YES 
1: 1 F-1 
20.1. To what type of medicines? 
NO YES 
2 1. Are you allergic to any food? rI F71 
2 1.1. To what type of food? 
NO YES 
22. Are you allergic to a plant or a tree? Iý F1 
22.1. To which plant or tree? 
Your home 
23. How many years have you lived in your present home? 
YEARS 
24. How many years have you lived in 
YEARS 
25. When was your present home built? IICK ONE 
BOX ONLY 
a) before 1960? 
b) 1961-1970? 
c) 1971-1980? 
d) 1981 or later? 
e) don't know 
26. Which best describes the street where your house is? 'nCK ONE 
BOX ONLY 
a) a main street 
b) a secondary street 
c) a small street (mews, etc) 
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b) a secondary street 
c) a small street (mews, etc) 











29. Which of the following fuels do you use for heating or for hot water? 
NO YES 
29.1 open coal, 
29.2 wood fire 
29.3 gas 
29.4 paraffin heater 
29.5 electricity 
29.6 other: 
30. What kind of stove do you mostly use for cooking? TICK ONE 
BOX ONLY 






3 1. Do you have an extractor fan over the cooker? F 11-1 
IF INO'OR'DON'T KNOW' GO TO QUESTION 32, IF'YES': 
3 1.1 When cooking, do you use the fan 7ICK ONE 
BOX ONLY 
a) all of the time? 
b) some of the time? 
c) none of the time? 
NO YES 
31.2 Does the fan take the fumes outside the house? FI F] 
32. Do you cook? Fý F] 
IF'NO'OR'DON'T KNOW'GO TO QUESTION 35, IF'YES': 
b) some of the time? 
c) none of the time? 
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MINUTES 
32.1 On average, how much time do you spend cooking every day? 
33. In winter, is the door of the kitchen ever left open when cooking? NO YES 
33.1 All the time 
33.2 A few hours 
33.3 Rarely 
33.4 Never 
34. On which floor of the house is your bedroom? 
NO YES 
35. Does your bedroom have upholstered or soft fumishings? F-I F-1 
36. Does the room where you spend most of your time in the house ? 
NO YES 
36.1 have fitted carpets covering the whole floor? 
36.2 contain rugs? 
36.3 have curtains? 
36.4 have upholstered or soft furnishings? 
37. If you have rugs, for how long have you had the oldest one in your house?: 
TICK ONE 
BOX ONLY 
37.1 less than a year 
37.2 1-5 years 
37.3 more than 5 years 
37.4 don't have 
38. Of what material is your mattress?: NO YES 
38.1 Wool 
38.2 Sponge 
38.3 Other (specify) 
39. For how long have you had your mattress? 'nCK ONE 
BOX ONLY 
39.1 less than a year 
39.2 1-5 years 
39.3 more than 5 years 
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39.2 1-5 years 
39.3 more than 5 years 








40.6 other (specify) 
4 1. The walls of your bedroom: NO YES 
4 1.1 are painted? 
41.2 have wall paper? 
41.3 are varnished? 
41.4 none of the above 
NO YES 
42. Is your house humid? F 11-1 
DONT 
43. Has there ever been any mould or mildew on any surface, other than NO YES KNOW 
food, inside the home? rýr 11-1 
IF INO'OR 'DON'T KNOW' GO TO QUESTION 45, IPYES: 
43.1 Which rooms have been affected? 
43.1.1 bathroom(s) 
43.1.2 bedroom(s) 
43.1.3 living area(s) 
43.1.4 kitchen 
43.1.5 basement or attic 
43.1.6 other: 
44. Has there been mould inside the house in the last 12 months? 
45. Does your house get wet inside if it rains? 
46. Has there ever been any water damage to the building or its contents, 
for example, from broken pipes, leaks or floods? 
Animals 







NO YES KNOW 




IF'NO'GO TO QUESTION 48, IF'YES': 
NO YES 
47.1 Is your cat ever allowed into your bedroom? D o 
47.2 Do all your cats stay outside the house? 
NO YES 
48. Do you keep a dog? Fý FI 
IF INO'GO TO QUESTION 49, IF'YES': 
NO YES 
48.1 Is your dog ever allowed into your bedroom? 0 0 
48.2 Do all your dogs stay outside the house? 
49. Were there any cats in your house NO YES 
49.1 during your first year of life? 
49.2 when you were between I and 4 years old? 
49.3 when you were between 5 and 15 years old? 
50. Were there any dogs in your house NO YES 
50.1 during your first year of life? 
50.2 when you were between I and 4 years old? 
50.3 when you were between 5 and 15 years old? 





51.3 others (specify) 
51.4 did not grow any animals 
52. When you are near animals, such as cats, dogs or horses, near feathers, 
including pillows, quilts or duvets, or in a dusty part of the house, do you ever 
NO YES 
52.1 start to cough? 
52.2 start to wheeze? 
52.3 get a feeling of tightness in your chest? 
52.4 start to feel short of breath? 
52.5 get a runny or stuffy nose or start to sneeze? 
52.6 get itchy or watering eyes? 
52.7 get skin allergy? 
53. When you are near dust in the house or after scrubbing? 
NO YES 
53.1 start to cough? rI F1 
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53.2 start to wheeze? 
53.3 get a feeling of tightness in your chest? 
53.4 start to feel short of breath? 
53.5 get a runny or stuffy nose or start to sneeze? 
53.6 get itchy or watering eyes? 
53.7 get skin allergy? 
54. When you are near trees, grass or flowers, or when there is a lot of pollen 
about, do you ever 
NO YES 
a) start to cough? 
b) start to wheeze? 
c) get a feeling of tightness in your chest? 
d) start to feel short of breath? 
e) get a runny or stuffy nose or start to sneeze? 
f) get itchy or watering eyes? 
g) get skin allergy? 
IF IYES'TO ANY OF THE ABOVE: 





d) autumn F-I F-I 
Diet 
55. How often do you eat pre-packaged food, such as tinned food or pre-prepared 
frozen meals? TICK ONE 
BOX ONLY 
a) every day or most days 
b) at least once a week 
c) occasionally 
c) never 
56. Have you ever had an illness or trouble caused by eating aparticular NO YES 
food or foods? Fý F71 
IF'NO'GO TO QUESTION 57, IF'YES': 
56.1 Have you nearly always had the same illness or trouble after eating NO YES 
this type of food? F-I F-I 
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56.2 What type of food was this? 
56.3 Did this illness or trouble include 
NO YES 
a) a rash or itchy skin? 
b) diarrhoea or vomiting? 
c) runny or stuffy nose? 




57. Have you ever smoked for as long as a year? 
NEVER NO YES 
F-I F-I Fý 
['YES' means at least 20 packs of cigarettes or 12 oz (360 grams) of tobacco 
in a lifetime, or at least one cigarette per day or one cigar a week for one year] 
IF'NEVER'GO TO QUESTION 58, IF'NO'GO TO QUESTION 57.4, IF'YES': 
YEARS 
57.1 How old were you when you started smoking? 
NO YES 
57.2 Do you now smoke, as of one month ago? IýFI 
57.3 How much do you now smoke on average 
NUMBER 
a) number of cigarettes per day 
b) number of cigarillos per day 
GRAMS 
c) grams of pipe tobacco a week I 
YEARS 
57.4 How old were you when you stopped or cut down smoking? 
57.5 On average of the entire time you smoked, before you 
stopped or cut down, how much did you smoke? 
NUMBER 
a) number of cigarettes per day 
b) number of cigars a week 
c) grams of pipe tobacco a week 
NO YES 
57.6 Do you or did you inhale the smoke? Iý FI- 
b) number of cigars a week 
c) grams of pipe tobacco a week 
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58. Have you been regularly exposed to tobacco smoke in the last 12 NO YES 
months? ['Regularly' means on most days or nights] FI[I 
IF INO'GO TO QUESTION 59, IF'YES': 
58.1 Not counting yourself, how many people in your household smoke NUMBER 
regularly? 
NO YES 
58.2 Do people smoke regularly in the room where you work? [-ý F-I 
58.3 How many hours per day are you exposed to otherpeople's HOURS 
tobacco smoke? 
59. Medicines 
If you have received any medicine for the alleviation of your breathing problems, congestion 
or allergy in the last 12 months, please indicate them: 
Name of the 
medicine 
How do you take them? 
Inhaled Nebulised Syrup Tablets Times/day Last month you 
Took them 
NO YES 
60. Do you take aspirin? 
60.1 How often? Daily, weekly, occasionally 
61. Do you take paracetamol? 
61.1 How often? Daily, weekly, occasionally 
YEAR 
62. When were you bom? IIII 
FEMALE MALE 
63. Please indicate, are you 
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64. How old was your mother when you were born? 
YEARS 
III 





c) more than once 
c) don't know 
DON'T 
66. Did you normally share your bedroom with older children NO YES KNOW 
when you were younger than 5 years old? 
II 
DON'T 
67. Did you go to a nursery with other children before NOYES KNOW 
you were 5 years old? II 
DON'T 
68. Did you ever have any important respiratory infection NO YES KNOW 
before 5 years old? III 
DON'T 
69. Were you ever admitted into hospital due NOYES KNOW 
to a pulmonary disease before you were 2 years old? III 
NO YES 
70. Are you a full-time student? 
7 1. What is your current work?. If you don't work at present, what was your last job? 
71.1 The work you currently have is: 
1) Professional 
2) Professional in the public service 
3) Business 
4) Employee at a middle level in the private or public sector 
5) Employee of basic level 
6) Specialised hand worker 
7) Non specialised. hand worker 
8) House wife 




72. Have you ever had any of the following jobs?: 
1) Worker in a farmer 
2) Painter 
3) Working with metallic objects 
4) Working with plastic objects 
5) Cleaner, domestic work 
6) Bird grow farms 




73. Has any of the jobs you have worked on caused you wheezing or 
chest tightness? F1 
73.1 Which job? 
NO YES 
74. Have you needed to leave yourjob because it was causing you 
breathing problems? 
1ý 
IF'NO', GO TO QUESTION 75, IF'YES': 
74.1 Which job was causing you this problem? 
NO YES 
75. Have you ever been exposed to vapours, gases, dust or fume? FI 
IF 'NO', GO TO QUESTION 76, IF 'YES': 
75. Which job was this? 
Physical activity TICK ONE 
BOX ONLY 
76. In relation to your work, would you consider it to bes: 
1) very active 
2) relatively active 
3) not very active 
4) not active at all 
NO YES 




78. How often do you exercise until you break sweat or are left breathlessness? 
a) every day or most days 
b) 4-6 times a week 
c) 2-3 times a week 
d) once a week 
e) once a month 
f) less than once a month 
g) never 
If you answered less than once a month or never: NO YES 
79. Do you avoid exercising because you have difficulty with your breathing 
or because it gives you asthma? 
1111 
80. During the week, how many hours do you normally watch TV per day? F-I F-I 
81. Do you watch TV during the day on weekends? F-I 1-1 
82. Do you have a computer at home? F-1 F-1 
83. If you answered yes, how many hours of your free time do you dedicate 
to use the PC? 
1111 
84. What does describe best the place where you used to live when were less than 5y ars; old? 
a) Countryside 
b) Village in the country (with more than 50 and less than 100 people) 
c) Nearby a big city 
d) Centre of a big city 
85. How many people live in your house? 
a) In the same house 
b) Sharing the same food 
86. Would you consider your family as? 
b) Nuclear (parents, children) 
c) Extended family (parents, children, other relatives) 
d) extended (parents, children, other persons that are not relatives) 
NUMBER 
87. How many brothers and sisters do you have? 
NUMBER 
88. How many elder brothers do you have? 
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NUMBER 
89. How many elder sisters do you have? 
YEAR 
90. What was your last course approved? 
NO YES 
91. Are you the breadwinner in your family? II F1 
92. If is not yourself, what activity does the breadwinner? 
93. Indicate within which range the income of your family is: TICK ONE 
BOX ONLY 
a) Less than $ 100,000 
b) Between $100,000 y $200,000 
c) Between $200,000 and $500,000 
d) Between $500,000 and $800,000 
e) Between $800,000 and $1,300,000 
f) Between $1,300,000 and $2,000,000 
g) Above $2,000,000 
TICK ONE 
BOX ONLY 
94. What was the last course that your father approved in school? FI 
YEARS 
95. How old is your mother? Fý 
YEAR 
96. What was the last course that your mother approved in school? FI 
Your house: 
97. Is your house a 
TICK ONE 
BOX ONLY 
a) House or flat with 4 bedrooms? 
b) Solid flat or house (2 to 3 bedroorns)? 
c) Council flat or house? 
d) Light wooden house? 
e) Very light material and precarious house? 
98. In the house where you live now, you are: TICK ONE 
BOX ONLY 
a) Owner, paying mortgage 
b) Letting 
c) Owner with no mortgage 
d) Friend or relative receiving free board and lodging 
e) Have taken that piece of land illegally 
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99. How many bedrooms does your house have? (excluding bathroom 
and kitchen) 
11 
100. Which of the following consurnables are in your house? 
a) Fridge 
b) Hot water heating device in working conditions 
c) Washing mashing in working order 
d) Microwave 
NO YES 
101. Does your family have any cars? Fý [7-1 
IF'NO', GO TO QUESTION 102, IF'YES': 
101.1 How many vehicles do you have? 
101.2 How many of these vehicles are for a working purpose? 
NO YES 
102. Is your family registered with the Social Security Agency? FI F1 
NO YES 
103. Over the last five years, have you gained more than 8 kgs? F] II 
104. How much did you weight 5 years ago? 
Finally, some measurements: 
OFIEIEI 
105. Arterial pressure 
Systolic pressure (mmHg) I" measurement 
Diastolic pressure (mmHg) I" measurement 
Systolic pressure (mmHg) 2nd measurement 
Diastolic pressure (mmHg) 2nd measurement 
Systolic pressure (mmHg) P measurement 
Diastolic pressure (mmHg) 3"d measurement 
106. Brachial perimeter (cms) 
107. Tricipital fold (mm) 
108. Waist circumference (cm) 
Name of Fieldworker 
Observations ................................................................................................................ 
....................................................................................................................................... 
Questionnaire checked and approved by supervisor ....................................... 
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B. LUNG FUNCTION PROTOCOL (PART 1) 
Identification Number E: IEIEIEl 
Date ElOODE-10 
Day Month Year 
Before starting this questionnaire please ask the following questions: 
NO YES 
Have you had a cigarette in the last hour? EIF-1 
NO YES 
Have you used an inhaler (puffer) in the last 24 hours DID 
If yes, delay lung function tests until one hour after the last cigarette or inhaler 
use (responses do not have to be included in data recorder). 
1. How many times have you been woken at night with shortness of breath 
in the last two weeks? 
00 
2. During the last two weeks, has your breathing been TICK ONE 
BOX ONLY 
1. worse than usual? 
2. same as usual? 
3. better than usual? 
NO YES 
Have you had wheezing or whistling in your chest in the last 3 days? EIEJ 




5. Have you been woken by an attack of shortness of breath in the last 3 days NO YES 
FF 
NO YES 
6. Have you woken by an attack of coughing in the last 3 days? EIEI 
NO YES 
7. Have you had an attack of asthma in the last 3 days ? FIM 
8. Have you taken any medicine (including inhalers, aerosols or tablets) for asthma in 
the last 3 months? NO YES 
FIM 
Have you had any symptoms of hay fever or nasal allergy in the last 3 days? 
NO YES 
F1F-] 




I I. Have you used an inhaler in the last 24 hours ? EID 
If 'NO', go to question 12, if 'YES': 




If the subject has used a beta-2-agonist inhaler or an anti-muscarinic inhaler in the 
last six hours, do: 
a) Wait until four hours since last use has elapsed 
b) Reschedule for another day if the subject is willing. 
12. Have you used any other medicine (including pills, capsules or suppositories) to 
help your breathing, or any oral anti-muscarinic in the last 24 hours? 
NO YES 
DO 
If 'NO', go to question 13, if 'YES', 
12.1 What medicine(s) did you take and how many hours ago did you take it? 
Drug Hours 
........................................................................................ ... EIE: 1 EIEI 
................................................................................................. .... Eln CEI 
If the subject has ta4en an oral beta-2-agonist, an oral theophylline or an oral 
anti-muscarinic, reschedule for another day. 
NO YES 
13. Have you had an heart attack in the last three months? 00 
NO YES 
14. Are you currently taking any medicine(s) for your heart? EIEJ 
NO YES 
15. Are you currently taking any medicines for epilepsy? FEI 
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16. Do you usually take any medicines containing beta-blockers, including eye-drops? 
NO YES 
00 
Only for women. 
NO YES 
17. Are you pregnant? EIEI 
NO YES 
18. Are you breast feeding? 00 
If the answer is 'YES' to questions 13-18, measure baseline spirometry only, do not 
challenge with methacholine. 
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B. LUNG FUNCTION PROTOCOL, DATA COLLECTION SHEETS (PART 2) 
Identification Number 
Date: 
Date of birth: 
I. - Height (m) 
2. - Weight (kg) 
3. - Age (years) 
4. - Sex Male= I Female =2 
5. Time of the day 




Each participant now has five attempts to produce a technically satisfactory 
manoeuvre. If after five attempts there have not produced at least two manoeuvres - 
four more attempts are allowed. Maximum number of attempts allowed is nine 
7. - INITIAL FEVI AND FVC 
FEVI (L) 
I 
FVC (L) PEF (L) 
EIFT-] 
2 1: 1.01: 1 FTEIEJ EIEJEJ 
3 El-E-11: 1 0-1: 11: 1 000 
4 EI-Ell: l 1: 1-1: 11 1: 100 
5 EI-Ell: l 1: 1-1: 11: 1 EIEJEI 
PEF = Peak expiratory flow (Vmax) 
7.1 Number of rejected attempts 
F-I 




Day Month Year 
ETIFIETIE] 
Day Month Year 
DETIE] 




If best initial FEV1: a) less than 70% predicted or 
b) less than 1,5 litres 
GO TO BRONCHODILATOR CHALLENGE - DO NOT DO METHACHOLINE 
CHALLENGE 
METHACHOLINE CHALLENGE 
Give four inhalations of diluent. Two minutes later record FEV, 
9. - Control FEF, following inhalation of diluent 
9.1. Record two technically satisfactory manoeuvres 
9.2. Number of rejected attempts 
10. BEST CONTROL (post-diluent)FEV, as % of inicial FEV, 
i. EITTý 
nnEl 
If best control FEV, <90% of bet initial FEV, stop methacholine challenge and go to 
reversal of bronchoconstriction 
I I. -Methacholine batch number MFIM 
Date of preparation of original solution EJEIEIFIOEJ 
Day Month Year 
Concentration of Absolute value of FEV, % ofchange Rejected 







12. - Why was methacholine challenge stopped?: 
a) end of test reached (inhaled 16 mg) 
b) >20% fall in FEV, occurred 
c) two satisfactory manoeuvres not achieved 












e) other ........................................................................................ 
El 
I IF PARTICIPANT'S FEVI HAS FALLEN BY MORE THAN 10% 
Reversal of bronchoconstriction 
GIVE 400 gg SALBUTAMOL VIA INHALER AND 10 MINUTES LATER 
RECORD FEV1 
13. - FEV1 AND FVC 
13.1. Record first two tecnically satisfactory manoeuvres (up to five attempts) 
FEV, E], ME] FVCE], U-1 
FEV, EJ, EJEJ IFVC EJ, E]F-l 
13.2. Number of rejected attempts F-I 
14. - Best post-bronchodilator FEV, as % of initial FEV1 EIDE] 
15. - Has the participant's FEVI returned to within 10% of initial FEV1 NO YES 
F-I F-I 
IF'YES'THE PARTICINAT MAY LEAVE THE CENTRE. 
IF'NO'FURTHERACTION MUST BE TAKEN TORESTORE BASELINE 
LUNG FUNCTION 
BRONCHODILATOR CHALLENGE ONLY 
GIVE 400 gg DE SALBUTAMOL VIA INHALER VOLUMATIC AND 10 
MINUTES LATER RECORD FEV1 
16, FEV, and FVC 
16.1. Record first two technically satisfactory manoeuvres (up to five attempts) 
FEV, R, E]E] IFVC R, RF-1 
VEFIE], E]E] FVCE], FýF-l 
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Association between BHR and respiratory symptoms with 
food and nutrient intake, flavonoids and plasma 
biomarkers 
This appendix provides analyses on individual food items and nutrients in relation to 
the outcomes that are studied in the primary hypothesis of this thesis. As no food 
item studied showed evidence a for non-linear relationship with any of the outcomes 
in analyses using quintiles of intake, most of them were analysed as the continuous 
increase for 100g of their consumption. Garlic and salt were analysed as per lOg of 
increase, because their normal consumption is very unlikely to reach 100 ga day in 
the usual dietary pattern of adults. There were some food items whose intake were 
insufficient to classify them into quintiles, so were dichotomised as eating any 
amount equal to or above I g/day, or eating less than I g/day of that food item. 
The macronutrients studied were proteins, carbohydrates, lipids (MUFA, SFA, 
PUFA, omega 3, omega 6 fatty acids, ratio WO). Micronutrients analysed included 
vitamins and minerals. Among the first were retinol, beta carotene, and total vitamin 
A, vitamins B (B I, B2, niacin, B6, B12), Vitamin C, vitamin E (alpha- tocopherol), 
folic acid, and pantotenic acid. The minerals analysed were calcium, copper, iron, 
magnesium, phosphorus, potassium, selenium, sodium, and zinc. 
Model I shows crude associations. Two models of multiple linear regression 
analyses were used to assess the association between measurement of BHR, with 
individual foods, as well as with antioxidant nutrients. Model 2 adjusted for age, 
sex, socio-economic confounders, weight at birth, BMI, FEVI%, FEVI%FVC and 
atopy. Model 3 added TEL This was aimed to assess whether adjustment for TEI 
would affect the associations found, if any. Bonferroni correction was applied in 
those tests in Appendices 2 and 3 that showed nominal statistical significance. 
Eeach respiratory outcome was analysed using three statistical models assessing 
associations with individual food items, nutrients and grouped flavonoids. The 
analyses of separate multivariable models were intended to evaluate the possibly 
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confounding effect that different sets of variables could have on both respiratory 
symptoms and dietary intake. The statistical models included the same variables than 
that for BHR slope except FEV, %, FEV, %FVC and atopy. 
To examine the association between the outcomes studied and biomarkers as 
independent variables, only two models were analysed. The rationale for this is that 
TEI is unlikely to affect levels of biomarkers of oxidative stress or antioxidant status 
such as those included in the current study. 
A few associations of nominal statistical significance were found, but all the P- 
values were raised above the level of significance after Bonferroni correction. 
Intakes of garlic (Table A (1)), and vitamin C (Table A (2)) were negatively 
associated with BHR slope. This association remained statistically significant across 
the three models studied, but disappeared after Bonferroni correction. Contrary, 
positive associations of nominal statistical significance were found between BHR 
slope and selenium and sodium intake (Table A (2)), but the P-value was raised 
above 0.3 after Bonferroni correction. 
Waking with shortness of breath was negatively associated with intake of rice and 
positively associated with sugar (Table C (1)) (Model 3: OR 0.37,95% CI 0.17 to 
0.81, and OR 2.26,95% CI 1.18 to 4.35, respectively). Having at least one 
respiratory symptom was negatively associated with intake of lentils (OR 0.42,95% 
Cl 0.20 to 0.88) and positively and statistically significantly associated with intake of 
sweet pepper, sugar, tea and coffee (Table D (1)). In addition, a negative association 
was found between this outcome and intake of calcium (OR 0.78,95% CI 0.64 to 
0.95), which remained statistically significant across the three models (Table D (2)). 
Finally, plasma levels of F2-ip were negatively associated with having at least one 
respiratory symptom both univariately and in the multivariable model (Table D (4)). 
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Association between FEVI, and ratio FEVI/FVC with intake 
and food items, nutrients, flavonoids and plasma biomarkers 
In this appendix information on association between lung function outcomes and 
individual food items and nutrients is provided. It also includes the analyses for per- 
quintile intake of flavonoids and plasma biomarkers. As described in appendix 2, there 
was no evidence for non-linearity in the associations between outcomes and food and 
nutrient intake, therefore these are presented per 100g, 10g, or dichotomised. 
Three statistical models are provided, one with unadjsuted associations, and two with 
potential confounders. Model two included: age, sex, height (in the case of FEVI only), 
socio-economic confounders, birth weight, and adult BMI. Model 3 added TEL 
Bonferroni correction was applied in those test that showed nominal statistical 
significance. 
To examine the association between the outcomes studied and biomarkers as independent 
variables, only two models were analysed. The rationale for this is that TEI is unlikely to 
affect levels of biomarkers of oxidative stress or antioxidant status like those included in 
the current study. 
Univariately, intake of several food items was associated with a greater FEVI. Most of 
these associations were no longer observed after adjusting for potential confounders, 
with the exceptions of garlic, onion, juices, and red wine, whose intake remained 
statistically significantly associated with a greater FEVI (Table E (1)). After Bonferroni 
correction, all the P-values were raised above 0.1. 
In relation to nutrients, nearly all of them, with the exception of ratio WO, 0-carotene, 
and total vitamin A, were positively associated with a greater FEVI. After controlling for 
confounders only folic acid showed a nominal statistically significant and positive 
association with this outcome, which was no longer significant after Bonferroni 
258 
correction (Table E (2)). There was some evidence of a positive association between 
intake of total catechins and FEVI but this was of borderline statistical significance after 
controlling for confounders (Table E (3)). A negative association of nominal statistical 
significance was found between FRAP and FEVI in the univariate and multivariable 
analyses, which remained so after Bonferroni correction. No associations were found for 
the other biomarkers (Table E (4)). 
A decrease in the ratio FEVI/FVC was associated with a 100 g increase in intake of 
pumpkin and jam, whereas it was positively associated with intake of pork ribs and 
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